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Nucleobindin 1 (NUCB1) is a widely expressed multi-domain Ca2+-
binding protein whose precise physiological and biochemical functions are 
not well understood. We engineered and heterologously expressed a 
soluble form of NUCB1 (sNUCB1) and characterized its biophysical and 
biochemical properties.  We show that sNUCB1 exists as a dimer in 
solution and that each monomer binds two divalent Ca2+ cations.  Ca2+-
binding causes conformational changes in sNUCB1 as judged by circular 
dichroism and fluorescence spectroscopy experiments.  Earlier reports 
suggested that NUCB1 might interact with heterotrimeric G protein α-
subunits. We show that dimeric Ca2+-free sNUCB1 binds to 
heterologously expressed Gαi1 and that Ca2+-binding inhibits this 
interaction.  We further show that the binding of sNUCB1 to Gαi1 inhibits 
its basal rate of GDP release and slows its rate and extent of GTPγS 
uptake. We conclude that sNUCB1 is a Ca2+-dependent guanine-
nucleotide dissociation inhibitor (GDI) for Gαi1. To our knowledge 
sNUCB1 is the first example of a calcium-dependent GDI for 
heterotrimeric G proteins.  
 
In addition, we also established novel and unique anti-amyloidogenic 
functional ability of sNUCB1. We show that Ca2+-free sNUCB1 can 
inhibit fibril formation by highly amyloidogenic human Islet Amyloid 
PolyPeptide (hIAPP) and Amyloid-β 42 (Aβ42) peptides, as relevant to 
Type-2 Diabetes and Alzheimer’s disease. In addition, we also show that 
Ca2+-free sNUCB1 can effectively dissociate amyloid fibrils formed by 
both hIAPP and Aβ42. Interestingly, Ca2+ disrupts this unique functional 
ability of sNUCB1. In order to circumvent this, we designed and purified a 
Ca2+-insentive mutant namely sNUCB1(tetramutant) that is functionally 
similar to sNUCB1 even in the presence of excess Ca2+ in the reaction 
mixture. Mechanistically, we show that sNUCB1 inhibits fibril formation 
by capping the ends of high molecular mass prefibrillar species. 
Subsequently, we also isolated a 39-amino-acid long C-terminal (CT) 
peptide fragment of NUCB1 namely NUCB1(381-419) which, similar to 
sNUCB1, inhibits and disaggregates hIAPP fibrillization. Finally we have 
also extended this work to other amyloidogenic proteins namely tau 
K19(C322S), a synthetic construct comprising microtubule binding 
domain of human tau protein. Specifically, we show that Ca2+-free 
sNUCB1 effectively inhibits amyloid fibril formation by tauK19(C322S).  
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 1 
CHAPTER 1 
Nucleobindin 1 is a Calcium Regulated Guanine Nucleotide Dissociation 
Inhibitor of Gαi1 
 
1.0 INTRODUCTION 
Heterotrimeric guanine nucleotide-binding proteins, G proteins, couple to 
heptahelical cell surface G protein-coupled receptors (GPCRs) and 
participate in intracellular signaling events. The G protein heterotrimer is 
composed of the GTPase Gα subunit and the Gβγ heterodimer. Upon 
ligand-mediated activation, GPCRs catalyze the exchange of GDP for 
GTP on Gα leading to dissociation of the heterotrimer into Gα•GTP and 
Gβγ subunits (1-3). These individual subunits then regulate downstream 
signaling cascades involving effector systems like adenylyl cyclases, Ca2+ 
and K+ channels, phospholipase C isozymes and cyclic nucleotide 
phosphodiesterases (4, 5). Thereafter, the intrinsic GTPase activity of Gα 
reverts it back to the GDP-bound state, which can reassociate with Gβγ. 
This inhibits the interaction of G protein subunits with downstream 
effectors, which results in turning-off of the signaling pathways. Hence, 
signaling by heterotrimeric G proteins is directly dependent on the lifetime 
of the GTP-bound state of Gα. This lifetime is regulated by GTPase 
accelerating proteins (GAPs), which catalyze the rapid hydrolysis of the 
Gα bound GTP to GDP and by guanine nucleotide dissociation inhibitors 
(GDIs), which inhibit the exchange of GDP for GTP in the catalytic 
pocket of Gα (6).  
 2 
Together, GAPs and GDIs exert a regulatory control on G protein 
signaling. In recent years, novel interacting partners of heterotrimeric G 
proteins called the regulators of G protein signaling or RGS proteins have 
been discovered that possess GAP activity (7, 8). Interestingly, RGS12 
and RGS14 in addition to functioning as GAPs, can also act as GDIs (9, 
10). In 1999, Lanier and coworkers used yeast two-hybrid analysis to 
identify distinct receptor independent activators of G protein signaling or 
AGS proteins (11). Several members of this AGS family (AGS3-6) have 
been shown to function as GDIs of Gαi subunits (12). The observed GDI 
activity of both AGS and RGS proteins towards Gαi/o is attributed to a 19-
amino-acid consensus sequence called the GoLoco motif (9, 13, 14). 
Earlier in 1995, in an independent yeast two-hybrid screen, Mochizuki et 
al. established the interaction of a novel Golgi-resident Ca2+-binding 
protein Nucleobindin 1 or NUCB1, specifically with the heterotrimeric G 
protein α-subunit, Gαi2 (15). Subsequently, Lin et al. demonstrated that 
NUCB1 interacts exclusively with the adenylyl cyclase inhibitory (Gαi) 
and stimulatory (Gαs) classes of Gα subunits (16). In a recent study it was 
shown that overexpression of NUCB1 causes redistribution of only the 
Gαi1 subunits and not the Gβγ subunits to the plasma membrane and 
regulated secretion granules (17). However, a role of NUCB1 in 
modulating Gαi1 activation has not been observed so far. 
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NUCB1 is a 55 kDa multi-domain Ca2+-binding protein that was first 
identified as a novel B cell growth and differentiation factor associated 
with lupus syndrome (18). NUCB1 derives its trivial name, Calnuc, from 
its Ca2+-binding and DNA-binding ability (19). The DNA-binding domain 
of basic residues (172-218) lies at the N-terminus following the signal 
sequence. The Ca2+-binding domain is at the core of the protein sequence 
comprising of two EF hand motifs with an intervening acidic region (253-
316). The Ca2+-binding domain is followed by a leucine zipper domain 
(347-389), which has been postulated to induce NUCB1 dimerization (20) 
(Fig.1.1). The C-terminal (CT) region following the leucine zipper domain 
is predicted to be intrinsically disordered and unstructured (21). 
Intriguingly, NUCB1 is strongly conserved from flies to humans (22) and 
is widely distributed amongst Golgi (16, 23), nucleus (19, 24), 
endoplasmic reticulum (25, 26) and cytoplasm (17). The N-terminal signal 
sequence of NUCB1 targets it to different membrane compartments and its 
deletion renders NUCB1 cytosolic.  
 
Recently, Brodeur et al. reported the role of NUCB1 in LDLR related 
protein 9 (LRP9) trafficking where the cytosolic NUCB1 fraction helps in 
LRP9 endosomal sorting and prevents its delivery to lysosomes (27). The 
ubiquitous expression of NUCB1 in various cell and tissue types results in 
a diverse interactome comprising interacting partners like G protein α-
subunits, cyclooxygenases and amyloid precursor protein (16, 26-28). 
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Several classes of Gα subunits have been shown to interact with NUCB1 
(16, 26-28). Yeast-two hybrid experiments performed with various 
deletion constructs of either Gαi3 or NUCB1 mapped the CT α5 helix 
domain of G protein and the acidic region of NUCB1 (264-305) to be 
necessary for interaction (29). Immuno-fluorescence based studies showed 
that NUCB1 and Gαi protein subunits co-localize on the Golgi lumen and 
regulated secretion granules (17).  Since Gα subunits are ubiquitously 
involved in numerous signal transduction pathways in different tissue 
types, their interaction with NUCB1 might regulate downstream signaling 
events. 
 
We are interested in understanding the role of α5 helix of G protein α 
subunits in regulating nucleotide exchange rates (30-32). Since the α5 
helix of Gα is involved in interaction with NUCB1, we characterized and 
studied the interaction of NUCB1 with Gαi1 in detail. In the current study, 
we present the detailed biophysical and biochemical characterization of 
the Ca2+-binding ability and oligomeric state of a heterologously 
expressed N-terminally truncated soluble form of NUCB1, termed 
sNUCB1 (Fig.1.1). We show that sNUCB1 binds Ca2+ and exists as a 
dimer in solution. Ca2+-free sNUCB1 preferentially binds wild-type (WT) 
Gαi1 and inhibits its GDP release as demonstrated by several independent 
assays. We conclude that sNUCB1 serves as a novel Ca2+-regulated GDI 
 5 
of Gαi1. Our findings suggest that NUCB1 is involved in regulating 
cytoplasmic G protein signaling and trafficking. 
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1.1 MATERIALS AND METHODS 
1.1.1 REAGENTS 
Guanosine 5’-diphosphate (GDP) sodium salt and guanosine 5’-O-(3-
thiotriphosphate) (GTPγS) tetralithium salt were purchased from Sigma-
Aldrich (St. Louis, MO). The fluorescent GTPγS analogue, mant (2’,3’-O-
(N-methyl-anthraniloyl) - GTPγS was purchased from Jena Biosciences 
(Jena, Germany) whereas BODIPY (4,4-difluoro-4-bora-3a,4a-diaza-s-
indacene)-FL-GTPγS was purchased from Molecular Probes (Invitrogen). 
The His6-tagged truncation and point mutants of sNUCB1 were generated 
by site-directed mutagenesis using the high-fidelity thermostable DNA 
polymerase Pfu (Stratagene, CA). All reagents and chemicals used were of 
highest available purity. 
 
1.1.2. Heterologous expression of sNUCB1 and heterotrimeric G 
protein α-subunit Gα i1 
The cDNA clones for human NUCB1 and rat Gαi1 were obtained from 
ATCC and cDNA.org respectively. DNA fragment for the soluble form of 
NUCB1 or sNUCB1, corresponding to residues 31-461 of the human 
NUCB1 protein without the N-terminal signal sequence (residues 1-31) 
was cloned into the pET28a(+) expression vector (Amersham 
Biosciences). Similarly the DNA fragment corresponding to full-length 
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WT rat Gαi1 subunit (residues 1–354) was cloned into the pET28a(+) 
expression vector. The vector was used to transform BL21 (DE3) cells to 
express a N-terminal His6-tag protein containing a PreScission protease 
site directly after the His6-tag. The expressed construct for sNUCB1 
served as a template for introducing site-specific mutations using the 
Quick Change system (Stratagene, La Jolla, CA) to generate 
sNUCB1(W232A/W333A) or for introducing a missense mutation to 
generate the truncated version of the protein, namely sNUCB1(W333Ter). 
All proteins were expressed in BL21 (DE3) cells grown in the presence of 
50 µg / ml kanamycin. Cells were grown at 37 oC to A600nm of ~ 0.8 and 
then induced with 500 µ M isopropylthio-β-D-galactoside (IPTG) (US 
Biological). Post induction the culture was grown overnight at 17 oC and 
subsequently harvested. The resulting pellets were re-suspended in a 
buffer containing 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 50 mM β-
mercaptoethanol, bovine lung aprotinin (20 mg / ml), 2 mM 
phenylmethane sulfonyl fluoride (PMSF) and complete EDTA-free 
protease inhibitor cocktail tablets (Roche). Thereafter the cells were lysed 
and the expressed His6-tag protein was purified from crude extract by 
using affinity chromatography using Ni-NTA column pre-equilibrated 
with buffer A (50 mM Tris, pH 8.0, 150 mM NaCl, 50 mM β-
mercaptoethanol) for sNUCB1 and its variants and buffer A’ (50 mM Tris 
pH 8.0, 150 mM NaCl, 2 mM MgCl2•6H2O, 10 µM GDP, 50 mM β-
mercaptoethanol) for WT Gαi1. The bound His6-tag protein was eluted 
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from the column by using buffer A or buffer A’ supplemented with 500 
mM imidazole. The His6-tag was cleaved by a GST-tagged PreScissionTM 
protease, which was subsequently removed from the solution using GSH-
Sepharose column chromatography. In order to remove Ca2+ from 
sNUCB1 or its variants, the proteins were extensively dialyzed against 
buffer A supplemented with 5 mM EGTA and 1 mM EDTA, which were 
also eventually removed through dialysis. Finally, size exclusion 
chromatography (SEC) was done using Superdex200 26 / 60 HR column 
equilibrated with buffer S (50 mM Tris, pH 8.0, 150 mM NaCl) for 
sNUCB1 and its variants and equilibrated in buffer S’ (50 mM Tris, pH 
8.0, 150 mM NaCl, 2 mM MgCl2.6H2O, 10 µM GDP, 1mM DTT) for WT 
Gαi1 to obtain homogenously pure protein. The typical yield for sNUCB1 
and its variants was ~ 5-7 mg / L and for WT Gαi1 ~ 12-15 mg / L. The 
purity of the proteins was assessed by Coomassie brilliant blue staining 
after the proteins were separated through SDS-PAGE. The purity of all 
proteins was greater than 95%.  
 
1.1.3 Isothermal Titration Calorimetry (ITC) 
ITC was performed at 25 °C (298 K) using a MicroCal VP-ITC 
(MicroCal, Northhampton, MA) calorimeter. In order to measure 
quantitatively the binding of Ca2+ or WT Gαi1•GDP to sNUCB1, 2 ml of 
50 µM sNUCB1 (Ca2+-free) and 700 µl of either 500 µM CaCl2•6H2O 
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(prepared in 50 mM Tris, pH 8.0, 150 mM NaCl) or 600 µM WT 
Gαi1•GDP (prepared in 50 mM Tris, pH 8.0, 150 mM NaCl, 2 mM 
MgCl2.6H2O, 10 µM GDP, 1 mM TCEP) was used and thoroughly 
degassed. Contents of the sample cell were stirred continuously at 280 rpm 
during the experiment. A typical titration of sNUCB1 involved 50 
injections each of 5 µ l of CaCl2.6H2O (500 µM) or WT Gαi1•GDP (600 
µM) into a sample cell containing 1.4 ml of sNUCB1 (50 µM). The heat 
of dilution of the titrant (CaCl2•6H2O or WT Gαi1•GDP) was subtracted 
from the titration data for base-line correction. The base line-corrected 
data were analyzed with MicroCal OriginTM 6.0 software to determine 
the change in enthalpy (ΔH) and association constant (Ka). Thermal 
titration data fit showed two-sets of binding sites for Ca2+ to sNUBC1. 
Additionally, the data analysis also showed that one WT Gαi1•GDP 
subunit interacts with a dimer of Ca2+-free sNUCB1. The parameters were 
calculated based on 3 or more independent titration experiments. Each 
numerical value reported is the mean ± S.E.M. amongst the independent 
data sets.  
 
1.1.4 Size Exclusion Chromatography (SEC) 
Complex formation between sNUCB1 and WT Gα i1 
Complex formation between sNUCB1 and Gαi1 was monitored using 
SEC. 150 µM of sNUCB1 (- Ca2+ / +Ca2+) was incubated with 256 µM 
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Gαi1•(GDP / GTPγS) in 20 mM Tris, pH 8.0, 100 mM NaCl, 10 mM 
MgCl2, 10 µM GDP and 1 mM DTT at 30 oC for 20 min with minimal 
shaking to enable saturation binding. WT Gαi1 in the GTPγS-bound state 
was generated by incubating WT Gαi1•GDP with 5 mM GTPγS for 30 min 
at 30 oC to ensure complete exchange of nucleotide. Further the complete 
exchange was confirmed by AlF4¯ exchange assay. About 200 µl of the 
reaction mixture was injected onto a buffer equilibrated Superdex200 10 / 
30 GL column attached to AKTA FPLC (GE Healthcare) and run at 4 oC. 
Sample Elution was performed with the incubation buffer at a flow rate of 
0.5 ml / min with 0.35 ml fractions collected. Peak fractions were 
analyzed through SDS-PAGE followed by Coomassie staining to analyze 
the complex formation. 
 
Estimation of sNUCB1 molecular mass using heavy molecular weight 
standards 
Purified sNUCB1 or the heavy molecular weight standards (GE 
Healthcare) were injected onto a Superdex200 10 / 30 GL column pre-
equilibrated with Buffer S and the normalized absorbance of the eluting 
peak was plotted. A calibration curve of Kav [(Ve-Vo)/(Vc-Vo)] vs 
Log(molecular weight) was plotted, where Ve is the elution volume, Vo is 
the column void volume corresponding to the elution of Blue Dextran and 
Vc is the geometric column volume. The data were fit to a straight-line 
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curve like Y = A + Bx where A = 1.915 and B = 0.311 were obtained from 
the fit. Therefore for a Y = Kav value, the corresponding value of 
Log(Molecular weight) was obtained to estimate the molecular mass of 
sNUCB1 and sNUCB1(W333Ter). 
 
1.1.5 Light Scattering 
Multi-angle light scattering (MALS) and Dynamic Light Scattering 
(DLS) 
The light scattering data were collected using a Superdex200 10 / 30 HR 
SEC column (GE Healthcare, Piscataway, NJ), connected to High 
Performance Liquid Chromatography System (HPLC), Agilent 1200, 
(Agilent Technologies, Wilmington, DE) equipped with an autosampler.  
The elution from SEC was monitored by a photodiode array (PDA) UV / 
VIS detector (Agilent Technologies, Wilmington, DE), differential 
refractometer (OPT-Lab rEx Wyatt Corp., Santa Barbara, CA), static and 
dynamic, multiangle laser light scattering (LS) detector (HELEOS II with 
QELS capability, Wyatt Corp., Santa Barbara, CA).  The SEC-UV / LS / 
RI system was equilibrated in buffer (50 mM Tris, pH 8.0, 150 mM NaCl) 
for sNUCB1 alone and in buffer (50 mM Tris, pH 8.0, 100 mM NaCl, 10 
mM MgCl2, 10 µM GDP, 1 mM DTT) for WT and truncated sNUCB1 / G 
protein complex at the flow rate of 1.0 ml / min.  Two software packages 
were used for data collection and analysis: the Chemstation software 
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(Agilent Technologies, Wilmington, DE) controlled the HPLC operation 
and data collection from the multi-wavelength UV/VIS detector, while the 
ASTRA software (Wyatt Corp., Santa Barbara, CA) collected data from 
the refractive index (RI) detector and the LS detectors, and recorded the 
UV trace at 280 nm sent from the PDA detector. The weight-average 
molecular masses, Mw, were determined across the entire elution profile in 
the intervals of 1 s from static LS measurement using ASTRA software as 
previously described (33). The approach uses a Rayleigh-Debye-Gans 
light scattering model (equation 1), which relates the amount of scattered 
light to the concentration and weight average molecular weight of solute 
and second virial coefficient: 
   
€ 
K∗c
R(θ) =
1
Mw
+ 2A2c                                                 (1) 
where, R(θ) is the intensity of excess scattered light at angle θ, c is the 
concentration of the solute, Mw is the weight average molecular weight of 
the solute, A2 is the second virial coefficient, K* is an optical parameter 
equal to 
€ 
4π 2n2 (dn dc)
2
λ0
4NA
, where n is the refractive index, dn / dc is the 
refractive index increment for the solute,  NA  is Avogadro’s number, and 
λ0 is the wavelength of the scattered light.   
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DLS measurements were made “on line” at an angle of 100° with a 2 s 
collection time.  Time resolved scatter intensity fluctuations were analyzed 
using ASTRA Software (Wyatt Corp., Santa Barbara, CA), which 
implements the cumulants method (34) to determine the time dependence 
of diffusive motion also referred to as the intensity correlation function, 
G(T), (35): 
   
€ 
G(T) = B{1+α[exp(−DTq2t)]2}                                         (2) 
where, B is the average baseline intensity, α is an instrument-specific 
correction factor, DT  is the concentration-dependent translational 
diffusion constant of the solute, t is a delay time, and q is the scattering 
vector equal to 
€ 
4πn
λ
sinθ 2, where n is the refractive index of the solvent, 
λ is the wavelength of the scattered light and θ is the scattering angle. 
Equation 2 describes the relationship between the time dependency of 
fluctuation in scatter intensity and the translational diffusion coefficient.  
The value of DT can be used to estimate the apparent hydrodynamic radius 
of an equivalent sphere using Stokes-Einstein relationship (equation 3):  
   
€ 
Rh =
kT
6πηDT
                                                          (3) 
where, k is the Boltzmann constant, T is the absolute temperature, and η is 
the temperature corrected viscosity of the solution.   
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Determination of dimerization equilibrium constant from SEC-
UV/LS/RI 
The concentration dependent changes in the weight-average molar mass 
(Mw) determined for the apex of the eluting peak for sNUBC1 were used 
to determine the dimerization constant. The weight-average molar masses 
were plotted as a function of protein concentration for sNUCB1; error bars 
represent ± 3 % of Mw for concentration above 100 µg / ml; ± 5 % of Mw 
for concentration between 1-100 µg / ml and ± 10 % of Mw for 
concentration below 1 µg / ml. Lines represent the non-linear least-square 
fits to a monomer-dimer association model for sNUCB1 dimerization. 
 
Determination of Kd of complex formation from SEC-UV / LS / RI 
The concentration dependent changes in the weight average molar mass 
(Mw) determined for the apex of the eluting peak were used to determine 
the complexation of Gαi1 with sNUCB1 / sNUCB1(W333Ter). The 
weight-average molar mass values were plotted as a function of total 
protein concentration for complexation; error bars represent ± 3 % of Mw 
for concentration above 100 µg / ml; ± 5 % of Mw for concentration 
between 1-100 µg / ml and ± 10 % of Mw for concentration below 1 µg / 
ml. Lines represent the non-linear least-square fits to a stimulated 
complexation model using Origin 6.0. 
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1.1.6 Steady State Fluorescence Spectroscopy 
Steady-state Trp fluorescence upon Ca2+-binding 
Steady-state fluorescence measurements for sNUCB1 were carried out in a 
SPEX τ3 spectrofluorimeter (Jobin-Yvon Instruments, NJ) at 25 °C. The 
excitation wavelength was set at 295 nm, while emission spectra were 
collected from 310 nm to 460 nm. The excitation and emission slit widths 
were 2.5 nm and 5.0 nm, respectively. 178 nM of Ca2+-free sNUCB1 
equilibrated in buffer containing 50 mM Tris, pH 8.0, 100 mM NaCl was 
incubated with increasing concentrations of Ca2+ with constant stirring for 
5 min. Thereafter, Trp emission fluorescence spectra were collected for 
each concentration of Ca2+ added.  
 
Quenching of tryptophan fluorescence by small molecule quenchers 
The excitation wavelength was set at 295 nm and the emission spectra 
were collected from 315-460 nm with the excitation slit and emission slit 
width being 2.5 nm and 5 nm, respectively. 333 nM of protein was 
equilibrated in buffer containing 50 mM Tris, pH 8.0 and 100 mM NaCl. 
In order to study the interaction between the protein and the quenchers, 
small aliquots of the quenchers were added incrementally from a 
concentrated stock solution. In the case of potassium iodide, a small 
quantity of Na2S2O3 (0.1 mM) was added to prevent it from forming free 
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triiodide (I3-). The accessibility of Trp was monitored by analyzing the 
quenching data using Stern-Volmer equation (equation 4): 
                                 F0 / F = 1+ KSV [Q]                                      (4)                             
Where F0 and F are the fluorescence intensities in the absence and 
presence of quenchers respectively, [Q] is the concentration of the 
quenching molecules and KSV is the Stern-Volmer quenching constant. In 
the case of purely collisional quenching mechanism, the Stern-Volmer plot 
of F0 / F versus [Q] is linear with a slope equal to KSV. 
 
Fluorescence-based mant-GTPγS (mGTPγS) binding assays 
Steady-state fluorescence measurements experiments were carried out in a 
SPEX τ3 spectrofluorimeter (Jobin-Yvon Instruments, NJ) at 25 °C. 15 
µM of WT Gαi1 was incubated with 50 µM of sNUCB1(W232A/W333A) 
in the reaction buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 2 mM 
MgCl2 and 1 mM DTT) for 5 min with constant stirring. Thereafter, 
mGTPγS (15 µM) was added to the reaction mixture. FRET was 
monitored by exciting the intrinsic Trp fluorescence at 295 nm and 
measuring the fluorescence emission from 310 nm to 540 nm. In all cases, 
blank spectra containing buffer with sNUCB1(W232A/W333A) alone 
were subtracted from the final spectra.  
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1.1.7 Time based fluorescence spectroscopy 
Time-based fluorescence measurements were performed in a SPEX 
Fluorolog-2 spectrofluorometer (SPEX Industries, Edison, NJ) at 25oC. 
The excitation wavelength was set at 295 nm specifically for Trp residues, 
while emission wavelength was set at 340 nm. The excitation and 
emission slit width were 5 nm each. 
 
AlF4¯ uptake assay 
WT Gαi1 was incubated at 25oC in reaction buffer K (50 mM Tris-HCl, 
pH 8.0, 150 mM NaCl, 2 mM MgCl2 and 1 mM DTT) with increasing 
amounts of sNUCB1(W232A/W333A) for 10 mins with constant stirring. 
Thereafter for AlF4¯ dependent activation of Gαi1, a premixed solution of 
AlCl3¯ (20 mM) and NaF (1 M), respectively, was injected at 180 s. A 
time course of enhancement in Trp fluorescence coupled to activation was 
monitored in the presence of increasing concentrations of 
sNUCB1(W232A/W333A) in the reaction mixture. 
 
GTPγS nucleotide exchange assay 
WT Gαi1 was incubated at 25 oC with increasing concentration of 
sNUCB1(W232A/W333A) in reaction buffer K for 10 min with constant 
stirring. The base line fluorescence was monitored for 200 s after which 
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GTPγS (20 µM) was injected into the reaction mixture and the relative 
increase in intrinsic Trp fluorescence (λex = 295 nm, λem = 340 nm) was 
measured as a function of time for each concentration of 
sNUCB1(W232A/W333A). 
 
BODIPY-FL-GTPγS nucleotide exchange assay 
WT Gαi1 (20 µM) was incubated at 25oC in reaction buffer K with 
increasing concentration of Ca2+-free sNUCB1 for 10 min with constant 
stirring. BODIPY -FL-GTPγS (20 µM) was added to the reaction mixture 
and the relative increase in intrinsic fluorescence (λex = 485 nm, λem = 512 
nm) was measured for each concentration of Ca2+-free sNUCB1 as a 
function of time. 
 
BODIPY FL-GTPγS nucleotide binding assay 
WT Gαi1 (20 µM) was incubated alone and with Ca2+-free sNUCB1 (100 
µM) at room temperature in reaction buffer K. 10 µl samples were 
withdrawn from each reaction mixture at various time points and loaded 
onto a pre-equilibrated ZebaTM micro-desalt spin columns to remove the 
unbound nucleotide. The columns were spun at 1000 g for 1 min and the 
flowthrough collected. The amount of bound nucleotide in each 
flowthrough was measured by using BODIPY absorbance at 504 nm (ε = 
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80,000 M-1 cm-1). The absorbance at 280 nm was also monitored to ensure 
that the same amount of protein was being collected in each flowthrough 
sample. 
 
1.1.8 Circular Dichroism (CD) Spectroscopy 
Wavelength scan: All CD experiments were performed using an Aviv 
62A DS CD spectrophotometer. Far-UV CD spectra were recorded at the 
end of each kinetic run. Spectra were recorded over the wavelength range 
of 190-250 nm at 1 nm intervals with an averaging time of 3 s using a 0.1 
cm path length cell. Background spectrum was subtracted from each of the 
collected data sets. Each spectrum obtained was an average of 3 scans. 
The recorded spectra in millidegrees of ellipticity was converted to mean 
residue ellipticity in deg.cm2dmol-1 using the following equation (equation 
5): 
                             
€ 
θ[ ] = θ10 × c × l × n                                                         (5) 
where [θ] is the mean residue ellipticity in deg*cm2dmol-1, θ is the 
ellipticity in mdeg, c is the concentration in M, l is the path length in cm 
and n is the number of peptide bonds. 
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Thermal unfolding: The unfolding of the protein (8 µM) with temperature 
was monitored using CD at a wavelength of 222 nm, which is 
characteristic of an α-helix. The data points were averaged over 30 s for 
every unit increment in temperature. A plot of CD signal versus 
temperature was fit to the equation (equation 6): 
    
€ 
f (T) =
αN + βN ×T + (αD + βD ×T)•e
−ΔGD−No (T)
RT
1+ e −ΔGD−N
o (T)
RT
                             (6)                            
where,     
€ 
−ΔGD−No (T) = −ΔHD−No (Tm )∗ (1−
T
Tm
) −ΔCpo ∗{(Tm −T) + T ∗ ln
T
Tm
} 
f(T) is the signal as a function of temperature, T is the temperature, R is 
the gas constant, αN defines the intercept and βN is the slope of the post-
transition region of the curve, αD defines the intercept and βD is the slope 
of the pre-transition region of the curve, ΔGo is the free energy change for 
the unfolding reaction, ΔHoD-N is the change in enthalpy for unfolding at 
the Tm and ΔCpo is the change in heat capacity. Using the above 
expressions, Tm, the mid-point transition temperature was estimated along 
with the change in enthalpy ∆HoD-N, for the unfolding reaction at that Tm.  
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1.1.9 Radioligand [GTPγ35S] based nucleotide-exchange assay 
The effect of Ca2+-free sNUCB1 or Ca2+-free sNUCB1(W333Ter) binding 
to WT Gαi1•GDP on the nucleotide exchange was monitored using 
[35S]GTPγS exchange assay. 20 µM WT Gαi1•GDP alone or with 100 µM 
of Ca2+-free sNUCB1 / sNUCB1(W333Ter) was incubated in Buffer (10 
mM Tris pH 7.5, 100 mM NaCl, 2 mM MgCl2, 2 mM DTT) for 20 min at 
30 oC. After incubation, [35S]GTPγS solution diluted with GTPγS was 
added to the reaction mixtures such that the final GTPγS concentration in 
each reaction mixture was 100 µM with an associated radioactivity of 50 
nCi / 8 µ l of reaction volume. Thereafter 8 µ l samples (50 nCi) were 
withdrawn from each reaction mixture and added to Buffer equilibrated 
nitrocellulose filters. Subsequently, the filters were extensively washed 
with Wash Buffer (50 mM Tris pH 7.5, 5 mM MgCl2) to remove excess 
radioligand. For data analysis the counts were recorded and the value for 
buffer alone was subtracted from each reading. Each individual data point 
was scaled to the value of radioactivity within 8 µl of reaction volume to 
get the pmoles of radioligand bound to WT Gαi1 in each reaction. As a 
positive control, the CT GoLoco motif peptide from RGS14 namely 
R14GL(496-531) was used in an identical experimental setup. 
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1.1.10 Analytical UltraCentrifugation (AUC) 
Sedimentation equilibrium studies were carried out at different centrifugal 
speeds and protein concentrations for sNUCB1 and sNUCB1(W333Ter). 
AUC experiments for sNUCB1 (- / +Ca2+) were done at 25oC with protein 
concentrations of 50 µM, 100 µM and 150 µM each at speeds of 20,000 
rpm, 30,000 rpm and 40,000 rpm. Similarly for sNUCB1(W333Ter), AUC 
experiments were done with 32 µM, 70 µM and 150 µM protein 
concentrations each at speeds of 25,000 rpm, 30,000 rpm and 40,000 rpm. 
The individual protein samples were run for sufficiently long periods of 
time to allow for the equilibrium to generate a time invariant concentration 
gradient balanced by diffusion of the macromolecular species. The speeds 
were decided based on the molecular weight of the protein. Under no net 
transport conditions, the following correlation should be observed between 
concentration and the radial distance (36) (equation 7): 
 
€ 
Cr = Cro ∗e
(σ ∗ r)
2 (r
2 − ro2)  (7) 
where,  
€ 
σ = M(1−νρ)∗ ω
2
RT  
Cr is the concentration of macrosolute at any radial distance r, Cro is the 
concentration of the macrosolute at the reference radial distance r0, ν is the 
partial specific volume, ω is the angular velocity, ρ is the density, R is the 
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gas constant, T is the absolute temperature and M is the molecular mass. 
The data were analyzed using OptimaTM XL-A/XL-I Data Analysis 
Software (Beckman, 2001). 
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1.2 RESULTS 
1.2.1 Ca2+-binding to EF hand domains of sNUCB1 induces 
conformational changes 
A soluble form of NUCB1 namely sNUCB1 was engineered, expressed in 
E.coli and purified to homogeneity (Figs. 1.1, 1.2A). The domain 
architecture of sNUCB1 shows two EF hand Ca2+-binding regions 
sandwiched between a N-terminal DNA binding domain and a CT leucine 
zipper (20). The thermodynamics of Ca2+-binding to sNUCB1 were 
studied using Isothermal Titration Calorimetry (ITC). The Ca2+ binding 
was exothermic with ΔH1° = -2.1 ± 0.06 kcal mol-1 and ΔS1°  = 16.5 cal 
mol-1 K-1 for the first EF hand and ΔH2°  = -0.62 ± 0.31 kcal mol-1 and 
ΔS2°  = 17.1 cal mol-1 K-1 for Ca2+ binding to the second EF hand, 
suggesting a spontaneous uptake of Ca2+ by Ca2+-free sNUCB1. The 
recorded data were best fit to a “two-set of binding sites” model giving Kd 
values of 6.3 µM and 73.5 µM for Ca2+-binding (Fig. 1.2B). The 
difference in binding affinities arises due to the presence of a non-
canonical Arg residue substituting for the canonical Gly at the sixth 
position of the 12-residue Ca2+-binding loop of the second EF hand. Our 
results show that the two EF hands in sNUCB1 bind to Ca2+ differentially 
with an order of magnitude difference in their Kd values. In 2004, de Alba 
et al. heterologously expressed and purified only the EF hand domain 
(228-326) of NUCB1 and also reported two Ca2+-binding sites with 
different affinities (21).  
 25 
 
 
 
 
 
 
 
 
 
Figure 1.1. Domain architecture of human NUCB1 and engineered 
NUCB1 variants  (A) The modular nature of the NUCB1 protein 
structure is depicted schematically with its N-terminal signal sequence 
(grey square), putative DNA binding domain (green square), two EF hand 
loops (magenta rectangles), acidic region (blue oval) and leucine zipper 
domain (yellow hexagon).  The amino acid residues at domain borders are 
numbered.  We engineered a construct for expression in E. coli of a 
soluble form of NUCB1 that included an N-terminal hexa-His tag and a 
PreScission protease recognition sequence with an intervening spacer 
sequence as shown.  Endoprotease cleavage yields a soluble form of 
NUCB1 that begins with the amino acid sequence GPHMAS and 
continues with the remainder of the native sequence beginning at Gly32.  
We refer to this expressed protein construct as soluble NUCB1 or 
sNUCB1 throughout the text.  We also constructed a Trp double-
replacement mutant sNUCB1(W232A/W333A) and a truncation mutant 
sNUCB1(W333Ter) as shown. 
 
 26 
The EF hand regions undergo conformational changes upon Ca2+-binding, 
which can be monitored through change in intrinsic Trp fluorescence of 
sNUCB1. sNUCB1 has two Trp residues at position 232 and 333 lying 
sequentially before and after the EF hand domain, respectively. Steady-
state fluorescence measurements show a blue shift of 15 nm and an 
enhancement in fluorescence intensity as more Ca2+ was added to Ca2+-
free sNUCB1 (Fig. 1.2C). Thus, Ca2+-binding causes a conformational 
change in sNUCB1 causing reorientation of the Trp residues from a 
solvent exposed polar to a hydrophobic environment. Fluorescence 
quenching experiments with acrylamide and iodide were performed to 
probe these conformational changes around the Trp residues upon Ca2+ 
binding. Acrylamide is a diffusible neutral quencher of Trp fluorescence 
unaffected by the charges surrounding the fluorophore. I-, on the other 
hand, is an anionic quencher for surface exposed fluorophores only (37).  
Quenching experiments show that Trp residues are more accessible to 
acrylamide than I- for quenching. On binding to Ca2+, acrylamide 
quenching decreases much more than I- quenching (Fig. 1.2D). F0 / F vs 
quencher concentration gave a straight-line indicative of a dynamic 
quenching rather than static quenching. These observations suggest that 
conformational changes associated with Ca2+-binding make Trp residues 
less accessible by reorienting them into a hydrophobic environment. 
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Figure 1.2. Purification and effect of Ca2+-binding to sNUCB1. (A) 
The SDS-PAGE analysis of sNUCB1 shows a single band after final step 
of purification. The protein band migrates at ~ 51 kDa. sNUCB1 possesses 
two Ca2+-binding EF hand motifs. (B) We used isothermal titration 
calorimetry (ITC) to measure the Ca2+ binding affinity of sNUCB1. 
sNUCB1 presumably binds one Ca2+ cation at each of its two EF hand 
domains and a non-linear least squares fit of the calculated values using 
the “two-set of sites” model resulted in an excellent fit as shown in the 
inset.  The calculated dissociation constants for Ca2+-binding to the two 
EF hand domains of sNUCB1 are 6.3 ± 0.18 µM and 73.5 ± 0.19 µM. (C) 
Ca2+-free sNUCB1 was used for determining the conformational changes 
associated with Ca2+-binding to sNUCB1. 178 nM sNUCB1 was titrated 
with increasing amounts of Ca2+ while fluorescence emission was 
collected from 310 to 460 nm with the excitation set at 295 nm. Black 
trace indicates Ca2+-free sNUCB1, while the red, green, navy blue, yellow, 
light blue and pink traces represent 1 mM, 2 mM, 5 mM, 7 mM, 10 mM 
and 15 mM Ca2+ added to the protein solution. Inset: Change in the 
fluorescence intensity is indicated by black circles, while the red circles 
indicate the blue shift of the Trp fluorescence. With increasing 
concentration of Ca2+, the emission intensity enhanced by 50%, while 
there was a 15 nm blue shift on binding to Ca2+ to sNUCB1 indicative of 
the movement of Trp residues from a polar environment to a non-polar, 
hydrophobic region. (D) We measured the accessibility of Trp residues of 
sNUCB1 to small molecule quenchers, acrylamide and iodide, in the 
presence and absence of Ca2+. Steady-state fluorescence measurements 
were done at 25 °C with the excitation at 295 nm, while the emission 
spectra were collected from 315 nm to 460 nm. Stern-Volmer plot was 
calculated by taking the emission maxima at 330 nm. The top panel shows 
the quenching of sNUCB1 Trp residues in the presence (black trace) and 
absence (red trace) of Ca2+. The bottom panel shows quenching of 
sNUCB1 Trp residues by ionic quencher iodide in the presence (black 
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trace) and absence (red trace) of Ca2+. Fo / F vs quencher concentration 
gave a straight line indicative of a dynamic quenching rather than static 
quenching. The quenching by acrylamide both in the presence and absence 
of Ca2+ was larger than the iodide showing that the two Trp residues are in 
different environments. Ca2+-binding to sNUCB1 caused a considerably 
greater decrease in the observed acrylamide quenching relative to iodide. 
This shows that the conformational change associated with Ca2+-binding 
reorients the Trp residues in an environment inaccessible to either 
quencher. 
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Figure 1.2 
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The binding of Ca2+ to an EF hand motif forms an octahedral co-
ordination sphere, which can cause structural rearrangement in the protein 
(38). This secondary structural change can in principle be followed by 
circular dichroism (CD) spectroscopy. Ca2+-binding to sNUCB1 causes 
only a slight increase in helicity. Intriguingly, the far-UV CD spectra of 
sNUCB1 show a smooth structural transition from an α-helical secondary 
structure at lower concentrations to a predominant β-sheet structure at 
higher concentrations. These concentration-dependent structural changes 
were observed both in the absence and presence of Ca2+ (Fig. 1.3A). 
Furthermore, the thermal unfolding data for sNUCB1 showed an increase 
in apparent Tm of 4 oC on binding to Ca2+. The folding of sNUCB1 was 
observed to be non-cooperative and irreversible both in the absence and 
presence of Ca2+ (Fig. 1.3B). The increase in stabilization on binding to 
Ca2+ suggests a structural ordering of sNUCB1.  
 
1.2.2 NUCB1 is a dimer 
The domain diagram of NUCB1 reveals the presence of a CT-domain 
leucine zipper, which is a canonical structural motif known to cause 
dimerization (39) (Fig. 1.1). The oligomeric state of NUCB1 was 
evaluated through sedimentation equilibrium experiments using Analytical 
Ultra-Centrifugation (AUC). This experiment is insensitive to the shape of 
the molecule, and directly reports on the molar mass of the sedimenting  
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Figure 1.3. Secondary structure transition in sNUCB1 (- / + Ca2+) with 
increasing concentration. Far-UV circular dichroism spectra of (A) Ca2+-
free or (B) Ca2+-bound sNUCB1 were collected with increasing 
concentration. At lower concentrations, i.e. 4 µM (red), 8 µM (green), 16 
µM (yellow) and 24 µM (blue), CD spectra show that sNUCB1 is mainly 
helical. At 32 µM (pink), the CD spectrum shows a reduction in the helical 
content. Higher concentrations of sNUCB1, i.e. 40 µM (cyan), 50 µM 
(brown) and 64 µM (orange), show primarily β-sheet secondary structure. 
We also monitored thermal unfolding of sNUCB1. (B) Thermal unfolding 
transitions of recombinant Ca2+-free (top) and Ca2+-bound (bottom) 
sNUCB1 (8 µM) were monitored by recording CD signal at 222 nm at a 
heating rate of 1 oC / min. The trace is indicative of a multistep non-
cooperatively folded protein. The Tm for the Ca2+-bound sNUCB1 is 
higher than Tm for the Ca2+-free protein, indicating the enhanced stability 
of the protein in the Ca2+-bound state. (C) The CD spectrum for 
sNUCB1(W333Ter) at 50 µM concentration displays a majorly helical 
secondary structure. In each experiment, the spectrum for buffer (50 mM 
Tris pH 8.0, 150 mM NaCl) alone was subtracted from each of the spectra. 
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species characterized by Boltzmann distribution. Sedimentation 
equilibrium measurements were performed with Ca2+-free sNUCB1 for 
concentrations varying from 50 µM to 150 µM. The data could be well fit 
to a monomer-Nmer model, which gave a molecular mass of ~100 kDa 
corresponding to a dimer of sNUCB1 in solution (Fig. 1.4A). AUC 
analysis of Ca2+-bound sNUCB1 indicated that it is also primarily dimeric 
in solution (Fig. 1.4A, inset). In order to confirm that the dimerization of 
sNUCB1 is caused by the leucine zipper domain, a CT truncation mutant, 
sNUCB1(W333Ter), lacking the leucine zipper was designed and 
heterologously expressed. The far-UV CD spectrum of 
sNUCB1(W333Ter) showed an α-helical secondary structure even at high 
protein concentrations in contrast to the concentration dependent transition 
observed for sNUCB1 (Fig.1.3C). AUC analysis of sNUCB1(W333Ter) 
revealed a monomeric species in solution over the concentration range of 
32µM to 150µM (Fig. 1.4B). Similar to sNUCB1, the association state of 
sNUCB1(W333Ter) was unaffected upon binding to Ca2+. The 
experiments with the truncation mutant confirm that the leucine zipper 
domain of sNUCB1 is essential for the dimeric state of the protein in 
solution.  
 
The thermodynamics of the dimerization of sNUCB1 was further 
investigated using Multi-Angle Light Scattering (MALS). In a series of 
size-exclusion chromatography (SEC) experiments, Ca2+-free sNUCB1 
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was analyzed by gel filtration using a Superdex 200 10/30 HR column. 
The eluted protein peak was fractionated and subjected to MALS analysis 
at seven different angles to estimate the molecular mass of the eluting 
species. As shown in Fig.1.4C, a gradual increase in the weight-average 
molecular mass of the eluting species was observed with increasing 
concentration of the protein. At concentrations around 10 nM, sNUCB1 
exists as a monomer. As the concentration is gradually increased, a 
monomer-dimer equilibrium is observed with dimeric sNUCB1 
dominating at concentrations greater than 1µM. The data collected at 
different angles for each run were fit to a monomer-dimer equilibrium 
model giving a dissociation constant, Kd of dimerization, for sNUCB1 of 
0.26 ± 0.12 µM. sNUCB1(W333Ter) in MALS measurements continued 
to exist as a monomer even at high protein concentrations. Thus the 
leucine zipper region is responsible for the dimeric state of sNUCB1 in 
solution under physiological conditions.  
 
1.2.3 sNUCB1 is structurally asymmetric with an elongated CT  
Ca2+-free sNUCB1 in SEC experiments elutes at a much higher volume 
than a globular protein with molecular mass similar to that of a sNUCB1 
monomer or a dimer (Fig. 1.4D). A plot of the elution parameter, Kav, vs 
log(molecular mass) for a number of globular protein standards was 
utilized to estimate an apparent molecular mass of 300 kDa for sNUCB1  
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Figure 1.4. sNUCB1 forms a stable non-globular dimer mediated by 
its leucine zipper domain. (A) We carried out analytical 
ultracentrifugation (AUC) experiments to determine the oligomeric state 
of sNUCB1 in solution.  The sedimentation equilibrium plot for Ca2+-free 
sNUCB1 (50 µM monomeric concentration) shows the evolution of a 
sample concentration curve resulting from the applied centrifugal force.  
The data were fit to a monomer-Nmer equilibrium model, which gave a 
measured molecular mass of 98.9 ± 0.41 kDa, consistent with a dimeric 
structure for sNUCB1 in solution (the theoretical molecular mass of 
monomeric sNUCB1 is ~51 kDa).  The inset shows the sedimentation 
equilibrium plot for Ca2+-bound sNUCB1, which gave essentially an 
identical molecular mass of 99.4 ± 0.78 kDa. Thereafter, (B) AUC 
experiments were carried out on the truncation mutant, 
sNUCB1(W333Ter), which lacked the Leucine zipper domain in the C-
terminal region of the protein.  The AUC sedimentation equilibrium plot 
for Ca2+-free sNUCB1(W333Ter) (70 µM monomeric concentration) gave 
a molecular mass of 35.2 ± 0.05 kDa, consistent with a monomeric species 
in solution (the theoretical molecular mass of sNUCB1(W333Ter) is ~36.8 
kDa). (C) We studied the monomer-dimer equilibrium of sNUCB1 with 
multi-angle light scattering (MALS) of fractions with increasing protein 
concentration collected from Superdex200 10/30 HR size exclusion 
chromatography in 50 mM Tris-HCl (pH 8.0), 150 mM NaCl. The weight-
average molecular mass of the complex at a given protein concentration 
was determined from a non-linear least-square fit of a collection of values 
determined for the apex fractions of each eluting peak. A monomer-dimer 
association model of the values as a function of sNUCB1 concentration 
gave an apparent dissociation constant (Kd) for dimerization of 0.26 ± 0.12 
µM.  The error bars indicate the extent of variation in molecular mass 
determination originating from the light scattering measurement. (D) SEC 
of sNUCB1, heavy molecular weight standards along with known globular 
proteins was done using a Superdex200 10/30 HR column. Proteins were 
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individually injected onto the column and the elution profile for each 
protein was recorded as a function of elution volume. The void volume 
(Vo) of the column was derived from the elution of Blue Dextran, whereas 
elution volume (Ve) for each protein was obtained from the corresponding 
peak for each sample. In order to estimate the molecular mass of sNUCB1 
and sNUCB1(W333Ter), a calibration curve was prepared by plotting Kav 
[(Ve-Vo)/(Vc-Vo)] vs Log(molecular weight) where Vc is the geometric 
volume of the column. The data were fit to a linear equation. The 
estimated molecular mass of sNUCB1 and sNUCB1(W333Ter) were 
obtained from the plot by using their corresponding Kav values. The 
estimated masses suggest that sNUCB1 has a non-globular structure due to 
which it elutes at a higher volume compared to globular proteins of similar 
masses. We next measured dynamic light scattering (DLS) chromatograms 
for (E) sNUCB1 and (F) sNUCB1(W333Ter).  Each protein sample was 
injected onto a Superdex200 10/30 HR column and the refractive index 
detector was used to analyze the protein peak.  The change in refractive 
index as a function of protein concentration was used to compute the 
molecular mass as shown in green for sNUCB1 and red for 
sNUCB1(W333Ter). The molecular mass corresponds to a dimer for 
sNUCB1 and a monomer for sNUCB1(W333Ter).  The insets show the 
correlation functions as each protein diffuses through the solution in the 
DLS experiment. The diffusion coefficient from the correlation function 
gives the hydrodynamic radius (Rh) using Stokes equation.  The computed 
Rh values were 6.2 nm and 3.03 nm for sNUCB1 and sNUCB1(W333Ter), 
respectively.   
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Figure 1.4 
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(Fig.1.4D). This implies that either sNUCB1 exists as a trimer of dimers 
(3 x 100 kDa) or is asymmetric in its shape. Since AUC and MALS 
analysis convincingly ruled out any association of sNUCB1 dimers into 
higher order structures, we proceeded to derive structural information on 
sNUCB1 through Dynamic Light Scattering (DLS). DLS analysis of Ca2+-
free sNUCB1 yields a hydrodynamic radius (Rh) of 6.2 nm and a frictional 
coefficient (f/fo) of 2.03 (Fig.1.4E). The frictional coefficient of globular 
proteins usually lies in the range of 1.1 - 1.25 (40). A value of 2.03 for 
sNUCB1 indicates an asymmetric shape for the dimer, deviating 
considerably from a sphere. Interestingly, Ca2+-free sNUCB1(W333Ter) 
has a Rh of 3.3 nm and a f/fo of 1.59 showing that the deletion of CT 
domain reduces the radius of hydration by almost 50% (Fig. 1.4F). This 
suggests that while the N-terminus of sNUCB1 is relatively more compact 
and globular, the CT domain of the protein is elongated, contributing to 
the observed asymmetry in the shape of sNUCB1.  
 
1.2.4 sNUCB1 selectively interacts with GDP-bound WT Gα i1 in the 
absence of Ca2+ 
NUCB1 is a Ca2+-binding protein that has been shown to interact with Gi 
and Gs classes of α-subunits (16). Physiologically, Gα subunits can 
individually exist both in the “inactive” or GDP-bound state and the 
“active” or GTP-bound state. To investigate the interaction of sNUCB1 
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with WT Gαi1, sNUCB1 was incubated with WT Gαi1•GDP (Fig. 1.5, top 
left) and WT Gαi1•GTPγS (Fig. 1.5, top right), respectively, and the 
complex formation was analyzed by SEC using a Superdex200 10/30 HR 
column. As shown in the top panels of Fig. 1.5, the Coomassie stained 
gels of the fractionated peaks show elution of the complex containing both 
sNUCB1 and Gαi1 with excess Gαi1 fractionating at higher elution 
volume. The amount of Gαi1 eluting with sNUCB1 was significantly 
higher when Gαi1 was present in the GDP-bound state rather than in the 
GTPγS-bound state. Thus Ca2+-free sNUCB1 preferentially interacts with 
Gαi1 in the GDP-bound form. Interestingly, the interaction with Gαi1 in 
both the GDP- and GTPγS-bound states is absent when sNUCB1 is bound 
to Ca2+ as shown in the lower panels of Fig. 1.5. The two protein subunits 
elute out as individual components as the complex is disrupted in the 
presence of Ca2+. The inhibition of the complex formation between 
sNUCB1 and Gαi1 in the presence of Ca2+ can be explained by the 
structural rearrangement of EF hands upon Ca2+-binding. Yeast two-
hybrid analysis for interaction of Gα with deletion mutants of NUCB1 as 
bait proposed the EF hand intervening acidic region of NUCB1 to be 
involved in G protein binding (16). The conformational change induced 
upon Ca2+-binding can possibly result in the masking of the acidic region 
sandwiched between the two EF hands, thereby making it inaccessible for 
G protein binding.  
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The thermodynamics of Ca2+-free sNUCB1 complex formation with 
Gαi1•GDP was investigated using ITC. The exothermic nature of the 
reaction shows a thermodynamically favorable binding event between the 
two protein subunits with ΔHo = -1.45 ± 0.17 kcal mol-1 and ΔSo = 16.9 
cal mol-1 K-1. The data were best fit to a “one-set of binding sites” model 
with dimeric sNUCB1 and monomeric G protein as the interacting 
partners. The fit provides a Kd value of 18.3 ± 1.45 µM suggesting that 
sNUCB1 interacts relatively weakly with GDP-bound Gαi1 (Fig.1.6A). 
The association between Ca2+-free sNUCB1 and Gαi1•GDP was also 
monitored using light scattering. Protein samples with increasing 
concentrations of sNUCB1-Gαi1•GDP complex were injected onto a 
Superdex200 10/30 HR column and MALS was done on the complex 
elution peak. The analysis shows that binding of Gαi1•GDP to sNUCB1 
initiates only after dimerization of Ca2+-free sNUCB1. At lower 
concentrations, dimerization of sNUCB1 from molecular mass of 50 kDa 
to 100 kDa was traced. Once the dimer was formed, binding of one 
Gαi1•GDP subunit to sNUCB1 was evident from increase in molecular 
mass to 140 kDa (Fig.1.6B). The trace observed for sNUCB1-Gαi1•GDP 
complex formation can be understood from the experimental Kd values. 
The Kd for sNUCB1 dimerization is much smaller than Kd for binding to 
Gαi1•GDP, resulting in sNUCB1 dimerization prior to Gαi1•GDP binding. 
However sNUCB1-Gαi1•GDP association curve does not rule out the 
ability of sNUCB1 monomer to interact with Gαi1•GDP.  
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Figure 1.5.  sNUCB1 forms a stable complex with Gα i1•GDP only in 
the absence of Ca2+.  We used size-exclusion chromatography to 
determine the nature of the interaction between sNUCB1 and Gαi1 in 
solution under several conditions. sNUCB1 and Gαi1•GDP were incubated 
together in the absence (upper left), or presence (lower left) of Ca2+ and 
the mixture was subjected to size-exclusion chromatography using a 
Superdex200 10/30 HR column.  Peak fractions were analyzed by SDS-
PAGE with Coomassie-brilliant blue staining as shown in the insets.  In 
the absence of Ca2+, sNUCB1 and Gαi1•GDP formed a complex as judged 
by (i) the slight shift (from approximately 11.2 ml to 10.6 ml) and 
enhancement of the peak containing only sNUCB1 in the presence of 
Ca2+, and both sNUCB1 and Gαi1, in the absence of Ca2+, and (ii) the 
depletion, in the absence of Ca2+, of the peak eluting at about 14.6 ml, 
which contained only Gαi1.  The same experiment was repeated with 
sNUCB1 and Gαi1•GTPγS in the absence (upper right), or presence (lower 
right) of Ca2+.  Although the same general trend and Ca2+ dependency 
were observed, the apparent ability of Gαi1•GTPγS to form a stable 
complex with sNUCB1 was markedly diminished compared to that of 
Gαi1•GDP.   
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MALS experiments were also conducted with the monomeric truncation 
mutant sNUCB1(W333Ter). A plot of the weight-average molecular mass 
obtained from light scattering plotted vs the protein concentration shows 
that monomeric Ca2+-free sNUCB1(W333Ter) forms a 1:1 complex with 
Gαi1•GDP. The fit yields a Kd value of 1.99 ± 0.26 µM showing that the 
interaction of sNUCB1 with WT Gαi1•GDP becomes stronger on deletion 
of the CT region of sNUCB1 (Fig.1.6C). This suggests that the CT region 
of sNUCB1 possibly acts as a regulatory domain modulating the 
interaction of sNUCB1 with G protein α-subunit. Alternatively, the 
structural rearrangement associated with dimerization can also result in the 
reduced affinity of sNUCB1 for Gαi1 in comparison with 
sNUCB1(W333Ter).  
 
1.2.5 sNUCB1 affects nucleotide-exchange by WT Gα i1GDP 
GPCRs activate heterotrimeric G proteins by catalyzing the exchange of 
GTP for GDP on Gα subunits. The receptor facilitates the nucleotide 
exchange by using the CT-linked α5 helix of Gα subunits. The α5 helix 
region is postulated to be a molecular micro domain on Gα that 
allosterically couples the activation signal from the receptor to the 
catalytic pocket of G proteins (30, 31, 41, 42). Farquhar and coworkers 
have  
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Figure 1.6.  Interaction of sNUCB1 and Gα i1•GDP.   (A) We used ITC 
to measure the binding of Ca2+-free sNUCB1 to Gαi1•GDP.  The heat 
released per injection of aliquots of a solution of Gαi1•GDP (200 µM) into 
a buffered solution of Ca2+-free sNUCB1 (50 µM) was recorded and the 
area under the curve was integrated.  The heat of dilution for the addition 
of Gαi1•GDP to buffer alone was subtracted.  A non-linear least squares fit 
of the calculated values using the “one-set of sites” model for dimeric 
sNUCB1 resulted in a satisfactory fit with a dissociation constant of 18.3 
± 1.45 µM as shown in the inset.  We used multi-angle light scattering 
(MALS) to measure the formation of a complex between (B) sNUCB1 and 
Gαi1•GDP or (C) the truncation mutant sNUCB1(W333Ter) and 
Gαi1•GDP. MALS data were collected on protein complex peaks eluting 
from Superdex200 10/30 HR size exclusion chromatography connected to 
a high performance liquid chromatography system equipped with an 
autosampler.  Samples with increasing protein concentrations were 
successively injected onto the column, and the eluate was monitored using 
a photo-diode UV/Vis detector, a differential refractometer, and a static 
multi-angle laser light scattering detector.  The weight-average molecular 
mass of the complex was determined as a function of increasing protein 
concentration. The magenta curve in (B) inset and the red curve in (C) 
indicate non-linear least-square fits for a complex formation model of 
weight average molecular mass values determined for the apex of each 
eluting peak at various concentrations.  The error bars indicate extent of 
variation in molecular mass determination originating from the light-
scattering measurement. The data for sNUCB1-Gαi1•GDP complex 
formation shows that association between the protein subunits occurs only 
after dimerization of sNUCB1 (blue curve). The data suggest that one 
Gαi1 subunit binds to a dimer of sNUCB1 and a monomer of 
sNUCB1(W333Ter), respectively, and that the binding site for Gαi1 lies in 
the sNUCB1(W333Ter) sequence.  
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shown that NUCB1 possibly interacts with the CT α5 helix region of Gαi3 
(29). Thus, we measured the nucleotide exchange on Gα in the presence 
of Ca2+-free sNUCB1. The concentrations of both sNUCB1 and Gαi1 were 
kept above the determined Kd for sNUCB1-Gαi1 complex formation. 
Steady-state and time-based fluorescence experiments were performed by 
monitoring the enhancement in Trp fluorescence, which is coupled to 
activation of Gαi1. Any potential contribution from the Trp residues of 
sNUCB1 was eliminated by mutating both W232 and W333 to Ala, 
thereby generating sNUCB1(W232A/W333A) (Fig.1.1). Both AlF4¯ 
uptake (Fig.1.7A) and GTPγS binding (Fig.1.7B) to Gαi1•GDP showed an 
increase in Trp fluorescence as Gαi1 molecules were activated with time. 
However, Fig.1.7A and B show that binding to Ca2+-free 
sNUCB1(W232A/W333A) decreases the observed fluorescence 
enhancement observed for Trp residues coupled to activation of Gαi1. This 
suggests that Ca2+-free sNUCB1(W232A/W333A) possibly affects the 
nucleotide exchange by inhibiting the activation process. Furthermore, the 
G protein activation was also monitored using a fluorescent nucleotide 
analogue, BODIPY FL-GTPγS. The fluorescence of BODIPY FL-GTPγS 
in solution is self-quenched by the guanine ring of GTPγS. However, 
binding of the fluorescent nucleotide in the catalytic pocket of Gαi1 
relieves the self-quenching leading to the enhancement in the observed 
fluorescence of the bound fluorophore (43). As shown in Fig1.7C,  
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Figure 1.7.  sNUCB1 affects nucleotide-exchange by WT Gα i1. (A) We 
employed a time-based intrinsic Trp fluorescence assay to measure the 
rate of spontaneous nucleotide exchange by Gαi1•GDP in the presence of 
increasing concentrations of sNUCB1. The fluorescence emission of 
Trp211, which is situated on the Switch II region of Gαi1 increases 
dramatically on binding of AlF4¯ to Gαi1•GDP. To eliminate the influence 
of intrinsic Trp fluorescence from sNUCB1 on the measured activation 
rates, we used site-directed mutagenesis to engineer a Trp free version of 
sNUCB1, sNUCB1(W2323A/W333A). Gαi1•GDP alone (20 µM, black 
trace) was allowed to equilibrate while Trp fluorescence emission was 
recorded at 340 nm. Thereafter, AlF4¯ (20 mM) was injected at 180 
seconds and the fluorescence time course was monitored.  The same 
experiment was repeated in the presence of increasing concentrations of 
sNUCB1(W232A/W333A).  The rate of Gαi1•GDP activation by AlF4¯ is 
considerably decreased upon preincubation with equimolar (red) or excess 
(green) sNUCB1(W2323A/W333A). As a control, 
sNUCB1(W232A/W333A) alone shows no enhancement in Trp 
fluorescence upon addition of AlF4¯ (blue). (B) In an analogous 
experiment, we monitored the enhancement in fluorescence emission of 
Trp211 upon exchange of GDP for GTPγS, a non-hydrolyzable analogue 
of GTP. The results show that the rate and extent of GTPγS-mediated 
activation is less when Gαi1•GDP is bound to Ca2+-free 
sNUCB1(W232A/W333A). (C) In addition to measuring intrinsic Trp 
fluorescence, we also monitored nucleotide exchange by using the 
fluorescent analogue of GTPγS, BODIPY FL-GTPγS. BODIPY FL-
GTPγS was added to a buffered solution of 20 µM Gαi1•GDP alone or 
Gαi1•GDP precomplexed with increasing concentrations of sNUCB1. The 
binding of BODIPY FL-GTPγS to the catalytic pocket leads to 
enhancement of BODIPY fluorescence since self-quenching by guanine 
ring in solution is relieved. The observed time-based fluorescence 
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enhancement of BODIPY fluorophore on binding to Gαi1 decreased as 
increasing concentrations of Ca2+-free sNUCB1 were used. The data show 
that Ca2+-free sNUCB1 decreases the rate and extent of BODIPY FL-
GTPγS mediated activation of Gαi1•GDP. In a FRET based experiment 
(D) Gαi1•GDP activation was monitored through exchange of bound GDP 
for fluorescent mant-GTPγS nucleotide.  Upon uptake of mant-GTPγS by 
Gαi1, Trp211 moves into the catalytic pocket and forms a productive 
FRET pair which can transfer energy to the nucleotide analogue mant-
GTPγS.  FRET from Trp211 of Gαi1 to bound mant-GTPγS was measured 
at different times after addition of mant-GTPγS. The same experiment was 
carried out in the presence of sNUCB1(W2323A/W333A).  The addition 
of sNUCB1(W2323A/W333A) caused a decrease in the rate of FRET 
increase, indicating that uptake of mant-GTPγS by Gαi1 was inhibited.  
Maximum FRET intensity at 425 nm with increasing time was plotted. A 
fit to each data set clearly shows attenuation of FRET intensity for Gαi1 
complexed to Ca2+-free sNUCB1(W232A/W333A) in comparison to Gαi1 
alone, suggesting that Ca2+-free sNUCB1(W232A/W333A) inhibits 
nucleotide exchange. 
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Figure 1.7 
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incubation of increasing concentrations of Ca2+-free sNUCB1 with 
Gαi1•GDP leads to decrease in the fluorescence enhancement of BODIPY 
fluorophore suggesting that Ca2+-free sNUCB1 affects nucleotide-
exchange by inhibiting it.  
 
To monitor simultaneously the activation associated conformational 
change in Gαi1 and the uptake of nucleotide, a mant-GTPγS based FRET 
assay was also performed. The binding of mant-GTPγS in the catalytic 
pocket of Gαi1 brings it in close vicinity of Trp211 on the switch II region 
of Gαi1. Hence, FRET can be observed between the Trp and mant 
fluorophores upon Gαi1 activation (44). As shown in Fig.1.7D, the FRET 
intensity for Gαi1 alone at each time point is significantly higher in 
comparison to the FRET intensity for Gαi1 associated with Ca2+-free 
sNUCB1(W232A/W333A). A plot of the λmax at 425 nm with time shows 
that the FRET signal is significantly inhibited in the presence of 
sNUCB1(W232A/W333A) (Fig.1.7D). These experiments suggest 
towards a possible inhibitory effect of Ca2+-free sNUCB1 towards 
nucleotide-exchange. 
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Figure 1.8. NUCB1(381-419) does not bind to WT Gα i1GDP. (A) A 
CT 39 mer sequence of NUCB1 (residues 381-419) consist of the Glu-
Gln-Arg (397-399) triad preceded by an upstream Gln390. (B) The 
sequence alignment of NUCB1(381-419) with various GoLoco motif 
peptides shows the presence of the conserved Gln and the Asp/Glu-Gln-
Arg motif in the sequence. The stars indicate the positions of the 
conserved residues amongst different sequences. (C) We further used ITC 
to measure the binding of NUCB1(381-419) to WT Gαi1•GDP. 
NUCB1(381-419) (600 µM) was injected into a buffered solution of WT 
Gαi1•GDP (40 µM) in the reaction cell and the heat released per injection 
was recorded.  The heat of dilution for the addition of Gαi1•GDP to buffer 
alone was subtracted. The isotherm shows complete absence of any 
binding event indicating that NUCB1(381-419) does not interact with WT 
Gαi1•GDP. 
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1.2.6 The CT sNUCB1 peptide NUCB1(381-419) does not bind to WT 
Gα i1GDP 
The GDI activity of several G protein interacting partners is attributed to 
the presence of a GoLoco motif region, which directly binds to WT 
Gαi1GDP and inhibits nucleotide exchange. The GoLoco motif region is 
a 36-39 mer long structured fragment that consists of a conserved Gln 
residue followed by the presence of a conserved downstream Asp/Glu-
Gln-Arg triad wherein the Arg residue directly projects into the catalytic 
pocket and interacts with the bound GDP and stabilizes it (54). As shown 
in Fig.1.8A, the CT region of NUCB1 (residues 381-419) consists of a Gln 
at position 390 followed by a downstream Glu-Gln-Arg motif. A sequence 
alignment of NUCB1(381-419) with GoLoco motif sequences from 
various GDIs for Gαi1 shows that NUCB1(381-419) consists of the 
conserved Gln followed by the triad (Fig.1.8B). Hence in order to evaluate 
the binding of the NUCB1(381-419) to WT Gαi1•GDP, we performed ITC 
experiment by incubating 40 µM WT Gαi1•GDP in the reaction cell and 
using 600 µM of  NUCB1(381-419) as the injectant. The isotherm shows 
that NUCB1(381-419) does not bind to WT Gαi1•GDP (Fig. 1.8C). Hence 
the isolated CT NUCB1 peptide fragment NUCB1(381-419) does not bind 
to WT Gαi1GDP which indicates that the peptide alone cannot act as a 
GDI for G protein activation. 
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1.2.7 sNUCB1 is a Guanine-Nucleotide Dissociation Inhibitor (GDI) of 
Gα i1 
WT Gαi1•GDP subunit can readily self-exchange GDP for GTP albeit with 
poor efficiency. Our earlier results show that Ca2+-free sNUCB1 can affect 
nucleotide exchange by WT Gαi1•GDP. However for Ca2+-free  sNUCB1 
to be a GDI of nucleotide-exchange, it must cause a decrease in the 
number of sites for binding of GTP / GTPγS. In order to investigate the 
GDI activity, we incubated 20 µM WT Gαi1•GDP alone or in the presence 
of 100 µM Ca2+-free  sNUCB1 with 100 µM BODIPY FL-GTPγS present 
in the reaction mixture at 25 oC. Samples were withdrawn at various time 
points and amount of bound BODIPY FL-GTPγS was estimated by 
measuring the absorbance at 504 nm. The data shows that Ca2+-free 
sNUCB1 significantly inhibits the nucleotide-exchange by WT Gαi1•GDP 
by decreasing the number of binding sites available for BODIPY FL-
GTPγS (Fig.1.9A). In order to further substantiate the observed GDI 
acitivity of Ca2+-free  sNUCB1, we monitored the exchange of radioligand 
GTPγ35S by WT Gαi1•GDP in the presence and absence of Ca2+-free  
sNUCB1 / sNUCB1(W333Ter). The results show that both Ca2+-free 
sNUCB1 or sNUCB1(W333Ter) possess similar GDI activity (~ 58 % 
inhibition) suggesting that the C-terminus is not necessary for the activity 
(Fig.1.9B). As a positive control we also used a C-terminal peptide from 
RGS14 protein namely RGS14(496-531) which has been shown to possess 
GDI activity due to the presence of a canonical GoLoco motif. 
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Figure 1.9.  sNUCB1 acts as a GDI of Gα i1. (A) We determined the 
number of available nucleotide binding sites on Gαi1 in the absence or 
presence of Ca2+-free sNUCB1 by monitoring the absorbance of Gαi1-
bound BODIPY FL-GTPγS at 504 nm. Gαi1•GDP alone (20 µM, blue) or 
in complex with Ca2+-free sNUCB1 (100 µM, orange) was allowed to 
undergo nucleotide exchange with 100 µM BODIPY FL-GTPγS in the 
reaction mixture. Samples were withdrawn at different time points and 
unbound BODIPY FL-GTPγS was removed using a micro-spin desalting 
column. The amount of bound BODIPY FL-GTPγS was measured using 
the UV/VIS absorbance spectroscopy at each time point. A relative 
decrease in the number of nucleotide binding sites on Gαi1 was observed 
on association with sNUCB1. This shows that Ca2+-free sNUCB1 binds to 
Gαi1 in its GDP-bound form and inhibits nucleotide exchange. We further 
investigated the (B) guanine-nucleotide inhibitory activity of Ca2+-free 
sNUCB1 using the radioligand based assay. 20 µM WT Gαi1•GDP was 
incubated alone (blue) or with 100 µ M Ca2+-free sNUCB1 (green) / 
sNUCB1(W333Ter) (red) in the presence of GTPγ35S and samples were 
withdrawn at various time points to estimate the amount of radioligand 
bound upon nucleotide exchange. As a positive control, 100 µM of a CT 
GoLoco motif peptide from RGS14 namely RGS14(496-531) with 
established GDI activity was used as a positive control (magenta). The 
data shows that both Ca2+-free sNUCB1 or Ca2+-free sNUCB1(W333Ter) 
considerably inhibit nucleotide exchange with similar potency. The GDI 
peptide RGS14(496-531) shows complete inhibition of nucleotide 
exchange. Each experiment was repeated atleast 3 times and the data was 
plotted as mean ± S.E.M. amongst the independent measurements. 
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Figure 1.9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 56 
1.3 DISCUSSION 
NUCB1 is a ubiquitously expressed multi-domain Ca2+-binding protein 
whose physiological role(s) is not well understood. Our results provide the 
first direct evidence that NUCB1 is a Ca2+-regulated GDI of Gαi1. SEC 
experiments showed that Ca2+-free sNUCB1 interacts primarily with the 
GDP-bound state of Gαi1, and that no interaction occurs when sNUCB1 is 
bound to Ca2+ (Fig.1.5,1.6). The role of Ca2+-binding as a regulatory 
switch for sNUCB1 association with Gαi1 can be explained structurally 
through the involvement of the acidic region of sNUCB1. The acidic 
region has been previously shown to be a G protein interaction site (29). 
Earlier, yeast two-hybrid experiments had suggested that the CT-linked α5 
helix of G protein interacts with NUCB1 (29). Interestingly, the α5 helix 
is conformationally identical in both the Gαi1•GDP and Gαi1•GTPγS 
structures. However, as Gα undergoes transition from the inactive to the 
active state, the structurally dynamic switch regions (switch I to IV) of Gα 
subunits change conformation (45). Thus, the preferential binding of Ca2+-
free sNUCB1 to Gαi1•GDP, which can modulate G protein activation, 
points toward a possible participation of switch regions in this interaction.  
 
The domain diagram of NUCB1 shows the presence of a CT leucine 
zipper domain that can facilitate dimerization (Fig.1.1). Our sedimentation 
equilibrium experiments using AUC alongwith MALS analysis show that 
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NUCB1 is a dimer in solution. Furthermore, analysis of the dimer of 
sNUCB1 using dynamic light scattering revealed that it is considerably 
asymmetric in its shape with a long axis of 12.4 nm (Fig1.4E,F). This 
elongated shape may facilitate simultaneous interaction of sNUCB1 with 
both the α5 helix and the switch regions of Gαi1•GDP. Interestingly, 
deletion of the leucine zipper domain along with the CT region of 
sNUCB1 increased the binding affinity of monomeric sNUCB1(W333Ter) 
for  Gαi1•GDP and decreased the Rh to 3.3 nm (Fig.1.6C). This suggests 
that the deleted CT of sNUCB1 may play a regulatory role in sNUCB1-
Gαi1•GDP interaction. 
 
NUCB1 is a major Ca2+-binding protein of Golgi. In 1998, Lin et al. used 
labeling studies to show that NUCB1 is concentrated on the membranes of 
the stacked Golgi cisternae and associated vesicles on the cis side (16). 
NUCB1 assists in Ca2+ uptake, storage and release from the Golgi 
apparatus (46). Optimal Golgi Ca2+ levels are required for anterograde 
(ER to Golgi), retrograde (Golgi to ER) and intra-Golgi transport (47). 
Thus, NUCB1 along with Cab45 (48), the only other known Ca2+-binding 
Golgi resident protein, may be involved in maintaining the essential Ca2+ 
levels and gradient from cis to trans Golgi. The Ca2+ concentration in the 
cis-Golgi is around 0.3 mM under unstimulated conditions (47). Thus, the 
NUCB1 pool in Golgi should largely be Ca2+ bound given the Kd values 
for Ca2+-binding. However, at cytosolic Ca2+ concentrations (100-125 nM) 
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(49), NUCB1 should essentially be in a Ca2+-free state, suggesting that 
this Ca2+-free cytosolic pool of NUCB1 can interact with cytosolic Gαi1. 
NUCB1, like heterotrimeric G proteins, exists in both the cytosolic and 
membrane fractions (17). Co-immunoprecipitation and FRET analysis 
have convincingly shown that NUCB1 interacts with Gαi and co-localizes 
on Golgi lumen (50). Our MALS analysis alongwith the results from ITC 
experiments establish the interaction of one Gαi1•GDP subunit with a 
dimer of Ca2+-free sNUCB1.  
 
Earlier work by Siderovski and coworkers has unraveled several 
interacting partners of Gαi1•GDP namely, RGS12, RGS14, AGS3, 
GPSM2, PCP-2 and G18, all of which possess GDI activity (9, 14, 51-53). 
The GDI activity was attributed to the presence of a single or tandem 
repeats of a 19-amino-acid long conserved GoLoco motif region present in 
each of these proteins. The crystal structure of Gαi1•GDP complexed to 
RGS14 derived GoLoco peptide showed that the conserved CT of the 19-
amino-acid GoLoco motif makes contacts with both the switch I region 
and the bound nucleotide. Each GoLoco motif ends in a conserved triad of 
Asp/Glu-Gln-Arg. On binding to Gα, the Arg side chain extends into the 
catalytic pocket to interact directly with the bound GDP and stabilize it. In 
addition, the highly conserved Asp/Glu and Gln residues are absolutely 
essential for binding to G protein α-subunit as they are involved in both 
intra- and inter-molecular H-bonding interactions (54). A sequence 
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alignment of CT residues 381-419 of NUCB1 with GoLoco motif regions 
of several GDIs of Gαi subunits reveals that NUCB1 also possesses the 
highly conserved triad of Glu-Gln-Arg preceded by a conserved upstream 
Gln (Fig.1.8B). The other residues in the aligned sequence of NUCB1 
show relatively poor conservation across the GoLoco motif. Nevertheless, 
the presence of the most conserved regions suggests that mechanistically 
NUCB1 might act as a GDI by stabilizing the GDP-bound state of Gαi1 in 
a manner analogous to GoLoco region of RGS14.  
 
Nucleotide-exchange assays with GTPγS and its fluorescent analogues 
showed that Ca2+-free sNUCB1 interacts with WT Gαi1•GDP and can 
possibly affect the nucleotide exchange (Fig.1.7). The results show an 
inhibition in fluorescence intensity of Trp residues of Gαi1 on addition of 
Ca2+-free sNUCB1 / sNUCB1(W232A/W333A) indicating that Ca2+-free 
sNUCB1 inhibits conformational changes in WT Gαi1•GDP associated 
with nucleotide exchange. In order to directly show that Ca2+-free 
sNUCB1 is a GDI, we used BODIPY FL-GTPγS and radioligand 
(GTPγ35S) binding assays to measure the number binding sites available 
on WT Gαi1•GDP (Fig.1.9). Our results show that Ca2+-free sNUCB1 
significantly inhibits nucleotide exchange by Gαi1•GDP. Interestingly, 
even the truncation mutant sNUCB1(W333Ter) possesses the ability to 
inhibit nucleotide exchange suggesting that the C-terminal domain of 
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sNUCB1 is not essential for its GDI activity. Hence unlike other GDIs 
with GoLoco motifs, the GDI activity of NUCB1 is not due to the 
presence of a conserved CT Glu-Gln-Arg triad characteristic of a GoLoco 
motif. 
 
As shown by the sequence alignment, the core GoLoco motifs between 
different GDIs are highly conserved, whereas the residues C-terminus to it 
are quite divergent. Evidently, longer GoLoco peptides with additional CT 
residues display significantly higher affinity towards Gαi than the minimal 
19-amino-acid peptides. The GoLoco motif peptides derived from RGS 
proteins have nanomolar binding affinity for Gαi•GDP in comparison to 
micromolar binding affinities observed for GPSM2, PCP-2 or G18 derived 
GoLoco motif peptides. The binding affinities for full length GDIs like 
RGS14, GPSM2 and others with GoLoco motif regions towards Gαi•GDP 
is unknown. Unlike these, our in vitro assays estimate that the binding 
affinity of full-length ~100 kDa sNUCB1 dimer to Gαi1 is 18.3 µM 
(Fig.1.6A). The crystal structure of RGS14 GoLoco motif region bound to 
Gαi1 showed numerous stabilizing interactions between the residues CT to 
the GoLoco motif and Gαi1•GDP. The activation studies with chimeric Gα 
subunits showed that both the CT region of the GoLoco motif and the 
helical domain of Gα determine binding of the GoLoco motif towards a 
particular class of Gα subunits (54). Yeast two-hybrid analysis by Lin et 
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al. showed that NUCB1 preferentially interacts with Gαi1 and Gαi3 with 
higher affinity than with Gαi2 and Gαs (16). Future studies of NUCB1 
interaction with different classes of Gα subunits are planned to reveal the 
selectivity of its GDI activity. Our G protein interaction and nucleotide 
exchange studies with the truncation mutant sNUCB1(W333Ter) 
(Fig.1.6C, 1.9B) suggest that unlike known GDIs, sNUCB1 interacts with 
Gαi1•GDP in a novel manner. A co-crystal structure of the minimum 
subunit of NUCB1 bound to Gαi1•GDP that has GDI activity would be 
immensely helpful in understanding the precise molecular details of this 
interaction and may provide understanding of the Ca2+-dependence of this 
interaction. 
 
G proteins are widely expressed in different tissue types and are involved 
in various signal transduction pathways interacting with a number of 
binding partners. The interaction of NUCB1 with Gαi1 has been previous 
established but no GEF or GDI activity was observed because the 
experimental concentrations used were below the Kd value of association. 
Our results show that the interaction of Gαi1 with sNUCB1 is regulated by 
Ca2+-binding. We have evaluated this interaction in terms of cytosolic 
Ca2+ concentrations where NUCB1 should exist in a Ca2+-free state 
capable of binding to Gαi1. Based on the available evidence, we propose a 
model for the role of a cytosolic pool of NUCB1 in regulating G protein 
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signaling. According to the model, G protein heterotrimer (Gαβγ) upon 
activation by GPCRs, dissociates into Gα and Gβγ subunits to initiate 
downstream signaling cascades. RGS proteins acting as GAPs, rapidly 
accelerate the hydrolysis of GTP to GDP, thereby bringing the α-subunit 
back to the GDP-bound state. Thereafter, the GDP-bound state of Gαi1 can 
be stabilized by the Ca2+-free cytosolic pool of NUCB1 to inhibit basal 
nucleotide exchange. The GDI activity of NUCB1 would inhibit the self-
activation of Gαi1 subunit and in turn augment the Gβγ-dependent 
signaling cascade. Subsequently, NUCB1 would be displaced by Gβγ at 
the plasma membrane to promote formation of the heterotrimer, thereby 
initiating another cycle of receptor mediated G protein signal transduction. 
Future cell-based assays should provide information about the 
physiological importance of this interaction and how it affects the ligand 
mediated signal transduction cascade which involves activation of 
heterotrimeric G proteins. 
 
In summary, our results show that sNUCB1 is a physiological dimer, 
which interacts with the GDP-bound Gαi1. This association inhibits the 
nucleotide exchange by Gαi1, thus demonstrating the GDI activity of 
NUCB1. Ca2+-binding to sNUCB1 regulates NUCB1-Gαi1•GDP complex 
formation and possibly modulates this interaction in different cellular 
compartments. NUCB1 is a novel Ca2+-binding GDI with a role in 
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trafficking and Ca2+ buffering. In addition, NUCB1 also has a nuclear 
localization signal sequence within the DNA binding region. Recently, its 
role in affecting the biogenesis of amyloid precursor protein was reported 
(16). Such a potential for diverse functionality makes the comprehensive 
understanding of the physiological role of NUCB1 difficult. Based on our 
current knowledge, NUCB1 seems to be neither a RGS nor an AGS 
protein. Future experiments will unravel the functional relevance of the 
interaction of NUCB1 with other Gα subunits. Understanding the role of 
NUCB1 in the context of different Gα subunits will highlight the signaling 
pathways modulated by NUCB1. Our discovery of the Ca2+-regulated GDI 
activity of NUCB1 adds a new level of understanding to the role of 
NUCB1 and to the complexity of G protein-mediated signal regulation.  
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CHAPTER 2 
Nucleobindin 1 and its Engineered Mutant Disaggregate human Islet 
Amyloid Polypeptide fibrils and Inhibit its Aggregation by forming Dead-
end Prefibrillar Species 
 
2.0 INTRODUCTION 
Amyloid deposition is an underlying pathophysiological hallmark of a 
number of severe biological disorders like Alzheimer’s Disease, 
Creutzfeldt-Jacob disease, Parkinson’s disease, Huntington’s disease and 
Type 2 diabetes (T2D) (55, 56). Amyloid deposits are insoluble fibrous 
aggregates with a β-pleated sheet structure, formed by aggregation of 
natively unfolded or misfolded / partially denatured proteins or peptides. 
In T2D, aggregation of human islet amyloid polypeptide (hIAPP) results 
in islet amyloid deposits, which has been proposed as an aetiological 
factor contributing to the observed pathology in T2D (57, 58). T2D is a 
metabolic disorder that stems from disruption of glucose homeostasis 
caused by reduced insulin secretion from pancreatic islets and enhanced 
insulin resistance of peripheral tissues. In addition, extensive islet amyloid 
deposits have been observed extracellularly and adjacent to islet 
capillaries in 70-90% of T2D patients (59-61). These amyloid deposits are 
composed of unstructured and highly hydrophobic 37-amino-acid long 
polypeptide called human Islet Amyloid Polypeptide (hIAPP) or Amylin 
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(62, 63). Once formed, these amyloid deposits are highly toxic and cause 
β-cell death. This irreversible loss of β-cell results in insulin depletion and 
aggravates T2D. Physiologically, hIAPP is present in both normal and 
diabetic individuals but is somehow kept from aggregating into toxic 
deposits in non-diabetic populations. The physiological checkpoints / 
factors that keep this most amyloidogenic sequence from aggregating into 
insoluble and toxic amyloid deposits are poorly understood. Thus arises a 
need for investigation of factors that can inhibit the aggregation process 
and preferably disaggregate the pre-formed fibrils to facilitate their 
clearance from the system. 
 
hIAPP is a glucomodulatory polypeptide co-secreted with insulin from 
pancreatic β-cells in response to glucose uptake. The gene for IAPP is 
located on the short arm of chromosome 12 and transcribes a 89-amino-
acid long precursor protein. This larger precursor is sequentially processed 
by proconvertases PC1/3 and PC2 to generate the mature 37-amino-acid 
long polypeptide, which has a free N-terminus and an amidated C-
terminus with a disulfide bond between Cys2 and Cys7 (58) (Fig.2.1). The 
mature form of hIAPP is a natively unstructured neuroendocrine hormone 
that regulates food intake and fat storage (64). It suppresses glucagon 
secretion and inhibits the secretion of gastric acid, bile and pancreatic 
enzymes (65). These functions of hIAPP allow for both exogenous and 
endogenous modulation of the rate of glucose appearance in the blood. 
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Thus, hIAPP together with insulin constitutes an essential glucoregulatory 
cascade (66). The aggregation of hIAPP into amyloid deposits, however, 
disrupts this underlying cascade and promotes β-cell death resulting in the 
loss of β-cell mass (67).  
 
hIAPP is a very hydrophobic peptide with a significantly high propensity 
to rapidly aggregate in aqueous solution at low micromolar concentrations. 
Physiologically, the concentration of hIAPP in the secretory granules can 
vary from 100 µM to 4 mM. However, even at such high concentrations, 
hIAPP does not aggregate under normal environment of secretory granules 
(65). Several studies have shown that the physiological molar ratio of 
IAPP to insulin, proinsulin and C-peptide protects against IAPP 
aggregation (68, 69). Additionally, transgenic mice under normal 
metabolic conditions did not develop any amyloid deposits (70). Thus 
synthesis and secretion of IAPP alone is not sufficient for islet 
amyloidosis. Rather, defects in either IAPP biosynthesis, folding, 
trafficking or processing have been postulated as possible mechanisms 
facilitating the initiation of amyloid formation (57, 58, 71-73) 
Furthermore, the role of several chaperones and proteases has come to 
light explaining how the physiological defense mechanisms prevent these 
naturally occurring amyloidogenic proteins from aggregating in healthy 
individuals. In particular, heat shock proteins Hsp70 and sHsp20 have 
been shown to inhibit amyloidogenesis of Aβ which contributes to the 
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pathophysiology of Alzheimer’s disease (74, 75). Additionally, the 
extracellular chaperone Clusterin has been shown to inhibit the 
aggregation of prion protein, Aβ and Apolipoprotein C-II (76, 77) into 
amyloid fibrils. Along with the chaperones, Insulin Degrading Enzyme 
(IDE), a Zn2+-dependent metallo-endoprotease, has been shown to 
proteolytically cleave monomeric hIAPP and may play an important role 
in regulating the physiological concentration and eventual clearance of the 
peptide (78, 79). In addition, a number of novel approaches towards 
preventing both in vivo and in vitro amyloid formation by IAPP have been 
undertaken. Administration of drugs that increase insulin sensitivity in 
transgenic mouse model of hIAPP overexpression and thereby decrease β-
cell demand to produce more IAPP have shown to reduce amyloid 
formation (80). Several peptide fragments and derivatives of hIAPP have 
been identified that inhibit fibril formation in vitro by targeting the 
amyloidogenic region (residues 8-20 and 20-29) of hIAPP (81-84). 
However we still lack a deeper understanding of the physiological factors 
that inhibit aggregation of hIAPP into amyloid fibrils and help keep it in a 
soluble form. In this study, we present the anti-amyloidogenic properties 
of a ubiquitously expressed mammalian protein Nucleobindin 1 (NUCB1) 
or commonly known as Calnuc in inhibiting the progression of hIAPP 
aggregation into amyloid fibrils and more importantly, in disaggregating 
the formed fibrils.  
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NUCB1 is a 55 kDa protein, which was first reported as a growth and 
differentiation factor associated with lupus syndrome (19) (Fig.2.1). Since 
then NUCB1 has been postulated to be involved in several important 
cellular functions like matrix modulation and maintaining Ca2+-
homeostasis in Golgi (46). NUCB1 has also been shown to interact with 
heterotrimeric G protein α-subunits leading to possible intervention in the 
regulation of downstream signaling events (16, 29, 50). However, the 
selective pathways associated with the functionality of NUCB1, which 
require its strong conservation across the animal kingdom, still remain 
elusive. Since its discovery, NUCB1 has been reported to be widely 
expressed in cells and tissues and is conserved from flies to humans (85). 
This suggests that NUCB1 is an essential Ca2+-binding protein present in 
the eukaryotic proteome. It is primarily a Golgi-resident protein found in 
both cytosolic and membrane fractions (16). NUCB1 shows high 
homology with the ER resident protein Calreticulin and displays 
properties suggesting its role in both Ca2+-storage and homeostasis in 
Golgi.  
 
Recent in vitro studies have suggested that overexpression of NUCB1 
down-regulates the mRNA production of Amyloid precursor protein 
(APP) and inhibits its biogenesis. It was further shown that the expression 
level of NUCB1 is decreased by 50% in the brains of Alzheimer’s disease  
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Figure 2.1. Modular structure of human NUCB1 and the engineered 
NUCB1 variants. The domain diagram of NUCB1 is depicted 
schematically with its N-terminal signal sequence (grey square), putative 
DNA binding domain (green square), two EF hand loops (magenta 
rectangles), acidic region (blue oval) and leucine zipper domain (yellow 
hexagon). The amino acid residues at domain borders are numbered.  We 
engineered a construct for expression in E. coli of a soluble form of 
NUCB1 that included an N-terminal hexa-His tag and a PreScission 
protease recognition sequence with an intervening spacer sequence as 
shown for eNUCB1.  Endoprotease cleavage yields a soluble form of 
NUCB1 that begins with the amino acid sequence GPHMAS and 
continues with the remainder of the native sequence beginning at Gly32.  
We refer to this expressed protein construct as soluble NUCB1 or 
sNUCB1. Thereafter we used the sNUCB1 template to make point 
mutations in each EF hand as indicated by the arrows to generate 
sNUCB1(tetramutant) which lacks the ability to bind to Ca2+.Finally, we 
also generated a variant of sNUCB1 whereby the Ser44 was substituted by 
a Cys residue to generate sNUCB1(S44C), which was used for labeling 
studies. We also generated a CT peptide fragment of sNUCB1 namely 
NUCB1(381-419) which consists of residues 381-419. Thereafter the 
complete sequences for the mature human Islet Amyloid PolyPeptide 
(hIAPP) and its non-aggregating synthetic analog namely Pramlintide are 
listed. Both peptides have a free N-terminus and an amidated C-terminus. 
The highlighted residues (red) in the sequence of Pramlintide show 
prolines, which are absent in hIAPP.  
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Figure 2.1 
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patients (28). Thus in order to test for potent anti-amyloidogenic property 
and to understand the possible mechanism of action, we investigated the 
ability of NUCB1 towards inhibiting fibril formation by the highly 
amyloidogenic hIAPP .  
 
In the present study we show that soluble form of NUCB1, sNUCB1 
(Fig.2.1), inhibits hIAPP fibril formation at sub-stoichiometric amounts 
and also effectively disaggregates preformed fibrils in a Ca2+-dependent 
manner. Interestingly, the anti-amyloidogenic functional ability of 
sNUCB1 is completely absent when bound to Ca2+. In order to circumvent 
this, we designed a mutant of sNUCB1 namely sNUCB1(tetramutant), 
which similar to sNUCB1 can effectively inhibit hIAPP fibril formation 
and disaggregate hIAPP fibrils even in the presence of excess Ca2+. 
Interestingly, Ca2+-free sNUCB1 can bind to Zn2+ and ATP but does not 
possess protease activity towards hIAPP nor can it protect firefly 
Luciferase against heat denaturation. We further show that mechanistically 
Ca2+-free sNUCB1 binds to and stabilizes a prefibrillar species of hIAPP 
by “capping” the ends to inhibit their further association to form fibrils. 
Interestingly, these Ca2+-free sNUCB1 bound prefibrilar species form 
dead-end products incapable of seeding the aggregation reaction of hIAPP. 
Finally we also isolated a small peptide fragment from the C-terminal 
(CT) region of NUCB1 namely NUCB1(381-419) (Fig.2.1), which similar 
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to sNUCB1, inhibits hIAPP fibril formation and can also facilitate 
disaggregation of amyloid fibrils.  
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2.1 MATERIALS AND METHODS 
2.1.1 REAGENTS 
Thioflavin-T was purchased from Fisher Scientific and Uranyl Acetate 
was purchased from SPI-ChemTM. For TEM, 300 mesh carbon coated Cu 
grids were purchased from EMS diasum (Hatfield, PA). Nano-Au 
Maleimide was purchased from Invitrogen Molecular Probes (Cat # 
20345). Rabbit polyclonal hIAPP prediluted antibody (Cat # GTX15128) 
was purchased from Genetex Inc. (Irvine, CA) and Rabbit polyclonal 
NUCB1 antibody (Cat # P102230_T100) was purchased from Aviva 
Systems Biology (San Diego, CA).  NUCB1(381-419) was purchased 
from Keck facility at Yale University. All reagents and chemicals used 
were of the highest available purity. 
  
2.1.2 Heterologous expression and purification of sNUCB1 and its 
variants 
The cDNA clone for human NUCB1 was obtained from ATCC and the 
DNA fragment for the soluble form of NUCB1 or sNUCB1, 
corresponding to residues 31-461 of the human NUCB1 protein without 
the N-terminal signal sequence (residues 1-31) was cloned into a 
pET28a(+) expression vector (Amersham Biosciences) to generate a N-
terminal His6-tagged construct. The construct for sNUCB1 served as a 
template to generate the His6-tagged mutants of sNUCB1 namely 
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sNUCB1(tetramutant) and sNUCB1(S44C). For sNUCB1(tetramuant) the 
coding sequence changes leading to generation of D253K, E264A, D305K 
and E316A mutations were introduced by site-directed mutagenesis using 
the Quick Change system (Stratagene, La Jolla, CA) whereas a coding 
sequence for Ser44 was mutated to Cys to generate sNUCB1(S44C) . The 
vectors were then used to transform BL21 (DE3) cells to express a N-
terminal His6-tag protein containing a PreScission protease site following 
the His6-tag. Both proteins were expressed in BL21 (DE3) cells grown in 
the presence of 50 µg / ml kanamycin. Cells were grown at 37 oC to A600nm 
of ~ 0.7 and then induced with 500 µ M isopropylthio-β-D-galactoside 
(IPTG) (US Biological). Post induction the culture was grown overnight at 
17 oC and subsequently harvested. The resulting pellets were re-suspended 
in a buffer containing 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 50 mM β-
mercaptoethanol, bovine lung aprotinin (20 mg/ml), 2 mM phenylmethane 
sulfonyl fluoride (PMSF) and complete EDTA-free protease inhibitor 
cocktail tablets (Roche). Thereafter the cells were lysed and the expressed 
His6-tag protein was purified from crude extract by using affinity 
chromatography using Ni-NTA column pre-equilibrated with buffer A (50 
mM Tris, pH 8.0, 150 mM NaCl, 50 mM β-mercaptoethanol). The bound 
His6-tag protein was eluted from the column by using buffer A 
supplemented with 500 mM imidazole. The His6-tag was cleaved by 
PreScissionTM protease, which was subsequently removed. In order to 
remove Ca2+ from sNUCB1 or its variant, the proteins were extensively 
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dialyzed against buffer A supplemented with 5 mM EGTA and 1 mM 
EDTA, which were also eventually removed through dialysis. Finally, size 
exclusion chromatography (SEC) was done using Superdex200 26/60 HR 
column equilibrated with buffer S (50 mM Tris, pH 8.0, 150 mM NaCl, 1 
mM DTT) to obtain homogenously pure protein. The typical yield for 
sNUCB1 and its variant was ~ 5 mg / L. The purity of the proteins was 
assessed by Coomassie brilliant blue staining after the proteins were 
separated through SDS-PAGE. The purity of both the proteins was greater 
than 95%.  
 
2.1.3 Solid phase peptide synthesis and purification of hIAPP 
Wild type human IAPP (hIAPP) was synthesized and purified by Ruchi 
Gupta at Stony Brook University, NY in the lab of Dr Daniel P Raliegh. 
 
2.1.4 Monitoring hIAPP aggregation kinetics using thioflavin-T 
fluorescence 
The kinetics of aggregation of hIAPP was monitored in the absence and 
presence of Ca2+-free sNUCB1 using thioflavin-T or thio-T fluorescence. 
All fluorescence measurements were done on a Jobin Yvon Horiba 
fluorescence spectrophotometer using an excitation wavelength of 450 nm 
and an emission wavelength of 485 nm. The emission and excitation slits 
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were both set to 5 nm and a 1.0 cm cuvette was used. Experiments were 
performed by diluting a stock of hIAPP in 20 mM Tris pH 7.5. Each stock 
solution was filtered through a 0.45 µm pore size GHP Acrodisc syringe 
filter prior to the experiment.  The final reaction mixture contained hIAPP 
with or without a particular concentration Ca2+-free sNUCB1 along with 
32 µM thio-T in the reaction buffer at 25 oC with constant stirring. The 
fluorescence intensity observed for binding of thio-T to Ca2+-free 
sNUCB1 alone was subtracted from each kinetic curve.  
 
2.1.5 Transmission Electron Microscopy (TEM) 
TEM was performed at the Bioimaging facility at Rockefeller University. 
Samples were prepared by placing 5 µl of solution onto formvar coated 
300 mesh copper grids and counterstained with 2% aqueous uranyl acetate 
solution. Samples were viewed with a FEI Tecnai12 BioTwinG2 
transmission electron microscope at 80 kV.  Digital images were acquired 
with an AMT XR-60 CCD Digital Camera System and compiled using 
Adobe Photoshop CS2 and Image J. 
 
2.1.6 Size Exclusion Chromatography (SEC) 
Size exclusion chromatography (SEC) was done using a Superose 6 10 / 
30 GL column attached to an AKTA explorer FPLC. 200 µl of a reaction 
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mixture with Ca2+-free sNUCB1 (32 µM) alone in 20 mM Tris pH 7.5 or 
Ca2+-free sNUCB1 preincubated with equimolar amount of hIAPP in 
reaction buffer were injected onto a buffer equilibrated Superose 6 10 / 30 
GL column. The chromatogram corresponding to absorbance at 280 nm 
for each reaction was plotted as a function of elution volume.  
 
2.1.7 Dot Blot Assay 
Dot blot was done by blotting samples onto an activated polyvinylidene 
fluoride (PVDF) membrane and allowed to dry followed by blocking with 
5 % milk solution in TBS (20 mM Tris, pH 7.5, 150 mM NaCl) at room 
temperature. Subsequently the membrane was incubated with a solution of 
rabbit polyclonal primary antibody against hIAPP (1:2 dilution of 
prediluted stock) or NUCB1 (1:500 dilution of 1 µg / µl stock) in TBS for 
1 h at room temperature followed by three washes with TBS-T (20 mM 
Tris pH 7.5, 150 mM NaCl, 0.05 % Tween-20) for 5 min each.  After this, 
the membranes were incubated with horseradish peroxidase conjugated 
anti-rabbit secondary antibody (1:8000 dilution of the stock) in TBS for 30 
min at room temperature followed by two washes with TBS-T for 5 min 
each and a subsequent wash with TBS for 5 min. The blots were 
developed using the supersignal west femto maximum sensitivity substrate 
(Thermo Scientific).  
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2.1.8 Light Scattering 
The light scattering data was collected using a Superose6 10/30 GL SEC 
column (GE Healthcare, Piscataway, NJ), connected to High Performance 
Liquid Chromatography System (HPLC), Agilent 1200, (Agilent 
Technologies, Wilmington, DE) equipped with an autosampler.  The 
elution from SEC was monitored by a photodiode array (PDA) UV / VIS 
detector (Agilent Technologies, Wilmington, DE), differential 
refractometer (OPT-Lab rEx Wyatt Corp., Santa Barbara, CA), static and 
dynamic, multiangle laser light scattering (LS) detector (HELEOS II with 
QELS capability, Wyatt Corp., Santa Barbara, CA).  The SEC-UV / LS / 
RI system was pre-equilibrated in buffer (20 mM Tris pH 7.5) and 200 µl 
of reaction mixture containing either Ca2+-free sNUCB1 alone or 
incubated with equimolar amount of hIAPP were injected onto the 
column. Two software packages were used for data collection and 
analysis: the Chemstation software (Agilent Technologies, Wilmington, 
DE) controlled the HPLC operation and data collection from the multi-
wavelength UV / VIS detector, while the ASTRA software (Wyatt Corp., 
Santa Barbara, CA) collected data from the refractive index (RI) detector, 
the light scattering detectors, and recorded the UV trace at 280 nm sent 
from the PDA detector. Molecular masses were determined across the 
entire elution profile for each observed peak in the intervals of 1 sec from 
static LS measurement using ASTRA software as previously described 
(33). The approach uses a Rayleigh-Debye-Gans light scattering model 
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(equation 1), which relates the amount of scattered light to the 
concentration and molecular mass of solute and second virial coefficient: 
                   
€ 
K∗c
R(θ) =
1
Mw
+ 2A2c                                            (1) 
where R(θ) is the intensity of excess scattered light at angle θ, c is the 
concentration of the solute, Mw is the weight average molecular weight of 
the solute, A2 is the second virial coefficient, K* is an optical parameter 
equal to 
€ 
4π 2n2 (dn dc)
2
λ0
4NA
, where n is the refractive index, dn/dc is the 
refractive index increment for the solute,  NA  is Avogadro’s number, and 
λ0 is the wavelength of the scattered light.   
 
Dynamic light scattering (DLS) measurements were made “on line” at an 
angle of 100° with a 2 sec collection time across the elution peaks.  Time 
resolved scatter intensity fluctuations were analyzed using ASTRA 
Software (Wyatt Corp., Santa Barbara, CA) which implements the 
cumulants method (Koppel, 1972) to determine the time dependence of 
diffusive motion also referred to as the intensity correlation function, G(τ), 
(35): 
        
€ 
G(T) = B{1+α[exp(−DTq2t)]2}                                    (2) 
where B is the average baseline intensity, α  is an instrument-specific 
correction factor, DT  is the concentration-dependent translational 
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diffusion constant of the solute, t is a delay time, and q is the scattering 
vector equal to 
€ 
4πn
λ
sinθ 2, where n is the refractive index of the solvent, 
λ is the wavelength of the scattered light and θ  is the scattering angle. 
Equation 2 describes the relationship between the time dependency of 
fluctuation in scatter intensity and the translational diffusion coefficient.  
The value of DT was used to estimate the apparent hydrodynamic radius of 
an equivalent sphere using Stokes-Einstein relationship (equation 3):  
         
€ 
Rh =
kT
6πηDT
                                                    (3) 
where k is the Boltzmann constant, T is the absolute temperature, and η is 
the temperature corrected viscosity of the solution.   
 
2.1.9 Nano-Au labeling of sNUCB1(S44C) 
Heterologously purified Ca2+-free sNUCB1(S44C) was extensively 
dialyzed against phosphate buffer saline (PBS) pH 7.5 and concentration 
of the dialyzed protein was measured using UV / VIS spectroscopy. A 
nano-Au maleimide solution stock was prepared according to 
manufacturer’s protocol (Molecular Probes, Invitrogen) after which 2 
nmoles of buffer dialyzed Ca2+-free sNUCB1(S44C) protein was 
incubated with 6 nmoles of nano-Au maleimide in PBS supplemented with 
500 µM tris carboboxyethyl phosphine (TCEP) overnight at 4 oC. After 
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this the reaction mixture was injected onto a PBS equilibrated 
Superdex200 10 / 30 GL column and the elution profiles for absorbance at 
280 nm and 420 nm were recorded. The labeled protein elutes at a peak 
centred at 12.2 ml with the excess nano-Au eluting at higher elution 
volume. The efficiency of labeling was estimated using a Biorad DC assay 
kit. A calibration curve using serial dilutions of unlabeled Ca2+-free 
sNUCB1(S44C) was prepared to use for estimation of the concentration of 
the labeled protein by measuring absorbance at 750 nm. The concentration 
of nano-Au label was estimated by measuring absorbance at 420 nm 
where nano-Au probe absorbs strongly. A ratio of the protein 
concentration to nano-Au concentration gave a value of 1.02, indicating 
stoichiometric labeling of Ca2+-free sNUCB1(S44C) with each monomeric 
subunit labeled with one nano-Au probe. 
 
2.1.10 Nano-Au labeling of hIAPP 
32 µM of hIAPP was incubated in 20 mM Tris pH 7.5 buffer solution at 
room temperature. After fibrils were formed, the reaction mixture was 
sonicated for 15 sec and sonicated mixture was dialyzed against PBS at 4 
oC. Thereafter 2 nmoles of hIAPP solution were incubated with 6 nmoles 
of nano-Au maleimide in PBS supplemented with TCEP overnight at 4 oC. 
The excess nano-Au was removed through extensive dialysis. The labeled 
solution was then used to “seed” a hIAPP aggregation reaction and the 
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incorporation of nano-Au labeled hIAPP fragment into growing fibril was 
observed using TEM.   
 
2.1.11 Scanning Transmission Electron Microscopy (STEM) and mass 
per unit length measurements 
Dark-field micrographs of unstained freeze-dried specimens together with 
Tobacco Mosaic Virus (TMV) particles as a mass standard were prepared 
according to the standard “wet film” method of the Brookhaven STEM 
facility. This involved freeze-drying the sample with TMV on titanium 
grids supporting a 2 - to 3 - nm carbon film as described by Wall and 
Hainfeld. Grids were scanned at - 150 °C on a custom-built STEM at 
40 kV with a probe focused to 0.25 nm with a dwell time of 30 µs / pixel. 
Digital dark-field micrographs of freeze-dried specimens were recorded 
with 512 × 512 pixels at raster steps of 1.0 or 2.0 nm per pixel and an 
average radiation dose of 1 × 102 to 5 × 102 electron / nm2. The images 
were analyzed using the PCMass30 software (Brookhaven STEM 
resource). The resulting data were normalized to the known mass per unit 
length of TMV (131.4 kDa / nm).  
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2.1.12 BODIPY FL-Casein based Protease assay 
An experimental stock of 1 µg / µl was prepared for BODIPY FL-Casein 
(Molecular Probes), Trypsin (Sigma, NJ) and Ca2+-free sNUCB1 in 
digestion buffer (10 mM Tris pH 7.8, 100 µM NaN3). Thereafter 10 µg of 
BODIPY FL Casein substrate was incubated in digestion buffer at 25 oC 
and the fluorescence readout was measured with λex = 505 nm and λem = 
513 nm. After 60 sec, 100 µg of Ca2+-free sNUCB1 or 10 µg of Trypsin 
was added to the reaction mixture and enhancement in fluorescence was 
recorded. In addition, BODIPY FL Casein was also incubated with 
Trypsin, or with varying concentrations of sNUCB1(tetramutant) or Ca2+-
free sNUCB1  and samples were withdrawn after 5 min and 60 min and 
subjected to SDS-PAGE analysis followed by coomassie staining.  
 
2.1.13 Liquid chromatography Mass Spectrometry (LC-MS) 
HPLC-MS analysis was performed using an Acquity UPLC System 
(Waters, Milford, MA) in combination with a QSTAR QqTOF mass 
spectrometer (Applied Biosystems). The column used was a 150 mm × 2.1 
mm BEH C18 column. The LC was coupled with the mass spectrometer 
using a Pico Tip sprayer (New Objective, Woburn, MA) with an inner 
diameter of 15 µm. UPLC-MS / MS analysis was carried out at a flow rate 
of 100 µ l / min. Samples were loaded directly on the analytical column. 
After a washing period of 1 min with 1% B (acetonitrile with 0.01% 
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TFA), a linear gradient was from 99% A (water with 0.01% TFA), 1%B to 
30% A, 70% B in 10 minutes, respectively. Similar results were also 
obtained with nano-HPLC coupled to a LTQ mass spectrometer at 250 
nanoliter/minute and a linear gradient was from 99% A (water with 0.01% 
TFA), 1%B to 30% A, 70% B in 40 minutes. 
 
2.1.14 Matrix Metallaproteinase (MMP) assay 
The Sensolyte® 520 Matrix Metalloproteinase (MMP) substrate kit 
(AnaSpec) was used to assay for MMP activity of Ca2+-free sNUCB1. 
Sixteen synthetic FRET peptide (5-aminocarboxy fluorescein or 5-FAM 
and QXL™520 are used as the fluorophore / quencher pair) substrates 
were used as fluorogenic indicators to assay MMP activities. Within the 
peptide, QXL™520 quenches the fluorescence readout of 5-FAM whereas 
upon MMP mediated proteolytic cleavage of the peptide this internal 
quenching is be relieved and the fluorescence emission readout for 5-FAM 
can be monitored at Ex / Em wavelengths = 490 / 520 nm. The assay was 
done in a 96-well plate format. A serial dilution of the reference standard 
was done in the assay buffer to calibrate the optimal concentration of the 
substrate needed for the reaction. Thereafter we incubated the optimal 
concentration of each FRET peptide substrate with either 15 ng / 50 µ l / 
well of MMP-1 or with 7.5 or 750 ng / 50µl / well of Ca2+-free sNUCB1 
and the fluorescence emission was recorded at 10 min time intervals for 90 
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min. In order to eliminate the contribution from the background, the 
fluorescence emission for each FRET peptide alone was subtracted from 
all monitored reactions.  
 
2.1.15 Luciferase Assay 
The Luciferase assay kit was bought from Promega and the Luciferin 
(substrate) stock was prepared in the assay buffer according to the 
manufacturer’s protocol. Thereafter a serial dilution curve for Luciferase 
activity was generated by incubating the substrate with varying 
cconcentrations of Luciferase and quatifying the chemiluminiscence 
readout 10 min after substrate addition with an EnVision Multimode Plate 
Reader (Perkin Elmer). The analysis showed that 0.7 nM concentration of 
Luciferase was optimal and was used in all subsequent experiments. For 
renaturation assay, native Luciferase was denatured by incubating it at 40 
oC for 10 min. Thereafter, denatured Luciferase (0.7 nM) was 
independently incubated with 0.7 nM, 7 nM or 70 nM concentration of 
Ca2+-free sNUCB1 in a reaction mixture with substrate present and the 
chemiluminiscence recorded after 10 min, 20 min and 30 min. The 
chemiluminiscence of the substrate alone was substracted from each 
monitored reactions. In addition, we also tested for the ability of Ca2+-free 
sNUCB1 towards inhibiting heat denaturation of Luciferase. We 
preincubated 0.7 nM Luciferase separately with 0.7 nM and 70 nM 
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concentration of Ca2+-free sNUCB1 and heated each reaction mixture at 
42 oC for 10 min. The chemilumiscience from each reaction was 
monitored 10 min after addition of substrate post incubation period. Each 
experiment was repeated atleast 3 times. The error bars represent mean ± 
S.E.M. of independent measurements. 
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2.2 RESULTS 
2.2.1 Ca2+-free sNUCB1 inhibits hIAPP fibril formation at sub-
stoichiometric concentrations 
hIAPP is a 37-amino-acid long neuroendocrine hormone that readily 
aggregates into characteristic amyloid fibrils with β-sheet morphology. 
The aggregation kinetics of hIAPP alone or in the presence of equimolar 
or sub-stoichiometric amounts of Ca2+-free sNUCB1 were monitored 
using thioflavin-T binding assay (Fig.2.2A). For hIAPP alone, aggregation 
starts with a nucleation phase of “seed” formation within 5 min that 
extends into a rapidly growing elongation phase between 5 and 20 min. 
The growth phase finally plateaus into a stationary phase indicative of 
extensive fibril formation. Interestingly, in the presence of equimolar 
amount (32 µM) of Ca2+-free sNUCB1, there is significant decrease in the 
enhancement of thioflavin-T fluorescence suggesting that Ca2+-free 
sNUCB1 inhibits aggregation of hIAPP into amyloid fibrils. The 
inhibition persists even at sub-stoichiometric concentrations of 10.7 µM, 
6.4 µM and 3.2 µM Ca2+-free sNUCB1 with 32 µM hIAPP in the reaction 
mixture (Fig.2.2A). Interestingly, incubation with limiting concentration 
of 0.64 µM results in a similar aggregation profile as observed for hIAPP 
alone, suggesting that at this concentration Ca2+-free sNUCB1 cannot 
inhibit fibril formation. Subsequent TEM analysis of samples withdrawn 
from individual reactions show that hIAPP alone (32 µM) aggregates to  
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Figure 2.2. Concentration dependent inhibition of hIAPP fibril 
formation by Ca2+-free sNUCB1.   (A) We monitored the kinetics of 
hIAPP aggregation using enhancement in thioflavin-T fluorescence. The 
aggregation of 32 µ M hIAPP alone (blue) shows an initial nucleation 
phase which then extends into a rapid growth phase. The aggregation 
continues and reaches a plateau indicating the completion of aggregation 
with the formation of hIAPP amyloid fibrils. We then incubated hIAPP 
with different concentrations of Ca2+-free sNUCB1, ranging from 
equimolar (32 µ M) (black) to sub-stoichiometric amounts. The 
aggregation profiles show that Ca2+-free sNUCB1 effectively inhibits 
hIAPP aggregation when present at equimolar (32 µ M) concentrations. 
However, relative enhancement in thio-T fluorescence was observed when 
6.4 µM  (green) or 3.2 µ M (orange) Ca2+-free sNUCB1 was used. 
Interestingly, incubation with 0.64 µM (pink) concentration of Ca2+-free 
sNUCB1 results in an aggregation profile similar to hIAPP alone. We also 
monitored each reaction using TEM. As a control (B) hIAPP (32 µM) and 
Ca2+-free sNUCB1 were incubated alone and reaction was monitored by 
withdrawing samples at 7 min, 13 min and 60 min. hIAPP alone (32 µM) 
aggregates rapidly to form oligomers within 7 min which associate to form 
protofibrils and protofilaments within 13 min. These intermediates rapidly 
associate to form amyloid fibrils within 60 min. Unlike hIAPP, Ca2+-free 
sNUCB1 alone (32 µ M) does not aggregate to form higher order 
aggregates. (C) We also used TEM to monitor inhibition of hIAPP 
aggregation by varying concentrations of Ca2+-free sNUCB1. The 
micrographs show that Ca2+-free sNUCB1 when incubated with hIAPP at 
equimolar (32 µ M) or sub-stoichiometric concentration upto 3.2 µM 
concentration effectively inhibits hIAPP fibril formation. However at the 
limiting concentration of 0.64 µM, fibril formation is uninhibited as seen 
by the presence of amyloid fibrils in the 60 min sample. Thus inhibition of 
amyloid formation is a dose-dependent process. The scale bar represents 
200 nm.  
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Figure 2.2 
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form oligomers within 7 min, which continue to grow and form higher 
order intermediates protofilaments  and protofibrils as shown for the 
sample at 13 min. These protofibrillar intermediates associate and extend 
into mature amyloid fibrils within 60 min. In a control experiment, 32 µM 
Ca2+-free sNUCB1 alone does not aggregate when incubated at room 
temperature (Fig.2.2B). Thereafter, the reaction mixtures with 
stoichiometric or lower concentrations of Ca2+-free sNUCB1 preincubated 
with hIAPP (32 µM) were analyzed through TEM (Fig.2.2C). The samples 
withdrawn at 7 min and 13 min for reaction mixtures with 32 µM, 10.7 
µM, 6.4 µ M and 3.2 µ M concentration of Ca2+-free sNUCB1 show 
oligomeric species and the 60 min sample shows the presence of high 
order prefibrillar species in the reaction mixture. The formation of 
prefibrillar species in each of these reactions explains the observed 
increase in the thioflavin-T fluorescence as shown in Fig.2.2A. 
Furthermore, the absence of a lag phase in the presence of Ca2+-free 
sNUCB1 suggests towards a facilitated rapid association of hIAPP 
towards forming prefibrillar species by Ca2+-free sNUCB1. Interestingly, 
when 0.64 µM concentration of Ca2+-free sNUCB1 was used, fibrils were 
observed in the 60 min sample, showing that at this concentration Ca2+-
free sNUCB1 does not inhibit fibril formation by 32 µM hIAPP. Thus 
Ca2+-free sNUCB1 inhibits fibril formation by hIAPP in a dose-dependent 
manner. 
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2.2.2 Ca2+-bound sNUCB1 does not inhibit hIAPP fibril formation 
NUCB1 is a multi-domain protein with two Ca2+-binding EF hand 
domains (Fig.2.1). Ca2+ readily binds to sNUCB1 and induces 
conformational change within the protein subunit (Fig.1.2C,D). As shown 
earlier, Ca2+-free sNUCB1 effectively inhibits hIAPP aggregation into 
amyloid fibrils (Fig.2.2). In order to investigate the effect of Ca2+-binding 
on the functional efficacy of sNUCB1, we monitored inhibition of hIAPP 
aggregation by equimolar amounts (32 µM) of sNUCB1 in the absence or 
presence of 3 mM Ca2+ in the reaction mixture. The experiment was setup 
by first incubating Ca2+-free sNUCB1 in 20 mM Tris pH 7.5 
supplemented with or without 3 mM Ca2+. Thereafter stoichiometric 
amount (32 µ M) of hIAPP was added to each reaction mixture and 
samples were withdrawn at 15 min, 30 min and 60 min time points for 
analysis using TEM (Fig.2.3A). As shown, Ca2+-free sNUCB1 effectively 
inhibits fibril formation as only characteristic protofibrillar species are 
seen even at 60 min time point. In contrast, Ca2+-bound sNUCB1 does not 
inhibit fibril formation. TEM images for 15 min sample show presence of 
protofibrils and protofilaments, which continue to grow into fibrillar 
structures seen in coexistence with protofibrillar intermediates in the 30 
min sample. These eventually combine to form mature amyloid fibrils as 
shown for 60 min sample (Fig.2.3B). Thus Ca2+-binding nullifies the 
functional ability of sNUCB1 to effectively inhibit hIAPP fibril formation. 
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Figure 2.3. Ca2+-binding prevents sNUCB1 from inhibiting hIAPP 
fibril formation. We monitored aggregation of hIAPP in the presence of 
sNUCB1. (A) In the absence of Ca2+, equimolar amount (32 µ M) of 
sNUCB1 preincubated with hIAPP effectively inhibits aggregation of 
hIAPP into fibrils. The micrographs corresponding to 15 min and 30 min 
show the presence of oligomeric and protofibrillar species that do not 
progress to form fibrils as shown by the micrograph corresponding to the 
60 min sample. (B) However, in the presence of excess Ca2+ (3 mM) in the 
reaction mixture, sNUCB1 is unable to inhibit hIAPP aggregation. hIAPP 
aggregates to form protofibrils and protofilaments as observed at 15 min 
and 30 min respectively which eventually grow into mature fibrils within 
60 min. The scale bar on each micrograph represents 200 nm.   
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2.2.3 Engineered sNUCB1 Ca2+-insensitive mutant, 
sNUCB1(tetramutant), inhibits hIAPP fibril formation in a Ca2+-
independent manner 
sNUCB1 consists of two EF hand domains that bind to Ca2+. The 
sequence alignment of the 12-amino-acid long Ca2+-binding EF hand 
loops of NUCB1 with known Ca2+-binding proteins highlights the 
presence of completely conserved Asp residue at the 1st position followed 
by a Glu at the 12th position (marked by asterisk) (Fig2.4A). In order to 
disrupt the Ca2+-binding ability of sNUCB1, we mutated the Ca2+-
coordinating Asp253 and Asp305 in each EF hand domain to a Lys and 
Glu264 and Glu316 into Ala to generate a tetramutant namely 
sNUCB1(tetramutant) (Fig.2.1). The far-UV CD spectra of homogenously 
purified sNUCB1(tetramutant) showed a majorly helical structure 
(Fig.2.4B) similar to Ca2+-free  sNUCB1 itself (Fig.1.3A). Furthermore, 
the folding of sNUCB1(tetramutant) was observed to be non-cooperative 
and irreversible with an apparent Tm of 48.7 oC (Fig. 2.4B,inset). In 
addition, we performed ITC experiment to test for the ability of 
sNUCB1(tetramutant) to bind Ca2+. 5 µ l aliquots of 500 µM solution of 
Ca2+ were injected into a buffered solution of sNUCB1(tetramutant) in the 
reaction cell and the heat released per injection was recorded. The 
observed isotherm shows no significant heat release due to complete 
absence of Ca2+-binding to sNUCB1(tetramutant) (Fig.2.4C). Thereafter, 
in order to investigate the functional efficacy of sNUCB1(tetramutant)  
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Figure 2.4. sNUCB1(tetramutant) is majorly helical and does not bind 
to Ca2+. (A) A sequence alignment of the 12-residue Ca2+-binding loop 
within the EF hand domains of NUCB1 with similar regions from several 
known Ca2+-binding proteins is shown. The alignment highlights the 
presence of highly conserved aspartic acid at the beginning (pink) and 
glumatic acid (brown) at the end of the loop sequence. Interestingly, 
NUCB1 EF hand 1 loop sequence contains a conserved glycine at the 6th 
position (green) whereas it is an Arg (blue) in the EF hand 2 sequence. 
The respective aspartic and glutamic acid residues were mutated to 
generate sNUCB1(tetramutant). (B) The secondary structure analysis for 
sNUCB1(tetramutant) (8 µ M) was done using CD spectroscopy. The 
recorded spectrum shows that sNUCB1(tetramutant) is fully folded with a 
majorly helical secondary structure highlighted by the characteristic 
minima at 208 nm and 222 nm respectively. The inset shows the thermal 
unfolding transition for 8 µ M recombinant sNUCB1(tetramutant) 
monitored by recording CD signal at 222 nm at a heating rate of 1 oC / 
min. The trace is indicative of a multistep non-cooperatively folded 
protein with an apparent Tm of 48.7 oC. sNUCB1(tetramutant) was 
generated to nullify the Ca2+-binding ability of sNUCB1. Thus, (C) we 
used isothermal titration calorimetry (ITC) to measure the Ca2+-binding 
affinity of sNUCB1(tetramutant). 5 µl aliquots of 500 µM CaCl2.6H2O 
were injected into the reaction cell containing 50 µ M solution of 
sNUCB1(tetramutant) at 25 oC and the heat released per injection was 
recorded. The inset shows effectively no release of energy as Ca2+ is 
injected into the sample cell containing sNUCB1(tetramutant), indicating 
the absence of any binding event. 
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towards inhibiting hIAPP fibril formation we incubated equimolar 
amounts of hIAPP with sNUCB1(tetramutant) in the absence and presence 
of 3 mM Ca2+ in the reaction mixture. Samples were withdrawn at 15 min, 
30 min and 60 min time points and analyzed using TEM (Fig.2.5). As 
shown, sNUCB1(tetramutant) effectively inhibits hIAPP fibril formation 
in the absence of Ca2+ since no fibrillar aggregates are observed for the 60 
min sample (Fig.2.5A). Intriguingly, unlike sNUCB1, 
sNUCB1(tetramutant) also inhibits fibril formation in the presence of 
excess Ca2+ in the reaction mixture. TEM images of the samples 
withdrawn at various time points show complete absence of amyloid 
fibrils (Fig.2.5B). Hence the engineered sNUCB1(tetramutant) effectively 
inhibits hIAPP fibrils formation but unlike sNUCB1 is insensitive to the 
presence of Ca2+ in the reaction mixture. 
 
2.2.4 sNUCB1 and sNUCB1(tetramutant) disaggregate hIAPP fibrils 
hIAPP rapidly aggregates in vitro to form amyloid fibrils. As shown 
earlier, sNUCB1 and sNUCB1(tetramutant) effectively inhibit hIAPP 
fibril formation (Fig.2.3,2.5). We further investigated the functional ability 
of these proteins towards disaggregating preformed fibrils. 32 µM hIAPP 
was incubated in 20 mM Tris pH 7.5 buffer for 60 min to form mature 
amyloid fibrils. Thereafter, equimolar amounts of Ca2+-free sNUCB1 or 
sNUCB1(tetramutant) were added to the reaction mixture and samples 
were withdrawn after 15 min, 30 min and 60 min for analysis using TEM. 
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Figure 2.5. Ca2+ does not prevent sNUCB1(tetramutant) from 
inhibiting  hIAPP aggregation. We monitored aggregation of hIAPP in 
the presence of sNUCB1(tetramutant). (A) In the absence of Ca2+, 
equimolar amount (32 µ M) of sNUCB1(tetramutant) preincubated with 
hIAPP effectively inhibit aggregation of hIAPP into fibrils. The 
micrographs corresponding to 15 min and 30 min show the presence of 
oligomeric and protofibrillar species that do not progress to form fibrils as 
shown by the micrograph corresponding to the 60 min sample. (B) 
Interestingly, even in the presence of excess Ca2+ (3 mM in the reaction 
mixture, sNUCB1(tetramutant) is still effective at inhibiting fibril 
formation. The micrographs for the samples withdrawn at 15 min, 30 min 
and 60 min time points show complete absence of fibril formation. The 
scale bar on each micrograph represents 200 nm.   
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The micrographs show that in the absence of Ca2+ both sNUCB1 and 
sNUCB1(tetramutant) effectively disaggregate hIAPP fibrils into smaller 
molecular species within 15 min. These species do not associate to form 
fibrils even at 60 min time point (Fig.2.6A and B). Interestingly, Ca2+-
binding nullifies the functional ability of sNUCB1 towards disaggregating 
hIAPP fibrils. TEM images corresponding to samples withdrawn after 
addition of equimolar amount of sNUCB1 to fibrils in the presence of 3 
mM Ca2+ show fibrillar species in the micrographs at all monitored time 
points. Intriguingly, sNUCB1(tetramutant) is insensitive to the presence of 
Ca2+ in the reaction mixture and disaggregates hIAPP fibrils even in the 
presence of 3 mM Ca2+. TEM images for 15 min, 30 min and 60 min time 
point show that sNUCB1(tetramutant) effectively disaggregates hIAPP 
fibrils into smaller molecular species within 15 min which continue to 
exist even at 60 min (Fig2.6A and B). Thus Ca2+-binding disrupts the 
ability of sNUCB1 to disaggregate amyloid fibrils but 
sNUCB1(tetramutant) continues to perform its function even in the 
presence of excess Ca2+ in the reaction mixture. 
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Figure 2.6. Ca2+ prevents sNUCB1 but not sNUCB1(tetramutant) 
from disaggregating hIAPP fibrils. We monitored disaggregation of 
hIAPP fibrils in the presence of (A) sNUCB1 or (B) 
sNUCB1(tetramutant). In the absence of Ca2+, equimolar amount (32 µM) 
of sNUCB1 or sNUCB1(tetramutant) incubated with hIAPP fibrils 
effectively disaggregates them into smaller molecular species. The 
disaggregation was observed within 15 min of incubation and continues 
with effective disaggregation seen in 30 min and 60 min micrographs 
corresponding to samples withdrawn from the reaction mixture. However, 
when excess Ca2+ (3 mM) is present in the reaction mixture, sNUCB1 is 
unable to disaggregate hIAPP fibrils as shown by the presence of 
aggregates characteristic of fibrils for all monitored time points. Unlike 
sNUCB1, sNUCB1(tetramutant) is still effective at disaggregating hIAPP 
fibrils even in the presence of 3 mM Ca2+ in the reaction mixture. The 
microgrpahs for the 15 min, 30 min and 60 min show complete absence of 
any fibrillar aggregates, indicating that potent activity of 
sNUCB1(tetramutant) persists even in the presence of Ca2+. The scale bar 
represents 200 nm.   
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2.2.5 Ca2+-free sNUCB1 inhibits hIAPP fibrillization along any stage 
of amyloid formation pathway 
We monitored the aggregation of 32 µM hIAPP in 20 mM Tris pH 7.5 
using thioflavin-T binding assay (Fig.2.7). The aggregation curve 
represented by solid spheres shows the nucleation phase in blue, growth 
phase in green and the saturation phase corresponding to formation of 
mature amyloid fibrils in yellow. In order to monitor  the functional ability 
of Ca2+-free sNUCB1 towards inhibiting fibril formation when added at 
different states along the hIAPP aggregation pathway, 32 µM Ca2+-free 
sNUCB1 was  individually added to hIAPP aggregation reaction in the 
nucleation phase at 7 min, middle of growth phase at 13 min and in the 
steady-state phase at 40 min (pink spheres). As a control, TEM 
micrographs for samples prior to the addition of Ca2+-free sNUCB1 show 
presence of oligomers at 7 min, protofibrillar intermediates in 13 min and 
mature fibrils in 40 min. Subsequently each of these species was incubated 
with equimolar amount (32 µM) of Ca2+-free sNUCB1 and samples were 
withdrawn after 60 min for TEM analysis (Fig.2.7). Interestingly, TEM 
analysis for each reaction mixture shows complete absence of amyloid 
fibrils. This suggests that Ca2+-free sNUCB1 is effective at inhibiting fibril 
formation even when added at any intermediate state along the 
aggregation pathway. Moreover, as shown earlier, once the fibrils are 
formed Ca2+-free sNUCB1 can effectively disaggregate them into smaller 
molecular species, which do not aggregate into amyloid fibrils.  
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Figure 2.7. Ca2+-free sNUCB1 inhibits hIAPP amyloidogenesis in a 
state-independent manner. (A) We monitored hIAPP (32 µM) 
aggregation using thioflavin-T (32 µM) with the lag phase in blue, growth 
phase in green and stationary phase in yellow. The circles in pink indicate 
the corresponding time points at which sNUCB1 was added to the 
aggregation reaction. hIAPP (32 µM) aggregation was allowed to proceed 
to (A) nucleation phase at 7 min, (B) mid-point of growth phase at 15 min 
and (C) initiation of stationary phase at 40 min after which equimolar 
amount (32 µM) of Ca2+-free sNUCB1 was added to the reaction mixture. 
TEM images were collected immediately before addition of sNUCB1 and 
60 min after incubation with Ca2+-free sNUCB1. The micrographs 
corresponding to samples withdrawn at 60 min after addition show that 
Ca2+-free sNUCB1 both effectively inhibits the progression of seeds into 
mature fibrils and also disaggregates amyloid fibrils. The scale bar 
represents 200 nm. 
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Thus Ca2+-free sNUCB1 possesses the unique ability to inhibit 
amyloidogenesis of hIAPP at any stage of fibril formation. 
 
2.2.6 Ca2+-free sNUCB1 inhibits fibril formation by stabilizing hIAPP 
prefibrillar species 
Our earlier results showed that Ca2+-free sNUCB1 effectively inhibits 
hIAPP fibril formation and TEM analysis of samples withdrawn from the 
reaction mixture after 60 min show the presence of molecular species 
much smaller than the mature fibrils. Hence to characterize these observed 
molecular species we incubated 32 µM of Ca2+-free sNUCB1 with 32 µM 
hIAPP in 20 mM Tris pH 7.5 buffer at room temperature for 60 min. 
Thereafter, we injected 200 µ l of reaction mixture onto a buffer 
equilibrated Superose6 10 / 30 GL column and the elution profile 
corresponding to absorbance at 280 nm was recorded (Fig.2.8A, blue 
curve). Since hIAPP does not have any Trp residues, absorbance at 280 
nm must primarily result from contribution of Trp residues of sNUCB1. 
Injection of 32 µM solution of Ca2+-free sNUCB1 alone onto the column 
generates a peak centered at 12 ml (Fig.2.8A, dotted red curve) (Peak2). In 
order to determine the molecular constituents of Peak1 and Peak2, we 
fractionated the individual peaks and performed dot blot analysis. The 
results show that Ca2+-free sNUCB1 was present in both Peak1 and Peak2 
fractions whereas hIAPP was present only in the Peak1 fraction  
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Figure 2.8. Biophysical characterization of Ca2+-free sNUCB1 stabilized 
hIAPP protofibrillar species. (A) We used size exclusion chromatography 
using Superose6 10/30 GL column to elute Ca2+-free sNUCB1 alone (32 
µM) (red dotted curve). Thereafter a 60 min sample from a reaction mixture 
with equimolar concentration of hIAPP and Ca2+-free sNUCB1 incubated at 
t = 0 was injected and the fractions corresponding to the eluting peaks were 
collected (blue curve). Ca2+-free sNUCB1 alone elutes in Peak2 centered at 
12 ml while the reaction mixture gives an additional peak namely Peak1 
eluting at 7.8 ml. We further investigated the molecular constituents within 
each peak using dot-blot assay. (B) We blotted 5 µ l of Peak1 and Peak2 
fractions on a PVDF membrane and probed each of them with either anti-
sNUCB1 antibody or anti-hIAPP antibody. The upper blot shows that 
sNUCB1 is present in both peak fractions  whereas the lower blot shows 
that hIAPP is present only in Peak1 and not Peak2 fractions. As controls, 
hIAPP and sNUCB1 were blotted to show that the antibodies are specific 
with no cross-reactivity. Thereafter (C) we used TEM to analyze both 
Peak1 and Peak2 fractions. Micrograph corresponding to Peak1 shows the 
presence of oligomeric and prefibrillar species whereas Peak2 fraction 
shows no higher order structures. As a control, hIAPP fibrils formed within 
60 min with hIAPP alone are shown in the inset for micrograph 
corresponding to Peak1. (D) We used both multi-angle light scattering 
(MALS) (left) and dynamic light scattering (DLS) (right) analysis across 
Peak1 and Peak2 respectively.  MALS analysis across Peak1 estimates a 
molecular mass in the range of 2 - 6 MDa and DLS predicts hydrodynamic 
radii in the range of 22 - 42 nm. These numbers point towards an isolated 
sNUCB1-bound prefibrillar species of hIAPP. In addition, MALS analysis 
of Peak2 predicts a molecular mass in the range of 97 - 99 kDa, which 
corresponds to the molecular mass of a dimer of Ca2+-free sNUCB1. DLS 
analysis gives an invariant hydrodynamic radius of 6.2 nm, which is 
characteristic for Ca2+-free sNUCB1 dimer. Thereafter we utilized STEM to 
quantitatively determine a mass / unit length (M / L) distribution of 
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prefibrillar species in Peak1 fraction. (E) The analysis shows the presence 
of prefibrillar species with M / L ranging from 1 - 7 kDa / Å with species 
predominantly ranging from 2 - 5 kDa / Å. The adjacent micrograph shows 
a typical large-angle dark-field cryo-STEM image of Peak1 fraction with  
tobacco mosaic virus (TMV) helical rod as the calibration control for data 
analysis. The scale bar represents 100 nm. Furthermore, the images below 
represent examples of prefibrillar species observed in STEM wherein the 
width of each box represents 200 nm. (F) We further investigated the 
stability of the Peak1 fraction by incubating it at room temperature for 7 
days with constant stirring. Thereafter, we injected the reaction mixture 
onto a buffer pre-equilibrated Superose6 10/30 GL column and the elution 
profile at 280 nm was recorded. The trace shows that Peak1 is reproduced 
suggesting that Ca2+-free sNUCB1 bound hIAPP prefibrillar species is 
highly stable and does not proceed to form fibrillar aggregates as shown by 
the TEM of the eluting Peak1 fraction.  
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(Fig.2.8B). As a control, Ca2+-free sNUCB1 and hIAPP alone were blotted 
onto the membrane to test for the cross-reactivity of each antibody. Both 
Peak1 and Peak2 fractions were further subjected to TEM analysis. The 
corresponding micrograph shows the presence of only prefibrillar species 
in Peak1 fraction whereas Peak2 fraction shows a typical image 
corresponding to Ca2+-free sNUCB1 without any aggregates (Fig.2.8C).  
 
In order to characterize the species constituting the Peak1 and Peak2 
fractions, we performed multi-angle light scattering (MALS) and dynamic 
light scattering (DLS) analysis to estimate the average molecular mass and 
the hydrodynamic radii of the eluting species. MALS analysis across 
Peak1 estimates a molecular mass in the range of 2 - 6 MDa for the eluting 
species with the hydrodynamic radii of 22 - 42 nm obtained from the DLS 
analysis across Peak1 (Fig.2.8D). These numbers suggest that Ca2+-free 
sNUCB1 binds to and stabilizes a high molecular mass prefibrillar hIAPP 
aggregate. Similar analysis across Peak2 fraction gave a 97 - 99 kDa 
molecular mass species with a hydrodynamic radii of 6.2 nm (Fig.2.8D), 
characteristic for a dimer of Ca2+-free sNUCB1 alone (Fig.1.4). We 
further performed scanning transmission electron microscopy (STEM) 
analysis on Peak1 fraction to estimate the mass per unit length (M / L) for 
the observed prefibrillar species. Dark field images were collected for 
Peak1 fraction with Tobacco Mosaic Virus (TMV) as an internal standard 
and PCMass30 software was used for image analysis. The M / L data was 
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pooled and is presented in histograms. A typical dark field micrograph is 
shown with several prototypical examples with mass densities 
corresponding to the prefibrillar species shown below it. The data shows 
that Peak1 fraction comprises of molecular species with M / L ranging 
from 1 - 7 kDa / Å with predominant species varying from 2 - 5 kDa / Å 
(Fig.2.8E). Earlier, similar analysis by Goldsbury et al. on 100 nm long 
hIAPP fibril segments reported a M / L in the range of 2 - 5 kDa / Å with a 
median at 3 kDa / Å (86). This suggests that sNUCB1 stabilized 
prefibrillar species is comparable in mass density to the reported 
protofibrils. However, these 40-80 nm long prefibrillar species are 
stabilized by bound sNUCB1. Thus the M / L contributed by hIAPP alone 
to the prefibrillar species would be less when compared to protofibrils 
alone. We thus refer to this species as prefibrillar. We further investigated 
the stability of these Ca2+-free sNUCB1 bound prefibrillar species by 
incubating Peak1 fraction at room temperature to facilitate their 
association into mature fibrils. The reaction mixture was constantly stirred 
for 7 days after which it was injected onto a buffer equilibrated Superose6 
10 / 30 GL column. Interestingly, we were able to reproducibly generate 
the Peak1 as earlier. TEM analysis of the sample before and after elution 
from the column shows the characteristic prefibrillar species as observed 
before for Peak1 (Fig.2.8F). This shows that Ca2+-free sNUCB1 bound 
prefibrillar species is highly stable and does not associate further to form 
fibrils. These biophysical experiments prove that Ca2+-free sNUCB1 
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inhibits hIAPP fibril formation by stabilizing a high molecular mass 
prefibrillar species of hIAPP. 
  
As a control, we performed ITC experiments with Pramlintide (Fig2.1), a 
non-aggregating analog of hIAPP. We injected Pramlintide into a reaction 
cell with buffered solution of Ca2+-free sNUCB1 and heat released per 
injection was recorded. The result shows that Pramlintide does not interact 
with Ca2+-free sNUCB1 (Fig.2.9A). In addition, we also performed SEC 
experiments similar to as shown in Fig.2.8A. We incubated 32 µM of 
pramlintide with equimolar amount of Ca2+-free sNUCB1 for 3 h after 
which the reaction mixture was injected onto a buffer equilibrated 
Superose6 10 / 30 GL column. Unlike earlier, we did not observe an 
elution profile with Peak1 suggesting that Ca2+-free sNUCB1 interacts 
only with an aggregated form of hIAPP and probably not the monomeric 
form (Fig.2.9B).  
 
2.2.7 sNUCB1 does not possess protease activity and cannot cleave 
hIAPP 
The above-proposed mechanism of inhibition of hIAPP fibril formation 
does not rule out the possibility of a proteolytic activity of sNUCB1. An 
alternate hypothesis might be that sNUCB1 proteolytically cleaves hIAPP 
into smaller fragments, which can still aggregate to form protofibrils 
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Figure 2.9. Pramlintide does not bind to Ca2+-free sNUCB1.  (A) We used 
isothermal titration calorimetry (ITC) to measure the binding affinity of the non-
aggregating analog of hIAPP namely Pramlintide to Ca2+-free sNUCB1. 5 µl 
aliquots of 600 µ M Pramlintide solution were injected into the reaction cell 
containing 40 µM solution of Ca2+-free sNUCB1  at 25 oC and the heat released 
per injection was recorded. The inset shows effectively no release of energy as 
Pramlintide is injected into the reaction cell containing Ca2+-free sNUCB1, 
indicating the lack of any binding event. In addition, (B) we incubated 
Pramlintide with equimolar amount (32 µM) of Ca2+-free sNUCB1 for 5 h. 200 µl 
of the reaction was injected onto a buffer equilibrated Superose6 10 / 30 GL 
column and the chromatogram corresponding to sample absorbance at 280 nm 
was recorded. The plot shows the presence of only a single peak centered at the 
characteristic volume (~12 ml) for elution of Ca2+-free sNUCB1 alone. The 
absence of a lower elution volume peak suggests that Pramlintide does not 
aggregate into higher order structures due to which Ca2+-free sNUCB1 does not 
bind to it. 
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Figure 2.10. Ca2+-free sNUCB1 / sNUCB1(tetramuant) do not possess 
protease activity. (A) We incubated 10 µ g of BODIPY FL-Casein 
substrate in digestion buffer (10 mM Tris pH 7.8, 100 µM NaN3) for 5 
min at 25 oC followed by time-based fluorescence emission measurement 
with λex = 505 nm and λem = 513 nm. After 60 sec, 100 µg of Ca2+-free 
sNUCB1 (green) or 10 µg of Trypsin (orange) was added to the reaction 
mixture and enhancement in fluorescence was recorded. As shown, 
addition of Trypsin causes significant enhancement in the observed 
fluorescence intensity whereas even 10-fold excess of Ca2+-free sNUCB1 
did not result in any notable enhancement in fluorescence intensity. This 
suggests that Ca2+-free sNUCB1 possibly does not proteolytically cleave 
BODIPY FL-Casein. In addition, (B) protease digestion assays were setup 
with 20 µg of either Trypsin or sNUCB1(tetramuant) incubated with 20 
µg BODIPY FL-Casein substrate and samples were withdrawn at different 
subsequent time points for SDS-PAGE analysis. The Coomassie stained 
gel shows that Trypsin rapidly cleaves the substrate into smaller molecular 
fragments whereas sNUCB1(tetramutant) is unable to cleave the substrate 
even after 60 min of incubation. Similarly, (C) 30 µg BODIPY FL-Casein 
substrate was incubated with 3 µ g or 30 µ g of Ca2+-free sNUCB1 and 
samples were withdrawn after 5 min and 60 min for SDS-PAGE analysis. 
As earlier, the Coomassie stained gel image shows that similar to 
sNUCB1(tetramutant), Ca2+-free sNUCB1 also does not possess any 
proteolytic activity. In addition, (D) the proteolytic activity of Ca2+-free 
sNUCB1 towards hIAPP was also investigated using LC-MS. We 
incubated equimolar amount (32 µM) of Ca2+-free sNUCB1 with hIAPP 
and sample was withdrawn after 2 h for analysis using LC-MS. The mass 
spectrum shows characteristic peak pattern for sNUCB1 (pink) and a 
single peak for hIAPP (blue). The spectrum shows a complete absence of 
any smaller fragments of hIAPP confirming that Ca2+-free sNUCB1 does 
not protealytically cleave hIAPP. 
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similar to the observed sNUCB1-bound prefibrillar species. We thereby 
investigated for any proteolytic activity of Ca2+-free sNUCB1 by first 
using a fluorescence based protease assay with BODIPY FL-Casein as the 
substrate. In principle, if Ca2+-free sNUCB1 proteolytically cleaves 
Casein, the intrinsic quenching of the BODIPY fluorophore label on 
Casein would be relieved, resulting in enhanced fluorescence readout. As 
shown in figure 2.10A, addition of stoichiometric amount of Trypsin, a 
serine-protease, to a buffered solution of BODIPY FL-Casein substrate 
causes a significant enhancement in the fluorescence intensity. In contrast, 
addition of even 10-fold molar excess of Ca2+-free sNUCB1 does not 
result in any notable enhancement in the fluorescence intensity of labeled 
Casein. SDS-PAGE analysis of the samples withdrawn from the reaction 
mixtures with equimolar or excess Ca2+-free sNUCB1 incubated with 
BODIPY FL-Casein substrate show that unlike Trypsin (Fig.2.10B), 
neither sNUCB1(tetramuant) (Fig.2.10B) nor Ca2+-free sNUCB1 
(Fig.2.10C) cleave BODIPY FL-Casein. Reaction mixtures containing 
Trypsin show generation of lower molecular mass fragments due to 
proteolytic cleavage of BODIPY FL-Casein which is not observed upon 
incubation with either sNUCB1(tetramuant) or Ca2+-free sNUCB1. 
However, to directly rule out the proteolysis of hIAPP monomer by Ca2+-
free sNUCB1 as a contributing factor towards inhibition of fibril 
formation, we incubated Ca2+-free sNUCB1 with equimolar concentration 
(32 µM) of hIAPP for 45 min and subjected the reaction mixture to liquid 
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chromatography-mass spectrometry (LC-MS). As shown in figure 2.10D, 
the mass spectrum shows the peaks characteristic for sNUCB1 (pink 
spectrum) and a peptide peak for hIAPP alone (purple peak). This suggests 
that inhibition of hIAPP aggregation by Ca2+-free sNUCB1 does not 
involve proteolysis of hIAPP as no other cleavage products for hIAPP 
were observed. Thus sNUCB1 inhibits hIAPP fibril formation by capping 
the ends of a high molecular mass soluble prefibrillar species of hIAPP 
and thereby inhibiting their further association into mature amyloid fibrils.  
 
NUCB1 is a ubiquitously expressed protein, which is found both 
intracellularly and extracellularly. The above results show that NUCB1 is 
not an intracellular endopeptidase but since NUCB1 possesses a N-
terminal (NT) signal sequence and is found extracellularly, we could not 
rule out the possibility of it being an extracellular protease like a matrix 
metalloproteinase (MMP). MMPs are extracellular endopeptidases whose 
ability to proteolytically cleave their substrates is dependent on their 
ability to bind to Zn2+. Hence in order to test for matrix metalloproteinase 
activity of sNUCB1, we first measured the Zn2+-binding ability of Ca2+-
free sNUCB1 using ITC. 5 µ l aliquots of 400 µM ZnCl2 solution were 
injected into a buffered solution of 50 µ M Ca2+-free sNUCB1 in the 
reaction cell and heat released per injection was recorded. The data fit to a 
“one-set-of-site” model show binding of a monomer of sNUCB1 to one 
Zn2+-cation (N = 0.99 ± 0.08) with a Kd value of 22 ± 1.89 µM  
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Figure 2.11. Ca2+-free sNUCB1 binds to Zn2+ but is not a Matrix 
Metalloproteinase. (A) We used isothermal titration calorimetry (ITC) to 
measure the Zn2+-binding affinity of sNUCB1. 5 µl aliquots of 400 µM 
ZnCl2 were injected into the reaction cell containing 50 µM solution of 
Ca2+-free sNUCB1 at 25 oC and the heat released per injection was 
recorded. The inset shows a fit of the data using “one-set of sites” model 
using the concentration for Ca2+-free sNUCB1 monomer as the interacting 
subunit. The calculated dissociation constant for Zn2-binding to Ca2+-free 
sNUCB1 was 22µM ± 1.96 µM with a stoichiometry of N = 0.99 ± 0.07 
suggesting that each subunit of a dimer of Ca2+-free sNUCB1 binds to one 
Zn2+-cation. Thereafter we used FRET based assay to investigate the 
MMP activity of Zn2+-bound sNUCB1. Sixteen synthetic FRET peptide 
substrates were incubated with either (B) 15 ng MMP-1, (C) 7.5 ng Zn2+-
bound sNUCB1 or (D) 750 ng Zn2+-bound sNUCB1 and the fluorescence 
readout was recorded at 10 min intervals for 90 min at room temperature 
(λex = 490 nm, λem = 520 nm). The results show that (B) incubation of the 
peptide substrates with MMP-1 results in significant enhancement in the 
fluorescence readout for a number of substrates due to their proteolytic 
cleavage. However incubation with both (C) 7.5 ng and (D) 750 ng Zn2+-
bound sNUCB1 did not cause any enhancement. The fluorescence 
emission recorded for the substrate alone was subtracted from each 
monitored time point. The results show that  unlike MMP-1, Zn2+-bound 
sNUCB1 does not possess any MMP activity. 
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(Fig.2.11A). Thereafter, in order to check for matrix metalloproteinase 
activity of Zn2+-bound sNUCB1 we performed a MMP test assay using 
sixteen synthetic FRET peptides wherein 5-FAM (5-aminocarboxy 
fluorescein) and QXL™520 are used as the fluorophore / quencher pair. 
Within the peptide, QXL™520 quenches the fluorescence readout of 5-
FAM whereas upon MMP mediated proteolytic cleavage of the peptide 
this internal quenching is relieved and the fluorescence emission readout 
for 5-FAM can be monitored at Ex / Em wavelengths = 490 / 520 nm. As 
a control we incubated 15 ng of MMP-1 in 50 µl of reaction volume with 
optimal concentration of each substrate at room temperature and the 
fluorescence emission readout was recorded for 90 min at 10 min time 
intervals. As shown in Figure 2.11B, MMP-1 has strong proteolytic 
activity towards Substrate 14 and relatively weaker activity towards 
Substrates 3, 4, 11 and 12. The fluorescence emission readout for the 
peptide substrates alone was substracted at each monitored time point. 
Thereafter the MMP activity of Zn2+-bound sNUCB1 was monitored in an 
identical experimental setup. We incubated either 7.5 ng or 750 ng of 
Zn2+-bound sNUCB1 with the peptide substrates and the fluorescence 
emission readout was recorded. The results show that unlike MMP-1, 
Ca2+-free sNUCB1 does not cleave any of the peptide substrates 
(Fig.2.11C,D). This is in agreement with earlier observations that Ca2+-
free sNUCB1 does possess protease activity. Thus Ca2+-free sNUCB1 can 
bind to Zn2+ but is not a MMP. 
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2.2.8 Ca2+-free sNUCB1 binds to ATP with low affinity but neither 
reverts nor inhibits Luciferase heat denaturation 
NUCB1 is a multi-domain protein with an extended CT domain (Fig2.1, 
1.4). Our results so far do not rule out the possibility that sNUCB1 can 
have chaperone like activity wherein it can utilize energy from ATP 
hydrolysis to perform its function. Therefore, we investigated the ATP-
binding ability of Ca2+-free sNUCB1 using ITC. 5 µl aliquots of 600 µM 
solution of ATP were injected into a buffered solution of 40 µM Ca2+-free 
sNUCB1 in the reaction cell and the heat released per injection was 
recorded. The plotted data was fit to a “one-set-of-sites” model wherein 
the concentration of dimeric Ca2+-free sNUCB1 was used to obtain the fit. 
The results show that a dimer of Ca2+-free sNUCB1 binds to one (N= 1.26 
± 0.12) ATP molecule with a Kd value of 18.3 ± 0.86 µM (Fig.2.12A). In 
addition, Figure 2.12B shows that Ca2+-free sNUCB1 does not bind to 
ADP. Thereafter, the ATP-binding to Ca2+-free sNUCB1 was extended to 
test for its ability to refold denatured proteins using firefly Luciferase 
based chemiluminiscence assay (Fig.2.12C). Recombinant Luciferase was 
heat denatured at 42 oC for 10 min. The denatured Luciferase was then 
incubated in ATP containing buffer either alone or with Ca2+-free 
sNUCB1  and the chemiluminiscence of luciferin was recorded at different 
time intervals. The green bar in Fig.2.12C shows chemiluminiscence of 
heat denatured Luciferase at t = 0 in comparison to recombinant 
Luciferase chemiluminiscence (yellow bar). The significant decrease in  
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Figure 2.12. Ca2+-free sNUCB1 binds to ATP but cannot refold 
denatured Luciferase or protect it against heat denaturation. We used 
isothermal titration calorimetry (ITC) to measure the (A) ATP-binding or 
(B) ADP-binding affinity of Ca2+-free sNUCB1. 40 µM  Ca2+-free 
sNUCB1 was titrated with 600 µM ATP / ADP solution at 25 oC and the 
heat released per injection was recorded and integrated. The isotherms 
show that Ca2+-free sNUCB1 binds only to ATP and does not bind ADP. 
A non-linear least squares fit of the calculated values using the “one-set of 
sites” model by using the concentration for Ca2+-free sNUCB1 dimer 
resulted in an excellent fit as shown in the inset. The calculated 
dissociation constant for ATP-binding to Ca2+-free sNUCB1 was 18.4 ± 
0.86 µM with a stoichiometry of N = 1.26 ± 0.12 suggesting that each 
dimer of Ca2+-free sNUCB1 binds to one ATP molecule. Thereafter we 
used a Luciferase activity assay to test for the ability of Ca2+-free sNUCB1 
to affect the (C) refolding or (D) heat denaturation of Luciferase. (C) We 
incubated 0.7 nM of native (yellow) or heat denatured (green) firefly 
Luciferase with the substrate and the chemiluminiscence was recorded. 
Thereafter 0.7 nM of heat denatured Luciferase was incubated with 0.7 
nM (blue), 7 nM (orange) or 70 nM (red) of Ca2+-free sNUCB1 in a 
reaction mixture with the substrate and the chemiluminiscence was 
recorded after 10 min, 20 min and 30 min. The results show that Ca2+-free 
sNUCB1 does not influence refolding of denatured Luciferase. 
Subsequently, (D) we investigated the ability of Ca2+-free sNUCB1 to 
affect Luciferase heat denaturation. In the control experiment, similar 
chemiluminiscence was recorded for reaction with 0.7 nM Luciferase 
alone (yellow) or Luciferase incubated with 70 nM Ca2+-free sNUCB1 
(grey). Subsequently, Luciferase alone (brown) or with Ca2+-free sNUCB1 
(pink) was incubated at 42 oC for 10 min and the chemiluminiscence was 
monitored. The results show significant and similar decrease in the 
recorded chemiluminiscence suggesting that Ca2+-free sNUCB1 does not 
protect Luciferase against heat denaturation.  
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the recorded chemiluminiscence confirms the heat denaturation of 
Luciferase. Thereafter we incubated heat denatured Luciferase with 0.7 
nM (blue bar), 7 nM (orange bar) or 70 nM (red bar) Ca2+-free sNUCB1 in 
the presence of luciferin and ATP and the chemilumiscence was recorded 
at 10 min, 20 min and 30 min time points. The absence of any relative 
enhancement in the recorded chemiluminiscence with time suggests that 
Ca2+-free sNUCB1 cannot refold heat denatured Luciferase.   
 
In an additional experiment, we also investigated the ability of Ca2+-free 
sNUCB1 to inhibit heat denaturation of Luciferase (Fig.2.13D). As a 
control, we incubated 0.7 nM of Luciferase alone (yellow bar) or in the 
presence of 70 nM Ca2+-free sNUCB1 (grey bar) with the substrate and 
recorded the chemiluminiscence output. The results show that Ca2+-free 
sNUCB1 alone does not affect the enzymatic activity of Luciferase. 
Thereafter, we incubated 0.7 nM Luciferase alone (pink bar) or with 70 
nM Ca2+-free sNUCB1 (brown) at 42 oC for 10 min after which substrate 
was added to each solution and the chemiluminiscence recorded. As 
shown, incubation of Luciferase alone or with Ca2+-free sNUCB1 results 
in similar reduction in the recorded chemiluminiscence suggesting that 
Ca2+-free sNUCB1 does not inhibit Luciferase against heat denaturation. 
Hence although Ca2+-free sNUCB1 does not affect the catalytic activity of 
Luciferase, it cannot protect it against heat denaturation.  
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2.2.9 Ca2+-free sNUCB1 inhibits fibril formation by “capping” the 
ends of prefibrillar intermediates 
NUCB1 is a 461-amino-acid long polypeptide, which lacks cysteine 
residues in its primary sequence. This provides an opportunity to site-
specifically introduce cysteine residues that can be used for labeling the 
homogenously purified protein subunit. We generated a mutant of 
sNUCB1 namely sNUCB1(S44C) wherein a Ser44 residue was mutated to 
a Cys (Fig2.1). Ca2+-free sNUCB1(S44C) similar to sNUCB1, is stable in 
solution and does not aggregate. TEM analysis of a solution of 32 µM of 
Ca2+-free sNUCB1(S44C) incubated alone does not show any aggregation 
(Fig.2.13A). Thereafter we investigated inhibition of hIAPP fibril 
formation by incubating Ca2+-free sNUCB1(S44C) with equimolar 
concentration (32 µM) of hIAPP in 20 mM Tris pH 7.5 buffer solution. 
TEM analysis of sample withdrawn after 60 min shows complete absence 
of fibrillar aggregates, which suggests that Ca2+-free sNUCB1(S44C) can 
inhibit hIAPP fibril formation (Fig.2.13A).  
 
In order to chemically label Ca2+-free sNUCB1(S44C), we incubated the 
protein overnight at 4 oC with molar excess of nano-Au maleimide to 
covalently conjugate nano-Au to the cysteine residue. Thereafter the 
labeled subunit was separated from excess nano-Au in the reaction 
mixture by injecting the reaction mixture onto a Superose6 10 / 30 GL 
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Figure 2.13. Nano-Au labeled sNUCB1(S44C) “caps” hIAPP 
prefibrillar species. We designed a single-point mutant of sNUCB1 
namely sNUCB1(S44C) whereby a Ser44 was mutated to a Cys in the 
primary sequence of sNUCB1. (A) Ca2+-free sNUCB1(S44C) alone does 
not aggregate and upon incubation with equimolar concentration (32 µM) 
of hIAPP effectively inhibits fibril formation as seen by the complete 
absence of fibrillar species from a 60 min sample of the reaction mixture 
(Scale bar : 200 nm). We then utilized the presence of Cys44 in 
sNUCB1(S44C) to nano-Au label the protein. (B) Nano-Au labeled 
sNUCB1(S44C) was purified through SEC using Superose6 10/30 GL 
column. The elution chromatogram shows the co-elution of a 
characteristic 280 nm peak for the protein (black) and the 420 nm peak for 
nano-Au (red). The inset shows a schematic of the typical conjugation 
reaction that happens to covalently link the nano-Au to an unlabeled 
macromolecule through a Cys residue. Thereafter, (C) we prepared a 
calibration curve (blue) from a serial dilution series of unlabeled 
sNUCB1(S44C) to estimate the concentration of the nano-Au labeled 
protein in the eluting peak for the labeled protein. As shown, the 
concentration for the labeled protein is 751.9  µg / µl which is equivalent 
to 14.7 µM. The concentration of nano-Au in the labeled protein sample 
(15.08 µM) was estimated from the UV-Vis absorption of the sample at 
λ420nm , a wavelength at which only the nano-Au probe absorbs energy. 
The labeling efficiency from the ratio of the concetration of the labeled 
protein to the concentration of nano-Au which gives a value of 1.02, 
showing that we have stoichiometric labeling of Ca2+-free 
sNUCB1(S44C). (D) TEM analysis of the labeled sample shows the 
presence of two typical nano-Au densities next to each other 
corresponding to a dimer of a labeled Ca2+-free sNUCB1(S44C). In 
addition (E) we used the labeled protein to investigate the inhibition of 
hIAPP aggregation into fibrils. Nano-Au labeled Ca2+-free 
sNUCB1(S44C) was incubated with equimolar (32 µM) amount of hIAPP 
 124 
for 60 min after which samples were withdrawn from the reaction mixture. 
TEM analysis of the negatively stained samples show high molecular mass 
prefibrillar species with labeled ends. This suggests that sNUCB1(S44C) 
“caps” the ends of the prefibrillar species and possibly inhibits further 
aggregation into fibrils by preventing end-to-end association of prefibrillar 
species into mature fibrils. The scale bar represents 100 nm.  
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column equilibrated with phosphate buffer saline (PBS) pH 7.5. The 
recorded chromatograms show co-elution of 280 nm peak corresponding 
to elution of the protein and a 420 nm peak corresponding to nano-Au 
(Fig.2.13B). Since nano-Au label absorbs at 280 nm, we used BioRad DC 
assay to estimate the protein concentration by measuring absorbance at 
750 nm. The concentration of nano-Au was calculated by measuring 
absorbance at 420 nm. Using these we calculated a labeling efficiency of 
1.02, which suggests that each Ca2+-free sNUCB1(S44C) subunit has a 
nano-Au label attached to it (Fig.2.13C). TEM analysis of the collected 
peak fraction shows density for two nano-Au molecules next to each other 
consistent with the labeling of each protein subunit in a sNUCB1(S44C) 
dimer (Fig.2.13D). Thereafter we incubated equimolar amount (32 µM) of 
nano-Au labeled sNUCB1(S44C) with hIAPP to investigate inhibition of 
aggregation. TEM analysis of sample withdrawn at 60 min shows the 
presence of prefibrillar species with characteristic nano-Au density present 
at their ends (Fig.2.13E). This suggests that mechanistically 
sNUCB1(S44C) inhibits hIAPP fibril formation by stably interacting with 
and capping the ends of high molecular mass prefibrillar species. The 
capping probably inhibits further association to form mature fibrils. This 
provides evidence for a possible mechanism of action by which sNUCB1 
inhibits hIAPP fibril formation.  
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2.2.10 Ca2+-free sNUCB1 inhibits hIAPP fibrillization by promoting 
formation of Dead-End Prefibrillar (DEP) species 
hIAPP is a 37-amino-acid long peptide with two N-terminal cysteine 
residues which can be used for labeling the peptide (Fig.2.1). We 
incubated 32 µ M of hIAPP in a buffer solution to allow for fibril 
formation. Once fibrils were formed, we sonicated the fibrils for 15 s to 
generate smaller molecular mass protofibrillar fragments, which were used 
for nano-Au labeling. The labeled protofibrils were then used to “seed” a 
hIAPP aggregation reaction for fibril formation. As shown, the labeled 
protofibrils can get incorporated into a growing fibril with the presence of 
the characteristic nano-Au density distributed along the length of the fibril 
(Fig.2.14A).  As above, we incubated 32 µM Ca2+-free sNUCB1 with 32 
µM hIAPP and monitored the reaction for 2 h. Thereafter, we injected 200 
µl of the reaction volume onto a Superose6 10 / 30 GL column resulting in 
an elution profile with characteristic Peak1 and Peak2 as earlier 
(Fig.2.8A). We then collected the Peak1 fraction (Fig.2.14B) and used it 
for nano-Au labeling of hIAPP.  TEM analysis of samples withdrawn from 
the labeling reaction shows the presence of multiple nano-Au labels per 
prefibrillar species (Fig.2.14C). We then used the labeled protofibrils as 
“seed” in a hIAPP fibrillization reaction. TEM analysis of samples 
withdrawn from the aggregation reaction shows the presence of extensive 
fibrils which do not possess nano-Au label possibly due to inability of the 
sNUCB1 stabilized nano-Au labeled prefibrillar species to get  
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Figure 2.14. Ca2+-free sNUCB1 stabilized hIAPP prefibrillar species 
are not incorporated into growing fibrils. (A) We incubated hIAPP 
monomers at room temperature to form fibrils, which were then sonicated 
to generate protofibrils, and oligomers.  These were then labeled with 
nano-Au and used to seed the fibril assembly reaction upon incubation 
with soluble hIAPP. TEM analysis of the fibril formation reaction shows 
incorporation of the nano-Au labeled protofibrils into the fibrils. (B) 
Equimolar concentration (32 µ M) of Ca2+-free sNUCB1 was incubated 
with hIAPP for 60 min and the reaction mixture was subsequently injected 
onto a Superose6 10/30 GL column. The chromatogram shows Peak1 
consisting of Ca2+-free sNUCB1 stabilized hIAPP prefibrillar species and 
Peak2 corresponding to unbound Ca2+-free sNUCB1. (C) We 
subsequently collected the Peak1 fraction and labeled the Cys of hIAPP 
with nano-Au. TEM analysis of the reaction shows Ca2+-free sNUCB1 
stabilized nano-Au labeled protofibrils. (D) We then used these Ca2+-free 
sNUCB1 stabilized labeled protofibrils as seed in hIAPP aggregation 
reaction. TEM analysis of a 60 min reaction sample shows presence of 
mature hIAPP fibrils without the incorporation of nano-Au labeled 
protofibrils. The scale bar represents 200 nm. Thereafter, we used both 
post sonication hIAPP fragments and Peak1 fraction as seeds in 
independent hIAPP aggregation reactions monitored using thio-T binding 
assay. (E) The results show hIAPP aggregation (black, inset) gets 
accelerated in the presence of both 20 µ l (blue) or 50 µ l (red) seed as 
observed by a decreased lag phase of the process. Interestingly, even when 
50 µ l (orange), 100 µ l (purple) or 200 µ l (green) of Peak1 fraction was 
added to hIAPP aggregation reaction, no effect was observed on the lag 
phase of the process. This shows that sNUCB1 stabilized high molecular 
mass prefibrillar aggregate of hIAPP cannot get incorporated into a 
growing fiber and hence does not seed the aggregation reaction. 
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incorporated into a growing fibril (Fig2.14D). This suggests that Ca2+-free 
sNUCB1 stabilizes an intermediate that is a Dead End Prefibrillar (DEP) 
species and cannot be incorporated into a growing hIAPP amyloid fibril. 
In addition, we also monitored the effect of SEC purified prefibrillar 
species in Peak1 fraction on hIAPP aggregation by recording the 
enhancement in thioflavin-T fluorescence (Fig.2.14E). In principle, if a 
species can act as a seed for aggregation reaction it should shorten the lag 
phase of the process since nucleation is the rate limiting step in amyloid 
formation. The plot shows that incubation of hIAPP with increasing 
amounts of Peak1 fraction has little to no affect on the lag phase of the 
process. This suggests that in agreement with the above results, the 
prefibrillar species cannot “seed” a fibrillization reaction. As a control, 
incubation of hIAPP with seeds generated from sonication of hIAPP fibrils 
shorten the lag phase of the aggregation process (Fig.2.14E,inset). 
 
2.2.11 A CT peptide fragment of NUCB1 namely NUCB1(381-419) 
effectively inhibits hIAPP fibril formation and also disaggregates 
amyloid fibrils 
Our earlier results showed that Ca2+-free sNUCB1 effectively inhibits 
hIAPP fibril formation and also disaggregates preformed amyloid fibrils. 
However we are interested in isolating a smaller fragment of Ca2+-free 
sNUCB1 that exhibits similar activity. The CT of Ca2+-free sNUCB1 is  
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Figure 2.15. NUCB1(381-419) inhibits hIAPP aggregation and 
disaggregates hIAPP amyloid fibrils.  NUCB1(381-419) is a CT peptide 
fragment from sNUCB1. (A) We investigated the secondary structure of 
NUCB1(381-419) using CD spectroscopy. The spectra recorded for a 50 
µM solution of NUCB1(381-419) shows that the peptide is essentially 
unstructured. Thereafter we incubated 32 µM  (B) hIAPP for 1 h or (C) 
NUCB1(381-419) for 5 h alone in 50 mM Tris pH 8.0 at room temperature 
after which samples were withdrawn and monitored using TEM. The 
corresponding micrographs show that (B) hIAPP alone forms typical 
amyloid fibrils within 1 h whereas (C) NUCB1(381-419) does not 
aggregate to form higher molecular mass structrues. (D) We then 
incubated equimolar amount (32 µM) of hIAPP with NUCB1(381-419) in 
the buffer at room temperature and sample was withdrawn after 2 h for 
TEM analysis. The corresponding micrographs show that NUCB1(381-
419) inhibits hIAPP amyloid formation by stabilizing high molecular mass 
intermediates. Furthermore, we added (E) equimolar amount of 
NUCB1(381-419) to hIAPP fibrils. TEM analysis of sample withdrawn 
after 1 h of incubation shows that NUCB1(381-419) effectively 
disaggregates hIAPP fibrils into smaller molecular fragments. The scale 
bar represents 200 nm. 
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majorly unstructured and has an unusual PolyQ (residues 401-407) stretch 
(Fig.2.1) that may have important functional implications. Hence we 
designed a peptide fragment namely NUCB1(381-419) from the CT of 
sNUCB1 to test for its ability to inhibit or disaggregate hIAPP fibrils. As 
shown in Figure 2.15B, hIAPP alone (32 µ M) forms characteristic 
amyloid fibrils within 1 h. Interestingly, 32µM of NUCB1(381-419) even 
though unstructured (Fig.2.15A), does not aggregate even after 5 h as 
shown by the complete absence of higher order amyloid structures in the 
micrograph (Fig.2.15C). Thereafter we incubated equimolar amounts (32 
µM) of hIAPP with NUCB1(381-419) at room temperature and sample 
was withdrawn after 2 h for TEM analysis. The corresponding 
micrographs show that NUCB1(381-419) effectively inhibits hIAPP fibril 
formation by stabilizing high molecular mass protofibril like species 
(Fig.2.15D). Additionally, we also investigated the ability of NUCB1(381-
419) to disaggregate hIAPP fibrils. We incubated equimolar amount (32 
µM) of NUCB1(381-419) with hIAPP amyloid fibrils at room temperature 
and sample was withdrawn after 1 h for TEM analysis. The recorded 
micrographs show presence of smaller molecular mass fragments and 
complete absence of any amyloid fibrils suggesting that NUCB1(381-419) 
can disaggregate hIAPP amyloid fibrils (Fig.2.15E). Hence NUCB1(381-
419) similar to Ca2+-free sNUCB1 has the functional ability to inhibit 
hIAPP fibril formation and also disaggregate amyloid fibrils. 
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2.3 DISCUSSION 
IAPP is a neuroendocrine peptide hormone expressed in pancreatic islets 
of all mammals and can aggregate to form amyloid deposits depending on 
species-specific amino acid sequence. Amongst all naturally occurring 
hormones, hIAPP has the most hydrophobic and highly amyloidogenic 
sequence. It thus provides a useful model system to test for molecules with 
potent inhibitory acitivity against fibril formation. In the present study we 
report the anti-amyloidogenic property of Ca2+-free sNUCB1 towards 
inhibiting hIAPP fibril formation and disaggregate the preformed amyloid 
fibrils. In addition, our results show that sNUCB1 assisted inhibition of 
hIAPP fibril formation is dose-dependent and observed even at sub-
stoichiometric concentrations. Thus inhibition of hIAPP aggregation by 
sNUCB1 presents a crucial and interesting finding, possibly one of the 
several mechanisms at work in keeping these naturally occurring 
amyloidogenic peptides from aggregating into insoluble amyloid fibrils. 
Importantly, Ca2+-free sNUCB1 can inhibit fibril formation even when 
added either during nucleation or growth phase of amyloidogenesis. Thus 
if aggregation of hIAPP has been initiated, Ca2+-free sNUCB1 can prevent 
the growth of existing amyloidogenic intermediates into fibrils. 
Functionally, this ability is very unique and significant as it may not only 
assist in clearing the existing amyloid aggregates but also prevent further 
sequestration of functional monomers into amyloid deposits. It has been 
reported that IAPP monomers released during β-cell secretion can be 
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rapidly seeded at the nucleation site and assembled into fibrils (87). 
Several drug-based approaches to reduce IAPP secretion in animal models 
by increasing insulin sensitivity caused a marked reduction and retardation 
in islet amyloid formation. However, the cytotoxic effects of small IAPP 
amyloid aggregates were still observed. This suggests that therapeutic 
approaches to preventing β-cell loss not only require clearance of mature 
islet amyloid deposits but inhibition of formation of early aggregates as 
well (80). In this regard, the functional ability of NUCB1 to target both 
amyloid fibrils and intermediates may provide a therapeutically relevant 
approach to circumvent islet amyloidosis. 
 
Physiologically, both hIAPP and insulin are secreted as precursor pro-
peptides whose proteolytic processing by proconvertases generates the 
mature hormone (58) The disproportionate release of proinsulin relative to 
mature insulin is well documented in T2D (88-92). Functionally, it has 
been shown that only insulin and not proinsulin can inhibit fibril formation 
(68, 93). Thus incomplete processing of Insulin may promote Islet 
amyloid formation. In addition, recently it was shown that Insulin only 
impedes but does not completely inhibit IAPP fibril formation (94). Thus 
additional factors may be necessary towards keeping IAPP in a non-
aggregated and soluble form at millimolar concentrations in the secretory 
granules (95). Moreover, incomplete processing of proIAPP has also been 
postulated as a possible cause for facilitating amyloid formation. 
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Immunostaining assays have shown that proIAPP ubiquitinated at N-
terminus to be a component of intracellular fibrils (96). These intracellular 
fibrils are located in pre-Golgi part of the secretory pathway to be directed 
for lysosomal degradation (97). Lysosomal enzymes are however less 
efficient in clearing these aggregates whose accumulation results in 
cellular disintegration and apoptosis (68, 98). This release of hIAPP from 
intracellular compartments can stimulate IAPP aggregation. Thus 
inhibition of intracellular aggregation and clearance of fibrillar aggregates 
are both essential in preventing loss of β-cell mass. Physiologically, 
NUCB1 is present in both Golgi and ER (23, 26). RT-PCR of total RNA 
from rat insulinoma (RIN-m5F) cells and western blot analysis of RIN-
m5F cell lysate revealed presence of both NUCB1 mRNA and protein. 
Thus anti-amyloidogenic activity of NUCB1 could be crucial in 
preventing intracellular aggregation and clearing fibrillar aggregates of 
hIAPP in conjunction with the cellular chaperone machinery. We have 
shown that Ca2+-binding regulates the anti-amyloidogenic ability of 
sNUCB1. Both disruption of Ca2+-homeostasis in the cells and generation 
of reactive oxygen species have been shown to significantly contribute to 
the cytotoxicity associated with hIAPP (99). Higher concentrations of Ca2+ 
have been shown to promote aggregation of hIAPP (68). Under these 
conditions, our engineered Ca2+-insensitive mutant sNUCB1(tetramutant) 
can effectively inhibit hIAPP fibrillization and also dissociate the 
preformed amyloid fibrils. The Ca2+-insensitive mutant 
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sNUCB1(tetramutant) provides a handle for overriding the functional 
dependence of sNUCB1 on Ca2+ without any loss of anti-amyloidogenic 
ability.  
 
NUCB1 is a novel Ca2+-binding protein whose precise physiological 
role(s) is still poorly understood. Since it shows potential for anti-
amyloidogenic properties and can bind to ATP even though with weak 
affinity, we also investigated the ability of sNUCB1 to refold or inhibit 
denaturation of natively folded proteins. Using firefly Luciferase as a 
model system we showed that even though Ca2+-free sNUCB1 does bind 
to ATP, it alone cannot help refolding of denatured Luciferase or protect it 
against heat denaturation. This suggests that Ca2+-free sNUCB1 unlike 
several chaperones like Hsp70 lacks the ability to refold denatured or 
aggregated proteins (74, 75). However there is a possibility that similar to 
Hsp70 it may also require certain other cofactors to robustly perform its 
function (100). Future work pertaining to understanding the in vivo 
functional role of NUCB1 would be immensely helpful towards 
establishing it.   
 
Our biochemical results show that both Ca2+-free sNUCB1 and 
sNUCB1(tetramutant) possess anti-amyloidogenic properties but neither 
exhibited any proteolytic activity. Using BODIPY FL-Casein as a 
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substrate to test for proteolytic activity showed that unlike Trypsin, both 
Ca2+-free sNUCB1 and sNUCB1(tetramutant) lack the functional ability to 
cleave it. In addition, LC-MS analysis directly showed that Ca2+-free 
sNUCB1 does not proteolytically cleave hIAPP as evident from the 
complete absence of any smaller molecular fragments of hIAPP detected 
through LC-MS. Interestingly, our control experiments with the non-
aggregating analog of hIAPP namely Pramlintide also showed that Ca2+-
free sNUCB1 does not bind to it. It hints towards a preferential interaction 
of Ca2+-free sNUCB1 only with intermediate oligomeric species of hIAPP 
and not with monomeric hIAPP. Functionally, the ability of Ca2+-free 
sNUCB1 to bind to Zn2+ alongwith the observation that NUCB1 has a 
signal sequence and is found extracellularly raises a possibility that 
NUCB1 may act as a MMP. However our studies using fluorescently 
modified natural substrates of MMPs showed that unlike MMP-1, Ca2+-
free sNUCB1 does not proteolytically cleave them. Hence unlike the 
native Zn2+-dependent metalloproteases like IDE and Neprilysin, which 
facilitate clearance of amyloidogenic peptides like IAPP and Aβ by 
cleaving them (79) (Neprilysin), NUCB1 does not possess any proteolytic 
activity against Amylin. Thus the observed anti-amyloidogenic 
functionality of Ca2+-free sNUCB1 is not due to its protease activity. 
 
The biophysical characterization of Ca2+-free sNUCB1 stabilized 
prefibrillar species using light scattering analysis shows that Ca2+-free 
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sNUCB1 interacts with hIAPP to form a 2 - 6 MDa complex, which can 
be isolated by SEC. In addition, Ca2+-free sNUCB1 stabilized soluble 
species of hIAPP range from 40 - 80 nm in length with a predominant 
mass density of 2 - 5 kDa / Å. Mechanistically, the stabilization of the 
prefibrillar species is achieved by “capping” its ends as shown by our 
inhibition experiments followed by TEM analysis using nano-Au labeled 
Ca2+-free sNUCB1(S44C). Interestingly, these capped prefibrillar species 
neither aggregate when incubated for over a week nor seed the 
aggregation of hIAPP monomers to form amyloid fibrils. This presents a 
unique mechanism of action for activity of an amyloidogenesis inhibitor, 
in preventing the aggregation of hIAPP. In addition, the ability of 
sNUCB1 to disaggregate would further assist in clearing the pre-formed 
amyloid fibrils. Physiologically, Insulin degrading enzyme (IDE) can 
proteolytically cleave hIAPP, which provides a cellular mechanism to 
clear excess peptide from the system. However, IDE can only degrade 
monomeric hIAPP and is ineffective when hIAPP aggregates into higher 
order structures (79). We have shown that Ca2+-free sNUCB1 does not 
possess any proteolytic activity but is effective at inhibiting amyloid 
formation. Alternatively, several heat shock proteins (Hsps), small heat 
shock proteins (sHsps) and chaperones have been reported to inhibit 
aggregation of several amyloidogenic peptides. Both Hsp70 and 
extracellular chaperone Clusterin bind to prefibrillar species and prevent 
the formation of amyloid fibrils (76, 77). The results shown in the present 
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study however do not rule out the role of NUCB1 as a chaperone. It is 
possible that similar to sHsps, NUCB1 stabilizes the prefibrillar species 
and delivers them to Hsps for clearance from the system. These 
hypotheses will be addressed in our future studies.  
 
Ca2+-free sNUCB1 is a ~ 100 kDa protein which can limit its potency and 
usefulness towards usage as a therapeutic agent. Hence in search of a 
smaller molecular fragment of NUCB1 which retains the functional ability 
and efficacy to inhibit hIAPP fibril formation and preferably also 
dissociates amyloid fibrils, we isolated a 39-amino-acid long polypeptide 
namely NUCB1(381-419) from CT domain of NUCB1. Intriguingly, 
similar to Ca2+-free sNUCB1, the peptide inhibits hIAPP fibril formation 
as well as effectively dissociates amyloid fibrils at sub-stoichiometric 
concentrations. In addition to this functional ability, NUCB1(381-419) 
also provides a tool to override the inherent Ca2+-dependence on the 
functional efficacy of sNUCB1. It provides a molecular handle, which in 
its present or an altered form can be useful in designing agents for 
inhibiting amyloidogenesis of hIAPP. The extension of these in vitro 
results in relevant animal models will be useful in testing their in vivo 
efficacy. Future work pertaining to continuation of these results to other 
amyloidogenic proteins / peptides like Aβ and Tau as relevant to 
pathology of AD would be particularly interesting in understanding if the 
observed ability is specific or generic.  
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T2D is commonly associated with insulin resistance and reduced insulin 
secretion causing increase in plasma glucose levels. Thus most drugs 
administered to diabetic patients either stimulate β-cells to release more 
insulin or act as insulin sensitizers to promote skeletal muscle glucose 
uptake (80). However loss of β-cell mass is tightly correlated with IAPP 
cytotoxicity and islet amyloid formation (101). Transgenic mice over 
expressing hIAPP in their islet cells show amyloid deposits, β-cell 
depletion and develop non-insulin dependent diabetes mellitus (102, 103). 
The depletion of β-cells contributes to insulin resistance and decreased 
effectiveness of the administered drugs with time. This underlines the 
significance of strategies aimed at decreasing or preventing islet amyloid 
formation. The ability of Ca2+-free sNUCB1 to inhibit fibrillization of 
hIAPP at any stage of aggregation is therefore therapeutically relevant. It 
would be interesting to test for sNUCB1’s functional efficacy towards 
inhibiting the formation of amyloid plaques and disaggregating islet 
amyloids in relevant mouse models of diabetes. As shown here, the 
mechanism employed by sNUCB1 is unique and offers insights into 
designing strategies for inhibiting amyloidogenesis. However, the need for 
inhibition of aggregation and disaggregation of fibrillar deposits would 
require a molecule, which can effectively work under conditions of Ca2+ 
flux. The designed sNUCB1(tetramutant) or the isolated CT peptide 
fragment namely NUCB1(381-419) are Ca2+-insensitive and may 
efficiently execute the anti-amyloidogenic activity in the presence of high 
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concentrations of Ca2+. Interestingly, the truncation mutant 
sNUCB1(W333Ter) (Fig.1.1) neither inhibits not disaggregates hIAPP 
amyloid fibrils (data not shown). This can be explained by the possible 
role of the CT region comprising of residues 381-419 in sNUCB1 that is 
absent in the heterologously expressed sNUCB1(W333Ter).  
 
In vivo, the presence of amyloid fibrils leads to generation of reactive 
oxygen species. The particular susceptibility of β-cells to these species 
results from the physiologically low levels of antioxidant enzymes such as 
superoxide dismutase and catalase (104, 105). Hence the anti-
amyloidogenic properties of NUCB1 along with other contributing factors 
might be part of physiological machinery that protects the highly 
susceptible pancreatic β-cells from amyloid mediated toxicity. In 
conclusion, our data provides evidence that NUCB1 has novel anti-
amyloidogenic functional ability and provides opportunity to understand 
the possible defense mechanisms against islet amyloidosis as relevant to 
T2D. If apoptosis and β-cell depletion due to islet amyloid formation 
contribute to the observed loss of β-cell function, then the anti-
amyloidogenic activity of sNUCB1, its engineered mutant 
sNUCB1(tetramutant) or the isolated CT peptide fragment NUCB1(381-
419) can be crucial in designing therapeutics towards targeting islet 
amyloidosis. 
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CHAPTER 3 
Nucleobindin 1 and its Engineered Mutant Inhibit Aβ42 Aggregation and 
Disaggregate Aβ42 Fibrils into Non-toxic Species 
 
3.0 INTRODUCTION 
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized 
by the presence of extracellular β -amyloid (Aβ) fibril deposits with 
subsequent intra-neuronal accumulation of hyperphosphorylated tau into 
neurofibrillary tangles (NFTs), both of which trigger neuronal dystrophy 
(106). Evidently, a role of extracellular Aβ fibrillar deposits on 
intracellular tau hyperphosphorylation has been postulated (101, 107). In 
tissue culture experiments with hippocampal neurons from transgenic 
mice, it was shown that tau is essential to β-amyloid induced neurotoxicity 
(108). AD is a synaptic failure disease in which aggregation of Aβ, both 
intracellularly and extracellularly, causes neuritic and synaptic pathology 
through reduction in synaptic plasticity and associated proteins (109-111). 
Aβ is a 38 - 43 residue (~ 4 kDa) proteolytic fragment generated by the 
sequential cleavage of single-span transmembrane Amyloid Precursor 
Protein (APP) by membrane aspartyl proteases namely β- and γ-secretases 
respectively (112-119). Cell biological studies have shown that Aβ 
generation occurs majorly in trans-Golgi network (TGN) with much less 
in endoplasmic reticulum (ER). However, ER seems to be more selective 
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towards generation of more amyloidogenic Aβ42 than Aβ40. 
Mechanistically, Aβ40 has been shown to be the predominantly secreted 
form of Aβ peptide (120, 121). In a recent study, Cirrito et al. showed that 
synaptic activity increases the cell-surface levels of APP by stimulating its 
anterogade transport to synapses and plasma membrane. APP is then 
internalized from cell surface into endosomes where it is proteolytically 
cleaved to generate Aβ for release into the brain interstitial fluid (122). 
Functionally, Aβ42 monomers have also been shown to protect mature 
neurons from excitotoxicity and support the survival of developing 
neurons under trophic conditions (123). However, when Aβ monomers 
oligomerize into amyloidogenic intracellular aggregates, they cause 
neuritic dystrophy. Numerous studies have reported behavioral, 
physiological, oxidative and plaque mediated abnormalities in transgenic 
mouse models of AD much before the appearance of Aβ amyloid deposits 
(124-129). These observations point towards the pathogenic activity of 
intracellular Aβ aggregation in promoting cytotoxicity. Thereafter, the 
subsequent release of these aggregates into the extracellular space, 
possibly due to neuronal apoptosis or membrane disruption, impairs 
processes involved in learning and memory. Thus both intracellular and 
extracellular Aβ deposits contribute to cognitive impairment but early 
events involving intracellular amyloidogenesis initiate synaptic pathology 
as observed in AD (130, 131). Hence, preventing intraneuronal Aβ 
aggregation in addition to eliminating extracellular amyloid deposits might 
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be therapeutically relevant for the treatment and control of AD. Therefore 
the leading target of emerging AD therapies is the suppression of Aβ by 
reduced generation or enhanced degradation.  
 
Several decades of research in understanding AD has put forth different 
Aβ lowering strategies for potential drug development. These include 
suppression of Aβ generation by employing β - or γ-secretase inhibitors, 
preventing Aβ aggregation and immunization based approaches (132-134). 
Several small molecule inhibitors have been explored and tested that 
prevent Aβ fibril formation and seem to partially reverse the cognitive 
impairment (101). Naturally occurring Zn2+-dependent endopeptidases 
namely Insulin Degrading Enzyme (IDE) and Neprilysin (NEP) decrease 
amyloid load in the brain by proteolytically cleaving Aβ (79, 135-139). 
Recently, several heat shock proteins (Hsp’s) and small heat shock 
proteins (sHsp’s) have also been shown to effectively inhibit aggregation 
of amyloidogenic peptides. Interestingly, several members of sHsp’s like 
αB-crystallin, Hsp27, Hsp20 and HspB8 completely inhibit Aβ40 
amyloidogensis by binding to and stabilizing prefibrillar species (74, 75). 
In addition, extracellular chaperone clusterin has been shown to inhibit the 
fibril formation by prion protein, Aβ and apolipoprotein CII. Along with 
Hsp70, clusterin has been shown to bind to prefibrillar species and prevent 
the formation of amyloid fibrils. The stabilization of these prefibrillar 
species, however, resulted in enhanced toxicity in a cell culture based 
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assay (76, 77). Importantly, a direct role of apolipoprotein E  (apoE) and 
its isoforms in differentially promoting clearance of Aβ from extracellular 
space has also been established (140, 141). 
 
In a recent study Lin et al. showed that overexpression of a novel Ca2+-
binding protein Nucleobindin 1 or NUCB1 in an in vitro setup reduces 
APP mRNA level and regulates APP biosynthesis. This consequently 
causes a reduction in the proteolytic metabolites of APP including Aβ. 
Intriguingly, the expression level of NUCB1 was also reported to decrease 
by 50% in the brains of AD patients (28). NUCB1 is a 55 kDa multi-
domain protein that was first reported as a growth and differentiation 
factor associated with lupus syndrome in mice (18). Since its discovery, 
NUCB1 has been reported to be widely expressed in cells and tissues and 
is conserved from flies to humans (85). NUCB1 is primarily a Golgi-
resident protein also found in both cytosolic and membrane fractions 
(142). NUCB1 has been shown to function as a matrix modulator and may 
act as a Ca2+-buffer in Golgi (16, 46). In both sporadic and familial AD, 
Ca2+-dysregulation has been known to play a critical role. Abnormal Ca2+-
homeostasis has been observed in the dendritic spines adjacent to the 
amyloid plaques (143). Since NUCB1 interacts with APP in a Ca2+-
dependent manner and has been shown to regulate Aβ generation (28), we 
proceeded to test the effect of NUCB1 on the amyloidogenesis of 
synthetic Aβ42. In the present study, we use the heterologously expressed 
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and purified sNUCB1, a soluble form of NUCB1 without the signal 
sequence (residues 1-31) (Fig.3.1) and show that sNUCB1 in its Ca2+-free 
form completely inhibits Aβ fibril formation as well as effectively 
disaggregates pre-formed amyloid fibrils. We further engineered a Ca2+-
independent mutant of sNUCB1, namely sNUCB1(tetramutant), which 
continues to inhibit Aβ42 amyloidogenesis and disaggregates preformed 
Aβ42 fibrils even in the presence of Ca2+. In addition, in a tissue-culture 
based assay, the species generated upon Aβ42 fibril disaggregation by 
sNUCB1 or sNUCB1(tetramutant) were non-toxic. Finally, this anti-
amyloidogenic property of sNUCB1 was also tested against aggregation of 
tau K19(C322S), a heterologously expressed construct corresponding to 
the microtubule binding domain of human tau (htau) with only 3 repeat 
domains (Fig.3.1) (144). Our results show that similar to Aβ, Ca2+-free 
sNUCB1 inhibits fibrillarization of tau K19(C322S). 
 
 
 
 
 
 
 
 
 148 
Figure 3.1.  Domain architecture of human NUCB1 and engineered 
NUCB1 variants, human tau and tauK19. The modular nature of the 
NUCB1 protein structure is depicted schematically with its N-terminal 
signal sequence (grey square), putative DNA binding domain (green 
square), two EF hand loops (magenta rectangles), acidic region (blue oval) 
and leucine zipper domain (yellow hexagon).  The amino acid residues at 
domain borders are numbered.  We engineered a construct for expression 
in E. coli of a soluble form of NUCB1 that included an N-terminal hexa-
His tag and a PreScission protease recognition sequence with an 
intervening spacer sequence as shown.  Endoprotease cleavage yields a 
soluble form of NUCB1 that begins with the amino acid sequence 
GPHMAS and continues with the remainder of the native sequence 
beginning at Gly32.  We refer to this expressed protein construct as 
soluble NUCB1 or sNUCB1 throughout the text. Furthermore we used the 
sNUCB1 template to make point mutations in each EF hand as indicated 
by the arrows to generate sNUCB1(tetramutant) which lacks the ability to 
bind to calcium. Thereafter the domain diagram of the longest form of 
human Tau protein shows three alternatively spliced exons (exon 1, 2 and 
3) along with proline rich domains P1 and P2. The CT proximal 
microtubule-binding repeat domains are labeled R1-R4 followed by a low 
homology repeat domain namely R’. The domain diagram of tauK19 
consists of repeat domains R1, R3 and R4 followed by three residues KIE 
(370-372) from the R’ domain at its CT end. 
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Figure 3.1 
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3.1 MATERIALS AND METHODS 
3.1.1 REAGENTS 
Thioflavin-T was purchased from Fisher Scientific and Uranyl Acetate 
was purchased from SPI-ChemTM. For TEM, 300 mesh carbon coated Cu 
grids were purchased from EMS diasum (Hatfield, PA). Nano-Au 
Maleimide was purchased from Molecular Probes. Aβ42 peptide was 
purchased from the Keck peptide synthesis facility at Yale university, 
New Haven CT. Heterologously expressed, purified and lyophilized 
tauK19(C322S) was a generous gift from Dr David Eliezer (Weill, 
Cornell). All reagents and chemicals used were of the highest available 
purity. 
 
3.1.2 Heterologous expression and purification of sNUCB1 and its 
variants 
The cDNA clone for human NUCB1 was obtained from ATCC and the 
DNA fragment for the soluble form of NUCB1 or sNUCB1, 
corresponding to residues 31-461 of the human NUCB1 protein without 
the N-terminal signal sequence (residues 1-31) was cloned into a 
pET28a(+) expression vector (Amersham Biosciences) to generate a N-
terminal His6-tagged construct. The construct for sNUCB1 served as a 
template to generate the His6-tagged mutant of sNUCB1 namely 
sNUCB1(tetramutant. For sNUCB1(tetramuant) the coding sequence 
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changes leading to generation of D253K, E264A, D305K and E316A 
mutations were introduced by site-directed mutagenesis using the Quick 
Change system (Stratagene, La Jolla, CA). The vectors were then used to 
transform BL21 (DE3) cells to express a N-terminal His6-tag protein 
containing a PreScission protease site following the His6-tag. Both 
proteins were expressed in BL21 (DE3) cells grown in the presence of 50 
µg / ml kanamycin. Cells were grown at 37 oC to A600nm of ~ 0.7 and then 
induced with 500 µ M isopropylthio-β-D-galactoside (IPTG) (US 
Biological). Post induction the culture was grown overnight at 17 oC and 
subsequently harvested. The resulting pellets were re-suspended in a 
buffer containing 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 50 mM β-
mercaptoethanol, bovine lung aprotinin (20 mg/ml), 2 mM phenylmethane 
sulfonyl fluoride (PMSF) and complete EDTA-free protease inhibitor 
cocktail tablets (Roche). Thereafter the cells were lysed and the expressed 
His6-tag protein was purified from crude extract by using affinity 
chromatography using Ni-NTA column pre-equilibrated with buffer A (50 
mM Tris, pH 8.0, 150 mM NaCl, 50 mM β-mercaptoethanol). The bound 
His6-tag protein was eluted from the column by using buffer A 
supplemented with 500 mM imidazole. The His6-tag was cleaved by 
PreScissionTM protease, which was subsequently removed. In order to 
remove Ca2+ from sNUCB1 or its variant, the proteins were extensively 
dialyzed against buffer A supplemented with 5 mM EGTA and 1 mM 
EDTA, which were also eventually removed through dialysis. Finally, size 
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exclusion chromatography (SEC) was done using Superdex 200 26 / 60 
HR column equilibrated with buffer S (50 mM Tris, pH 8.0, 150 mM 
NaCl, 1 mM DTT) to obtain homogenously pure protein. The typical yield 
for sNUCB1 and its variant was ~ 5 mg / L. The purity of the proteins was 
assessed by Coomassie brilliant blue staining after the proteins were 
separated through SDS-PAGE. The purity of both the proteins was greater 
than 95%.  
  
3.1.3 Aβ42 fibril formation protocol 
In order to produce homogeneous Aβ fibrils, purified and lyophilized 
Aβ42 peptide (0.6 mg) was added to DDI water (0.2 ml) in a 
polypropylene eppendorf tube and allowed to stand for 2 min. Thereafter 
the sample was vortexed for 10 s, and an equal volume of 200 mM Tris 
pH 7.4 was added, followed by another round of vortexing for 10 s. The 
sample was then filtered through a 10 kDa cutoff filter by spinning it at 
17,200 g in a benchtop microcentrifuge for 3.5 min. Subsequently, the 
flowthrough was collected and the peptide concentration was determined 
by absorbance at 280 nm. This solution was used within 5-10 min to set up 
the fibrillization reaction to obtain mature, elongated and well resolved 
Aβ42 fibrils within 24 h. 
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3.1.4 tau K19(C322S) neurofibrillary tangle (NFT) formation protocol 
Lyophilized tau K19(C322S) was reconsistuted in a buffer solution (100 
mM NaH2PO4 pH 7.4, 150 mM NaCl) at a concentration of 50 µM. The 
reaction mixture was constantly stirred at room temperature and samples 
were withdrawn at successive time points and analyzed using TEM to 
confirm formation of NFTs. The analysis shows that tau K19(C322S) 
forms NFTs within 27 h as shown in the corresponding micrographs. 
 
3.1.5 Transmission Electron Microscopy (TEM) 
TEM was performed at the Bioimaging facility at Rockefeller University. 
Samples were prepared by placing 5 µl of solution onto formvar coated 
300 mesh copper grids and counterstained with 2% aqueous uranyl acetate 
solution. Samples were viewed with a FEI Tecnai12 BioTwinG2 
transmission electron microscope at 80 kV.  Digital images were acquired 
with an AMT XR-60 CCD Digital Camera System and compiled using 
Adobe Photoshop CS2 and Image J. 
 
3.1.6 MTT Assay 
In this assay, 7000 to 9000 undifferentiated PC12 cells in 100 µ l were 
plated in each well of a 96-well plate. Thereafter, cells were grown for an 
additional 12-16 h at 37 oC in an incubator with 5 % CO2 supply. To test 
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for toxicity, samples were added to the cells at a concentration of 10 µM / 
well followed by incubation for 4 h. Thereafter, 10 µl of the MTT (3-(4,5-
Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide) stock 
solution (Sigma-Aldrich, Cat # CGD1) was added to the cells followed by 
incubation for an additional 4 h. Finally, the media was withdrawn and 
200 µ l of DMSO was added to each well to dissolve the reduced MTT 
(formazan) crystals giving a characteristic purple color. 
Spectrophotometric measurement of the absorbance at 570 nm was done 
for each well and cell viability was calculated with respect to vehicle alone 
as the control.  
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3.2.1 Ca2+-free sNUCB1 inhibits Aβ42 fibril formation and 
disaggregates Aβ42 fibrils 
Aβ42 is the most amyloidogenic isoform generated from APP proteolytic 
cleavage and is the predominant species present in amyloid deposits in 
AD. APP mutants associated with early-onset AD show increased 
production of Aβ42 (145). Interestingly, preplaque increases in soluble 
Aβ42 but not Aβ40 are also observed in patients with Down’s Syndrome 
(146). Biochemically, Aβ42 forms fibrils at pH 7.4 much more rapidly 
than Aβ40. In addition, Aβ42 fibrils are comparatively more stable and 
resistant to sodium dodecyl sulphate treatment (147, 148). Hence, Aβ42 
was chosen to test the inhibitory activity of sNUCB1 in preventing fibril 
formation. Initially, in vitro aggregation of Aβ42 alone (32 µ M) was 
monitored using TEM analysis of samples withdrawn at time zero, 5 h, 
12h and 24 h respectively (Fig.3.2A). The corresponding micrographs 
show presence of oligomers and protofibrils for the 5h and 12 h sample 
respectively which eventually grow into long, unbranched and well-
resolved fibrils within 24 h (Fig.3.2A). Thereafter, we incubated 
equimolar (32 µM) amount of Ca2+-free sNUCB1 with Aβ42 and samples 
were withdrawn at time zero, 5 h 12 h and 24 h as above. TEM analysis of 
samples withdrawn at various time points show presence of high 
molecular mass species which do not progress to form fibrils even at 24 h 
(Fig.3.2B). Interestingly, samples withdrawn even after 24 h of incubation 
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Figure 3.2. Ca2+-free sNUCB1 inhibits Aβ42 fibril formation and 
disaggregates Aβ42 fibrils. Aβ42 alone slowly aggregates in vitro to 
form amyloid fibrils. (A) We monitored aggregation of 32 µM solution of 
Aβ42 with time using TEM. Samples withdrawn at time zero contain low 
molecular weight species. Thereafter as the aggregation of Aβ42 proceeds, 
the 5 h sample shows the presence of both oligomers and protofibrils. 
These continue to form and associate into fibrils as seen in the 12 h sample 
containing fibrils along with protofibrils and oligomers. The aggregation 
in complete at 24 h with the formation of characteristic amyloid fibrils. 
Thereafter, (B) we monitored inhibition of Aβ42 fibril formation in the 
presence of equimolar amount of Ca2+-free sNUCB1 (32 µM) added at 
time zero. TEM images collected after 5 h, 12 h and 24 h of incubation 
show no trace of fibril formation. Finally, (C) disaggregation of Aβ42 
fibrils by Ca2+-free sNUCB1 was monitored with time using TEM. Aβ42 
aggregates to form fibrils within 24 h, which were then incubated with 
equimolar amount (32 µM) of Ca2+-free sNUCB1. Samples withdrawn at 
60 min time point show that sNUCB1 effectively dissociates Aβ42 fibrils 
into smaller molecular mass fragments, which continue to exist even at 5 h 
or 24 h time point without reassociation to form fibrils. The scale bar 
represents 200 nm. 
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Figure 3.2 
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continued to show inhibition of fibril formation. This shows that Ca2+-free 
sNUCB1 effectively inhibits Aβ42 fibril formation. Subsequently, to 
explore the effect of Ca2+-free sNUCB1 towards disaggregating preformed 
Aβ42 fibrils, we added equimolar amount (32µM) of Ca2+-free sNUCB1 
to Aβ42 fibrils in a reaction mixture. TEM analysis shows that Ca2+-free 
sNUCB1 can effectively dissociate Aβ42 fibrils within 60 min and the 
disaggregated species continue to exist without progressing to form fibrils 
even at 24 h time point (Fig. 3.2C). Thus functionally, Ca2+-free sNUCB1 
inhibits Aβ42 aggregation and also effectively disaggregates the 
preformed fibrils.  
 
3.2.2 Ca2+ disrupts inhibition and disaggregation of Aβ42 fibrils by 
sNUCB1 
NUCB1 is a multi-domain protein with two characteristic Ca2+-binding EF 
hand motifs (Fig.3.1). Ca2+-binding to sNUCB1 has been shown to induce 
structural rearrangement in the protein (Fig.1.2). Hence, the effect of Ca2+-
binding on the anti-amyloidogenic properties of sNUCB1 was 
investigated. As earlier, Aβ42 was incubated with equimolar amount (32 
µM) of sNUCB1 in the presence of 1 mM Ca2+ in the reaction mixture.  
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Figure 3.3. Ca2+ prevents the ability of sNUCB1 to inhibit aggregation 
and dissociate Aβ42 fibrils. (A) 32 µM  Ca2+-free sNUCB1 was 
incubated with 1 mM Ca2+ in the reaction mixture at 25 oC with the 
subsequent addition of equimolar amount of Aβ42. Samples were 
withdrawn at the indicated time points and analyzed using TEM. As 
shown, Ca2+-bound sNUCB1 does not inhibit aggregation of Aβ42 as 
fibrils are present in the 12 h sample, which continue to grow extensively 
as seen in the 24 h sample. In addition, the ability of Ca2+-bound sNUCB1 
towards (B) disaggregating Aβ42 fibrils was monitored using TEM.  
Equimolar amount of Ca2+-bound sNUCB1 (32 µM) was added to Aβ42 
fibrils and samples were withdrawn at the indicated time points. As 
shown, fibrils are still present in the reaction mixture after 60 mins of 
incubation showing that Ca2+-bound sNUCB1 cannot dissociate Aβ42 
fibrils. The scale bar represents 200 nm. 
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Unlike with Ca2+-free sNUCB1, the TEM analysis of samples withdrawn 
from the reaction mixture at various time points show initiation of fibril 
formation within 12 h with extensive Aβ42 fibrils present at 24 h 
(Fig.3.3A), which is similar to the time frame of fibril formation by Aβ42 
alone (Fig.3.2A). This shows that binding of Ca2+ to sNUCB1 disrupts its 
functional ability towards inhibiting Aβ42 fibril formation and points 
towards Ca2+-free sNUCB1 as being the only functionally adept form in 
preventing Aβ42 amyloidogenesis. In addition, disaggregation of 
preformed Aβ42 fibrils by equimolar (32 µM) sNUCB1 was also 
examined in the presence of 1 mM Ca2+ in the reaction mixture. TEM 
analysis clearly shows that unlike Ca2+-free sNUCB1, Ca2+-bound 
sNUCB1 cannot dissociate Aβ42 fibrils as observed by the presence of 
fibrils in samples withdrawn after 5 min, 30 min and 60 min of incubation. 
Thus Ca2+-binding nullifies the anti-amyloidogenic properties of sNUCB1. 
 
3.2.3 sNUCB1(tetramutant) is insensitive to Ca2+ but functionally 
similar to sNUCB1 
Our earlier results showed that heterologously expressed and purified 
sNUCB1(tetramutant) is correctly folded and unlike sNUCB1, lacks the 
ability to bind to Ca2+. Hence in order to test the anti-amyloidogenic 
properties of sNUCB1(tetramutant)  towards Aβ42 in the presence of 
excess Ca2+, we incubated equimolar amount (32 µM) of Aβ42 with  
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Figure 3.4. Ca2+-insensitive anti-amyloidogenic activity of 
sNUCB1(tetramutant). sNUCB1(tetramutant) does not bind to Ca2+ and 
was tested for its ability to affect Aβ42 amyloid formation. We incubated 
Aβ42 with equimolar concentration of sNUCB1(tetramutant) (32 µM), 
both in the  (A) absence and (B) presence of 1 mM Ca2+. TEM analysis of 
samples withdrawn from each reaction mixture at T = 0 h, 5 h, 12 h and 24 
h time points show complete inhibition of fibril formation. Subsequently, 
the ability of sNUCB1(tetramutant) to disaggregate fibrils was 
investigated. Thereafter, we incubated stoichiometric amount of 
sNUCB1(tetramutant) (32 µM) with fibrils in a reaction mixture, both in 
the (C) absence or (D) presence of 1 mM Ca2+. As a control, micrographs 
with Aβ42 fibrils before addition of sNUCB1(tetramutant) are shown on 
the left. TEM images corresponding to samples withdrawn after 30 min 
and 60 min of sNUCB1(tetramutant) addition show that 
sNUCB1(tetramutant) can efficiently dissociate the preformed fibrils of 
Aβ42. The scale bar represents 200 nm. 
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Figure 3.4 
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sNUCB1(tetramutant) in a reaction mixture in the absence and presence of 
1 mM Ca2+. Samples were withdrawn at the indicated time points and 
effect of sNUCB1(tetramutant) on aggregation was analyzed using TEM. 
The corresponding micrographs show that similar to sNUCB1, 
sNUCB1(tetramutant) also effectively inhibits aggregation of Aβ42 to 
form amyloid fibrils (Fig.3.4A). However more importantly, even in the 
presence of excess Ca2+ in the reaction mixture, sNUCB1(tetramutant) 
continues to be functionally active and inhibits Aβ42 fibril formation as 
shown by the complete absence of any fibrillar aggregates in the 
micrograph corresponding to 24 h sample (Fig.3.4B). Thereafter we 
investigated the functional ability of sNUCB1(tetramutant) towards 
disaggregating Aβ42 fibrils and the effect of Ca2+ on it. Aβ42 alone (32 
µM) aggregates within 24 h to form fibrils. We then added equimolar 
amount (32 µ M) of sNUCB1(tetramutant) to it in the absence and 
presence of 1 mM Ca2+ in the reaction mixture (Fig.3.4C,D). Samples 
from each reaction were withdrawn after 30 min and 60 min for analysis 
using TEM. The corresponding micrographs show that 
sNUCB1(tetramutant) effectively disaggregates Aβ42 fibrils both in the 
absence (Fig.3.4C) and presence of Ca2+ (Fig.3.4D). Hence unlike 
sNUCB1, the functional ability of sNUCB1(tetramutant) is unaffected by 
Ca2+ and it retains its anti-amyloidogenic properties towards Aβ42 even in 
the presence of high concentrations of Ca2+ in the reaction mixture.  
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3.2.4 sNUCB1 / sNUCB1(tetramutant) mediated Aβ42 fibril 
dissociation generates non-toxic species 
Aβ42 aggregation leads to fibril formation through association of 
oligomers and protofibrils. Tissue culture based MTT assay can provide 
quantitative calorimetric estimate of the toxicity of intermediate species 
along with the fibrillar aggregates (149). As shown earlier, Ca2+-free 
sNUCB1 inhibits Aβ42 fibril formation and effectively disaggregates 
preformed Aβ42 fibrils. However, TEM analysis cannot rule out the 
presence of oligomeric species stabilized by sNUCB1 in the reaction 
mixture. Several studies have shown that along with fibrils, oligomeric 
species are also cytotoxic (150, 151). Hence, to test the potential toxicity 
of the species generated after Aβ42 fibril dissociation by Ca2+-free 
sNUCB1 or sNUCB1(tetramutant), MTT assays were conducted with 
undifferentiated PC12 cells. As a control, administration of either 
sNUCB1 or sNUCB1(tetramutant) to the cells showed that they are 
completely non-toxic to the cells. Thereafter in the first set of experiments, 
samples from Aβ42 aggregation reaction alone were withdrawn at time 
zero, 5 h and 24 hours and administered to cells at a final concentration of 
10 µM to assay for cytotoxicity by monitoring reduction of MTT. For time 
zero sample, neuronal cells showed 80% viability. As aggregation 
continues, monomers assemble into oligomers within 5 h for which the 
cell viability decreased to 60%. Eventually, administration of sample 
containing Aβ42 fibrils at 24 h further reduced the cell viability to 40% 
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Figure 3.5. Inhibition of cytotoxicity of Aβ42 fibrils by sNUCB1 and 
sNUCB1(tetramutant). We measured the cell viability of PC12 cells 
using the standard MTT reduction assay. The delivery vehicle alone was 
administered to the cells as the control. Both sNUCB1 and 
sNUCB1(tetramutant) individually resulted in 90% to 95% final cell 
viability, showing that each of the protein subunits by themselves are non-
toxic. Thereafter, we administered samples withdrawn from a Aβ42 
aggregation reaction at 0 h, 5 h and 24 h to PC12 cells such that the final 
concentration for each is 10 µM. Cell viability measurements using MTT 
reduction estimate that T = 0 h sample decreases the cell viability to 80%. 
The subsequent addition of samples consisting of essentially oligomers (T 
= 5h) and fibrils (T = 24h) continue to decrease cell viability to 55% and 
39% respectively. We then incubated the Aβ42 fibrils at T = 24 h with 
equimolar (32 µ M) amounts of sNUCB1 or sNUCB1(tetramutant) and 
samples were withdrawn after 5 min, 15 min, 30 min and 60 min 
respectively. Each sample was then administered to PC12 cells in culture 
at a final concentration of 10 µM and cell viability was estimated using 
MTT reduction. The results show ~ 90 % cell viability for samples 
withdrawn from reaction mixture containing sNUCB1 were administered 
whereas cell viability of ~ 95 % was observed for sNUCB1(tetramuant) 
containing samples. Each experiment was repeated atleast 3 times and the 
data was plotted as the mean ± S.E.M.     
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Figure 3.5 
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(Fig.3.5). In the next set of experiments, Aβ42 fibrils were incubated with 
equimolar amount of Ca2+-free sNUCB1 or sNUCB1(tetramutant) and 
samples were withdrawn at 5 min, 15 min, 30 min and 60 min time points 
for administration to PC12 cells at a final concentration of 10 µM. 
Intriguingly, MTT reduction dependent cell viability measurements 
estimated ~ 90 % viability for 5 min sample from the disaggregation 
reaction with either sNUCB1 or sNUCB1(tetramutant) and greater than 95 
% viability for later time points showing that disaggregated species are 
essentially non-toxic to PC12 cells (Fig.3.5). Thus, MTT assay shows that 
both sNUCB1 and sNUCB1(tetramutant) disaggregate cytotoxic Aβ42 
fibrillar aggregates into non-toxic species.  
 
3.2.5 Ca2+-free sNUCB1 inhibits tau K19(C322S) NeuroFibrillary 
Tangle (NFT) formation 
Human tau is a multi-domain protein with 31-32 residue long repeat 
regions (R1-R4) at the CT constituting the microtubule-association 
domain (Fig.3.1). Tau K19 represents a synthetic and truncated form of 
tau, which can aggregate in vitro to form NFTs. A growing role of tau in 
AD pathology has recently been reported. Hence in order to investigate the 
functional ability of Ca2+-free sNUCB1 towards inhibiting aggregation of  
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Figure 3.6. Ca2+-free sNUCB1 inhibits tau K19(C322S) neurofibrillary 
tangle (NFT) formation. Tau K19(C322S) slowly aggregates in vitro to 
form NFTs. (A) We monitored aggregation of 50 µM tau K19(C322S) in 
solution with time using TEM. Samples withdrawn from a constantly 
stirred solution at room temprature after 27 h show presence of NFTs of 
tau K19(C322S). In order to monitor the effect of Ca2+-free sNUCB1 on 
aggregation of tau K19(C322S) to form NFTs, (B) we incubated 
equimolar amount (50 µM) of tau K19(C322S) with Ca2+-free sNUCB1 
for 27 h. Samples were withdrawn after 27 h and analyzed using TEM. 
The micrographs show complete absence of any NFTs. This suggests that 
Ca2+-free sNUCB1 can effectively inhibit NFT formation by tau 
K19(C322S). The scale bar represents 200 nm. 
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tauK19 towards forming NFTs, we used the mutant tau K19(C322S), 
which lacks the ability to form intermolecular disulphide bonds. We 
incubated 50 µ M tau K19(C322S) alone or with equimolar amount of 
Ca2+-free sNUCB1 in 100 mM NaH2PO4 pH 7.4, 150 mM NaCl for 27 h at 
room temperature with constant stirring. TEM analysis of samples 
withdrawn from the reaction mixtures show that tau K19(C322S) alone 
aggregates within 27 h to form NFTs (Fig. 3.6A). However, incubation of 
tau K19(C322S) with Ca2+-free sNUCB1 completely inhibits NFT 
formation as seen by the complete absence of any fibrillar aggregates in 
the corresponding micrographs for the 27 h sample (Fig.3.6B).  Hence, 
Ca2+-free sNUCB1 effectively inhibits in vitro formation of NFTs by tau 
K19(322S). 
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3.3 DISCUSSION 
Amyloid hypothesis has been the central dogma of AD research. Both Aβ 
oligomers and fibrillar aggregates have been shown to exert neurotoxic 
effects (150, 152). For decades, generation of Aβ was thought to be a non-
essential product resulting from the erroneous cleavage of APP by γ-
secretase. However, recent work has revealed the neuroprotective role of 
monomeric Aβ and has highlighted the involvement of APP in synaptic 
transmission (110, 123). Thus neuritic dystrophy observed in AD can 
result from both the loss of function of Aβ and the neurotoxic effects of 
Aβ aggregates. In addition, a secondary role of tau hyperphosphorylation 
and its aggregation into NFTs dependent on Aβ fibril formation has also 
been postulated and shown to exacerbate cytotoxicity (153). Hence, 
preventing the aggregation of Aβ is the primary therapeutic target with 
significant interest in understanding and controlling intracellular tau 
aggregation. Our results show that the soluble form of NUCB1 can both 
inhibit Aβ42 aggregation and effectively disaggregate the pre-formed 
fibrils in a Ca2+-dependent manner. In addition, Ca2+-free sNUCB1 also 
inhibits aggregation of a truncated form of tau namely tauK19(C322S) 
into NFTs and thus might inhibit aggregation of hyperphosphorylated 
intracellular pool of full-length tau as relevant to AD pathology. Thus this 
dual anti-amyloidogenic functionality of sNUCB1 presents an ideal target 
that may be therapeutically relevant and useful. Clinically, the symptoms 
of cognitive impairment in an AD patient appear years after initiation of 
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Aβ aggregation, tau hyperphosphorylation, synaptic loss and neurite 
dystrophy (154). Thus prevention of neurodegeneration requires the 
clearance of deposited Aβ aggregates and inhibition of any further Aβ 
aggregation to restore physiological Aβ function. In accordance with this 
observation, our data shows that Ca2+-free sNUCB1 possesses the ability 
to both inhibit fibril formation and disaggregate them into non-toxic 
species.  
 
AD research in the past decade has unraveled the neurotoxicity effects of 
Aβ oligomers and fibrils. However, the events that initiate Aβ aggregation 
are still not clearly understood. In 2006, Yankner and coworkers showed 
that Ca2+ enhanced the aggregation of early protofibrillar species and 
increased their association to form fibrils. They proposed a potential role 
of Ca2+ in Aβ aggregation and toxicity in the AD brains (155). It is known 
that Ca2+-homeostasis plays a central role in many aspects of brain 
physiology including growth, plasticity, learning and memory as well as 
cell death and degeneration. Ca2+ ions are essential during signal 
transmission from one neuron to another and Ca2+-dysregulation has been 
repeatedly observed in AD research (156, 157). Aβ is believed to cause 
Ca2+-dysregulation either by interacting with cell surface receptors 
coupled with Ca2+-flux or by forming leaky membrane pores (56). 
NUCB1 is a Ca2+-binding protein, which maintains Ca2+-homeostasis and 
Ca2+-storage in Golgi (16, 46). NUCB1 is ubiquitously expressed, found 
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in ER and resides in Golgi for more than 12 hours (23). APP is 
synthesized in ER, transported through the Golgi apparatus into the TGN. 
Immunofluorescence assays have shown that Aβ42 generated from APP is 
present in ER under steady state conditions and is also localized in TGN 
(158). Co-localization of NUCB1 and APP has been reported in both 
cultured cells and mouse brains (28). Thus the role of NUCB1 in 
maintaining Ca2+-homeostasis and its interaction with APP and Aβ 
suggests towards a possible involvement of NUCB1 in AD pathology. 
 
An alternative hypothesis to initiation of Aβ aggregation could be the 
disruption of cellular machinery involving Hsps, sHsps, cellular proteases 
and trafficking molecules that normally prevent the aggregation and 
accumulation of Aβ. Both extracellular and intracellular chaperones have 
been shown to co-localize with Aβ deposits in senile plaques and inhibit 
Aβ aggregation and are involved in its clearance across the blood-brain 
barrier (74, 159). In addition, Zn2+-dependent metalloprotease Neprilysin 
targets Aβ diffuse deposits and neuritic plaques for their catalytic 
degradation (137). Synaptic activity has been shown to decrease 
intracellular Aβ levels. Upon APP cleavage, Aβ40 is generated which is 
secreted while intraneuronal Aβ42 is subjected to Neprilysin mediated 
degredation (110). Overexpression of IDE decreases the extracellular 
levels of both Aβ40 and Aβ42 monomers. The current prevailing evidence 
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also suggests a differential role of apolipoprotein E (apoE) isoforms in 
mediating clearance of Aβ from the extracellular space. Importantly, the 
apoE4 isoform, which is associated with increased risk for AD, has been 
shown to exhibit an impaired ability to promote Aβ proteolysis and thus 
clearance from the extracellular space compared to apoE2 and apoE3 
(140, 141). Furthermore, Low-density lipoprotein receptor-related protein 
1 or LRP1, was shown to bind Aβ or to its chaperone complex with β2 
Microglobulin or apoE4 and deliver the complex to lysosomes for 
degradation (160). A soluble form of LRP1 sequesters 70-90 % of plasma 
Aβ peptides and its levels and capacity to bind Aβ are reduced in AD 
brains (161). In a recent study, Brodeur et al. showed that NUCB1 
strongly binds to LRP, assists in its endosomal sorting and consequently 
prevents its lysosomal degradation (27). Functionally, NUCB1 has also 
been shown to affect the biogenesis of APP, which in turn attenuates Aβ 
production (28). Thus physiologically, NUCB1 can possibly regulate Aβ 
production, assist in its clearance through reduced degradation of LRP and 
inhibit the deposition of Aβ aggregates. Future work investigating the 
physiological role of NUCB1 should provide evidence in favor or against 
these hypotheses. 
 
Our results show that NUCB1 inhibits Aβ42 fibril formation only in its 
Ca2+-free form. This is consistent with the reported interaction of NUCB1 
with APP only in the absence of Ca2+. Physiologically, neuronal Ca2+ 
 174 
levels vary from 100 nM intracellular to 1 mM extracellular concentration. 
Given the Kd values of Ca2+-binding to sNUCB1 of 6.3 µM and 73.5 µM 
respectively (Fig1.3), NUCB1 should primarily exist in a Ca2+-free form 
intraneuronally and Ca2+-bound in the extracellular environment. This 
implies that NUCB1 can interact with Aβ42 intraneuronally but 
extracellular Ca2+ levels may inhibit this interaction. However, our 
engineered Ca2+-insensitive mutant, sNUCB1(tetramutant) should be 
functional both intra- and extracellularly. The role of intraneuronal and 
extracellular Aβ in facilitating tau hyperphosphorylation, mitochondrial 
and proteosomal disruption, dysregulation of Ca2+ homeostasis, synaptic 
failure and cognitive dysfunction has placed it at the forefront of AD 
research. Additionally, it has been shown that Aβ42 when generated is 
poorly secreted and has a high tendency to aggregate under physiological 
conditions. Thus the discovery of the functional role of NUCB1 in 
inhibiting Aβ42 aggregation and disaggregating its fibrils into non-toxic 
species becomes increasingly important. Furthermore, the ability of Ca2+-
free sNUCB1 towards inhibiting tau K19(C322S) aggregation to form 
NFTs suggests that NUCB1 might have some role in regulating the 
aggregation of full-length tau upon hyperphosphorylation. Future work 
investigating this observation both in an in vitro and in vivo model would 
be useful towards understanding and establishing the physiological role of 
NUCB1. In addition, the observed reduction of NUCB1 levels in the 
brains of AD patients along with the disruption of Ca2+-homeostasis could 
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individually or together cause progression of the diseased state in AD 
patients. sNUCB1(tetramutant) circumvents the Ca2+-dependence of the 
anti-amyloidogenic properties of NUCB1 and should be functional under 
disrupted Ca2+-homeostasic conditions. This can be a useful molecular 
handle and future studies with both sNUCB1 and sNUCB1(tetramutant) in 
relevant mouse models of AD should provide important insights into their 
functional capabilities. Hence understanding of the role of NUCB1 in AD 
pathology can be useful in designing novel and effective therapeutics.  
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Heptahelical G-protein (heterotrimeric guanine nucleotide-binding pro-
tein)-coupled receptors couple to heterotrimeric G proteins to relay
extracellular signals to intracellular signaling networks, but the molecular
mechanism underlying guanosine 5′-diphosphate (GDP) release by the G
protein α-subunit is not well understood. Amino acid substitutions in the
conserved α5 helix of Gi, which extends from the C-terminal region to the
nucleotide-binding pocket, cause dramatic increases in basal (receptor-
independent) GDP release rates. For example, mutant Gαi1-T329A shows
an 18-fold increase in basal GDP release rate and, when expressed in
culture, it causes a significant decrease in forskolin-stimulated cAMP
accumulation. The crystal structure of Gαi1-T329A·GDP shows substantial
conformational rearrangement of the switch I region and additional
striking alterations of side chains lining the catalytic pocket that disrupt
the Mg+2 coordination sphere and dislodge bound Mg+2. We propose a
“sequential release” mechanism whereby a transient conformational
change in the α5 helix alters switch I to induce GDP release. Interestingly,
this mechanistic model for heterotrimeric G protein activation is similar to
that suggested for the activation of the plant small G protein Rop4 by
RopGEF8.
© 2009 Elsevier Ltd. All rights reserved.
Edited by I. Wilson
Keywords: G-protein-coupled receptors (GPCRs); heterotrimeric G-proteins;
α5 helix; X-ray crystallography; activation mechanism
Introduction
Heterotrimeric guanine nucleotide-binding regula-
tory proteins,Gproteins (Gαβγ),1,2 relay signals from
heptahelical transmembrane G-protein-coupled
receptors (GPCRs) to downstream effector mole-
cules.3,4 GPCRs activate G proteins by inducing the
release of guanosine 5′-diphosphate (GDP) from the
Gα subunit in the active receptor (R⁎)–G protein
complex.5–7 Guanosine 5′-triphosphate (GTP) uptake
by Gα leads to the dissociation of the heterotrimer
into the Gα and Gβγ subunits, making them
available to interact with various downstream
effectors. The interface between the cytoplasmic
structure of an active GPCR and its bound G protein
might be as far as 30 Å away from the bound GDP.8,9
The agonist ligand-binding site on the receptor, as
judged by the crystal structures of inverse-agonist-
bound rhodopsin10 and adrenergic receptors,11,12 are
approximately an additional 40 Å away from the
inner surface of the bilayer. Howdoes ligand binding
to a GPCR induce GDP release from Gα at a distance
of ∼70 Å?
Although the crystal structures of several G pro-
tein subunit isoforms,13–18 complexes19–22 and
mutants with altered exchange rates23,24 have
been solved, we still lack a mechanistic under-
standing of how active GPCRs stimulate nucleotide
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Abbreviations used: G protein, heterotrimeric guanine
nucleotide-binding protein; GPCR, G-protein-coupled
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electron paramagnetic resonance; WT, wild type; FRET,
fluorescence resonance energy transfer; FK, forskolin;
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doi:10.1016/j.jmb.2009.08.043 J. Mol. Biol. (2009) 393, 882–897
Available online at www.sciencedirect.com
0022-2836/$ - see front matter © 2009 Elsevier Ltd. All rights reserved.
exchange by the Gα subunit. Nevertheless, these
structural studies have identified state-dependent
conformational differences within the Gα subunit
and suggest allosteric coupling ofwell-defined switch
regions to the activation process.15 The exchange of
GDP for GTP induces ordering in the switch regions,
making the GTP-bound state conformationally more
rigid.
During activation, R⁎ engages the C-terminus
(CT) of G protein α-subunit. Earlier mutagenesis
work with transducin (Gt) showed that activation
signal is transferred to the catalytic pocket via the α5
helix that connects the CT to the nucleotide-binding
β6–α5 loop.25 Additionally, site-directed muta-
genesis of α5 helix residues of Gt showed drastic
alterations in the basal rates of nucleotide ex-
change.26,27 Previous electron paramagnetic reso-
nance (EPR) studies with site-directed spin-labeled
G protein α-subunits proposed a rigid-body move-
ment of the α5 helix upon binding of receptor during
activation.28–30 Furthermore, the crystal structure of
Q333C–I56C Gαi1, a mimic of EPR-measured
receptor-associated conformation, suggests a shift
of α5 helix toward the bound nucleotide.31 The
recent structure of ligand-free opsin in complex
with a peptide analogue of the CT tail of the α-
subunit of Gt shows, as shown earlier by NMR,
32
that the Gt peptide binds at an angle of ∼40° to the
hypothetical plane of the bilayer and makes
contacts with several conserved amino acid resi-
dues on the receptor transmembrane border
regions, notably R135. The structure also suggests
how the G protein heterotrimer might dock to R⁎.33
However, the lack of a crystal structure of an active
GPCR in complex with the full-length G protein α-
subunit or heterotrimer limits our understanding of
the exact molecular determinants of receptor-
mediated G protein activation.
We present here themolecular details of a probable
intermediate state along the G protein activation
pathway. We carried out Ala-scanning mutagenesis
to make a panel of site-specific mutants of the α5
helix of Gαi1 and identified a number of mutants
with orders-of-magnitude increases in basal ex-
change rates of guanine nucleotides in the absence
of receptor. The mutant Gαi1-T329A, for example,
showed a nearly 20-fold increase in receptor-inde-
pendent basal nucleotide-exchange rate. In cell-
based assays, Gαi1-T329A significantly attenuated
forskolin (FK)-induced cAMP accumulation and
lowered basal cellular cAMP levels. We then solved
high-resolution crystal structures of Gαi1-T329A in
both GDP- and guanosine GTPγS-bound states and
compared the structures with other available G
protein structures. The T329A mutation caused
significant alterations in the structure of the switch
I region and affected the complexMg2+ coordination
sphere in the nucleotide-binding site. Based on the
new structures, we propose a “sequential release”
mechanism for receptor-induced nucleotide ex-
change where specific structural changes mediated
by the α5 helix destabilize bound Mg2+, which exits
the active site to facilitate GDP release.
Results
Fluorescence measurement of nucleotide
binding
We first constructed a set of single point mutants
of Gαi1 in which residues T329, V332 and F336 on
the α5 helix and residue Q52 on the α1 helix were
replaced with Ala (Fig. 1). A double-mutant
construct with both Q52 and T329 residues replaced
with alanine was also engineered. All single and
double mutants were expressed as recombinant
proteins in Escherichia coli and purified to homo-
geneity. The intrinsic fluorescence of W211, which is
present in the switch II region of Gαi1, increases
upon GTP binding due to its movement from a
solvent-exposed environment to a hydrophobic
pocket in the nucleotide-binding pocket14 and has
been used to measure the kinetics of GTP uptake
reaction.34 The rate of basal nucleotide exchange for
each mutant was measured by monitoring its
fluorescence in the presence of GTPγS (a nonhy-
drolyzable analogue of GTP) (Fig. 2a). Pseudo-first-
order rate constants for GTPγS uptake by wild-type
(WT) Gαi1 and the single and double Gαi1 mutants
were calculated.
The nucleotide-exchange reaction was also moni-
tored using the fluorescence nucleotide analogue,
mant [2′,3′-O-(N-methyl-anthraniloyl)]-GTPγS
(Fig. S1). As Gα takes up mant-GTPγS, W211
moves into its characteristic hydrophobic pocket in
the nucleotide-binding site. Since the excitation
spectrum of mant-GTPγS overlaps with the emis-
sion spectrum of Trp, fluorescence resonance energy
transfer (FRET) is observed upon mant-GTPγS
binding to Gαi1. Higher rates of FRET increase
were observed for the Gαi1 mutants compared with
that of the WT Gαi1, thereby corroborating the
results of the GTPγS uptake assay. In general, we
observed multifold increases in basal nucleotide-
exchange rates in the mutants compared with that in
WT Gαi1. In particular, Gαi1-T329A displayed an 18-
fold increase in its rate of GTPγS uptake compared
with that of WT Gαi1 and appeared to be stable in
solution over extended time periods (data not
shown). Therefore, we chose the Gαi1-T329Amutant
for additional detailed studies.
Physiological role of Gαi1-T329A
To investigate the potential physiological relevance
of the T329A mutation, we expressed the human
Gαi1-T329A mutant in mammalian HEK 293 cells. In
control experiments, HEK cells were transfectedwith
WT Gαi1 or a constitutively active, guanosine tripho-
sphatase (GTPase)-deficient mutant, Gαi1-Q204L.35
We nextmeasured FK-stimulated intracellular cAMP
levels in the transfected cells. FK directly activates
adenylyl cyclase (AC) and is commonly used as an
adjunct in assays designed to evaluate the ability of
Gs and Gi to activate or inhibit, respectively, cellular
AC activity. GTP-bound, active WT Gαi1 acts to
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inhibit AC, resulting in a decreased concentration of
intracellular cAMP.36,37 We tested the ability of the
Gαi1-T329A mutant to affect FK-stimulated cellular
cAMP levels, using a highly sensitive gene reporter
assay that relies on secreted alkaline phosphatase
(SEAP) to report intracellular cAMP concentra-
tion.38,39 Compared with WT, expression of the
constitutively active Gαi1-Q204L mutant caused a
dramatic decrease in FK-stimulated cAMP levels
(Fig. 2b and c). This effect is presumed to be a direct
result of increased inhibition of AC by the Gαi1-
Q204Lmutant. Interestingly, the Gαi1-T329Amutant
mimics the effect of the Q204Lmutant in its ability to
inhibit FK-stimulated cAMPproduction. Also, unlike
Fig. 1. The structure of Gαi1 showing sites of amino acid substitution on the α5 helix. (a) The structure of the GDP-
bound form of WT Gαi1 consists of the GTPase domain (green) and the helical domain (salmon) with the nucleotide
shown as a ball-and-stick model (yellow) sandwiched between them. The α5 helix (blue) connects the receptor interacting
C-terminal tail with the GDP-interacting β6–α5 loop (orange). (b) The structure in (a) has been rotated clockwise by 70°
along the vertical axis. The α5 helix, lying in a trough formed by the α1 helix and β1–β6 strands, is∼50% solvent-exposed
and oriented in an N- to C-terminal order coming out of the plane of paper. (c) A zoom into the α5 helix region shows the
sites of mutations on the α5 helix (F336, V332, T329) and the neighboring α1 helix (Q52A). As shown, T329 and Q52
residues could be involved in a possible H-bonding interaction via their side-chain groups that are placed 3.3 Å apart.
Each of the residues was mutated to alanine for generation of single- and double-point mutants. The bound nucleotide
close to the CT of the α1 helix is shown as a ball-and-stick model (yellow).
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residue Q204, T329 is not in close proximity to the
bound nucleotide and hence cannot directly influ-
ence the stability of the bound nucleotide even
though the T329A-Gαi1 mutant mimics a constitu-
tively active state. This suggests that the mutation
somehow allosterically modulates the fast rates of
nucleotide exchange on the Gαi1 subunit.
Crystal structure of Gαi1-T329A in the
GDP- or GTPγS-bound form
To probe the molecular determinants and structur-
al basis for the increased rates of nucleotide exchange
observed in themutant Gαi1 proteins, we determined
the crystal structures of Gαi1-T329A in both the GDP-
and the GTPγS-bound forms (Table 1). The intended
mutation of Thr to Ala in the protein was confirmed
by the crystal structure, where electron density at
position 329 corresponded to Ala (Fig. S2A). The
structure of the GDP-bound form of Gαi1-T329A was
refined to 2.5-Å resolution using the structure of
Gαi1·GDP·Mg
2+ [Protein Data Bank (PDB) code
1BOF] as a template for molecular replacement. In
the final model, the region corresponding to amino
acids M1–L5, Q204–C217 and V233–E239 is missing
due to lack of electron density for these residues.
Similarly, the structure of the GTPγS·Mg2+-bound
form of Gαi1-T329A was refined to a resolution of
2.3 Å, using the structure of Gαi1-G42V·GTPγS·Mg
2+
(PDB code 1AS0) as a template. In the final model, the
region corresponding to amino acids M1–R32 and
K349–F354 is missing due to lack of electron density
for these residues. The GDP- and GTPγS-bound
structures for T329A-Gαi1 were solved in space
groups identical to those of the WT Gαi1 structures.
We systematically compared and contrasted the
structures of the WT and mutant Gαi1 proteins.
Although the switch II (residues 199–219) and
switch III (residues 231–242) regions of Gαi1-
T329A·GDP are essentially disordered as in the
WT Gαi1·GDP, both of these switch regions are
nicely ordered and resolved in the active GTPγS-
bound states of both proteins.15 Interestingly, a
well-defined electron density for switch I (residues
177–187) shows that it has moved away from the
nucleotide in Gαi1-T329A·GDP compared with
switch I in WT Gαi1 (Fig. 3). Overall the root-mean-
square deviation (r.m.s.d.) between WT Gαi1·GDP
and Gαi1-T329A·GDP was 0.79 Å, whereas it was
only 0.29 Å for their GTPγS-bound structures.
Hence, overall the GTPγS-bound-state structures
WT Gαi1 and Gαi1-T329A are essentially identical
Fig. 2. Fluorescence assay of nucleotide uptake rates
and forskolin (FK)-induced SEAP assay. (a) Nucleotide
exchange was monitored by measuring the enhancement
in intrinsic Trp fluorescence as a function of time after
addition of GTPγS. Traces show the activation of the WT
Gαi1 (black) and T329A mutant (red) and rates of ex-
change for all proteins studied are given in the table (inset).
Uncatalyzed t1/2 values are presented as the mean±SEM
of at least three independent experiments. As observed,
substitutions of residues on the α5 helix (T329, V332, F336)
or residues in close proximity to the α5 helix (Q52) increase
the basal rate of exchange, indicating a possible involve-
ment of the α5 helix during the receptor-catalyzed
nucleotide-exchange process. (b) Gαi1 mutants, T329A
and Q204L, show increased inhibition of FK-induced
cAMP-dependent SEAP activity. Mock (black), WT (red),
T329A (green), Q204L (blue) and pCRE-SEAP cotrans-
fected cells were incubated for 6 h in the presence of FK
ranging from 0 to 12.5 μM prior to SEAP activity
measurement. Inset: expression levels were similar based
on immunoblot analysis. (c) Increased inhibition of basal as
well as FK-stimulated SEAP activity is observed in cells
transfected with Q204L and T329A Gαi1 mutants. SEAP
activity is expressed as a percentage of the activity
obtained with 12.5 μMFK stimulation in mock-transfected
cells. Data are mean+SEM from three independent experi-
ments done in triplicate.
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(Fig. S3),whereas significant differences are observed
in the GDP-bound-state structures (Fig. S4).
Changes in conformation of switch I region
Superimposition of the Gαi1·GDP·Mg
2+, Gαi1·
GTPγS·Mg2+, Gαi1-T329A·GDP and Gαi1-T329A·
GTPγS·Mg2+ structures shows striking differences
in the conformations of the switch I region (Fig. 3a).
The T329A replacement on the α5 helix allosterical-
ly induces an extensive outward movement of the
switch I region away from the nucleotide in the
GDP-bound state of the mutant Gαi1-T329A com-
pared with the GDP-bound state of WT Gαi1. This
conformational change leads to an overall increase
in the catalytic pocket size, thereby destabilizing the
bound nucleotide to facilitate faster GDP release.
Interestingly, the switch I regions in the activated
forms of the mutant Gαi1-T329A·GTPγS·Mg
2+ and
WT Gαi1·GTPγS·Mg
2+ exhibit identical conforma-
tional states. Switch I is tightly positioned in close
proximity to the nucleotide, probably due to the
bound Mg2+ divalent cation in the catalytic pocket.
Hence, the T329A substitution affects the confor-
mational state of the switch I region only in the
GDP-bound form. An electrostatic potential surface
rendering of Gαi1-T329A·GDP and WT Gαi1·GDP·
Mg2+ structures also highlights extensive outward
movement of the switch I region, allowing access
for a possible exit route of the bound GDP (Fig. 3b).
Changes in GDP interactome within the catalytic
pocket
The T329A substitution also induced structural
changes in several key amino acid side chains in the
catalytic pocket (Fig. 3c and d). Foremost is an
inversion (∼180°) of the guanidinium side chain of
R178, thereby preventing H-bonding interactions
with the oxygen of the α- and β-phosphate on GDP
demonstrated in the WT Gαi1·GDP·Mg
2+ crystal
structure. This conformational flip of R178 causes a
loss of stabilization of the bound GDP. The dramatic
movement of switch I in the Gαi1-T329Amutant also
orients the side chain of K180 away from the
catalytic pocket (Fig. 4a). The other residues parti-
cipating in electrostatic interactions with the gua-
nine ring of GDP (N269, D272, K270 and A326) have
similar orientations in the Gαi1-T329A mutant and
the WT Gαi1, although shorter H-bonding distances
in the mutant promote stronger interactions with the
bound GDP. Also, unlike the case in WT Gαi1, the
side chains of R178 and L273 in the Gαi1-T329A
mutant seem to be involved in hydrophobic inter-
actions with the guanine ring along with K270 and
T327. InWT Gαi1, the GDP ribose engages its 2′- and
3′-hydroxyl groups in an H-bond network with the
backbone carbonyl groups of L175 and R176. These
stabilizing interactions are substituted by the single
side-chain hydroxyl group of S151 in the Gαi1-T329A
mutant, resulting in weaker H-bonding potential
(Fig. 3c and d). Thus, despite apparent gains in
hydrophobic interactions, the loss of favorable
electrostatic and H-bonding interactions in Gαi1-
T329A destabilizes the bound GDP, resulting in a
faster rate of release from the catalytic pocket.
Loss of Mg2+ from the catalytic pocket in the
Gαi1-T329A·GDP structure
Mg2+ was absent from the catalytic pocket in the
crystal structure of Gαi1-T329A·GDP (Fig. S2b
and c). Two key residues of the Mg2+ coordination
sphere in WT Gαi1·GDP·Mg
2+, T181 (on the switch I
region) and S47 (on the α1 helix), display consider-
able structural alterations upon substitution of T329
(Fig. 4a). T181 moves away from the Mg2+-binding
site due to the extensive outward movement of the
switch I region. The S47 side chain also orients away
from the Mg2+-binding site, disrupting the favorable
interaction present in WT Gαi1. The displacement of
nucleotide in the catalytic pocket also compromises
the favorable interactions between the β-phosphate
Table 1. Crystallographic data and refinement statistics
T329A Gαi1
(GDP)
T329A Gαi1
(GTPγS)
Data processinga
Space group I4 P3221
Unit cell dimensions
a, b, c (Å) 121.76, 121.76,
68.71
79.29, 79.29,
105.6
α, β, γ (degrees) 90, 90, 90 90, 90, 120
Crystal dimensions (mm) 0.2×0.5×0.7 0.1×0.2×0.3
Total no. of reflections 118,368 92,656
Unique reflections 16,157 17,460
No. of molecules
per asymmetric unit
1 1
Rmerge on I
b 6.0 (27.5) 8.3 (22.6)
Mean I/σIc 8.4 (2.6) 6.7 (3.3)
Completeness (%) 100 (100) 100(100)
Multiplicity 7.3 (7.5) 5.3 (5.5)
Model for MR (PDB) 1BOF 1AS0
Refinement statistics
Resolution (Å) 59.8–2.5 68.4–2.3
Reflections in file 16,157 17,447
Reflections used 15,346 16,564
Rwork (%)
d 18.1 18.5
Rfree (5% of data) 22.6 25.2
No. of atoms
Protein 2690 2627
Ions
Mg2+ 0 1
SO4
2− 1 1
Ligand (GDP/GTPγS) 1 1
Water 46 49
B-factor
Average 40.0 30.0
Ligand 27.0 12.0
r.m.s.d.'s
Bond lengths (Å) 0.02 0.02
Bond angles (°) 1.79 1.82
Chiral angles (°) 0.11 0.11
a Numbers in parentheses indicate statistics for the highest-
resolution shell.
b Rmerge=∑hkl∑i│I(hkl)i− 〈I(hkl)〉│/∑hkl∑i〈I(hkl)i〉.
c I/∑I, signal-to-noise ratio, where I is the integrated intensity of
ameasured reflection andσI is the estimated error inmeasurement.
d ∑│FP−FP(calc)│/∑FP, where FP and FP(calc) are the observed
and calculated structure factor amplitudes. Rfree is calculated
similarly using test set reflections never used during refinement.
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and bound Mg2+ (Fig. 4a). The integration of these
changes essentially dismantles the Mg2+ coordina-
tion sphere in the Gαi1-T329A mutant, and the loss
of bound Mg2+ further decreases the stability of the
bound GDP. In the WT Gαi1·GDP·Mg
2+structure
(PDB code 1BOF), several water molecules populate
the catalytic pocket, with water molecules W801,
W802 and W803 forming part of the octahedral
coordination sphere of Mg2+. These water molecules
are completely absent from the catalytic pocket of
the Gαi1-T329A·GDP structure (Fig. 4b), further
corroborating the loss of Mg2+ from the catalytic
pocket. Other proximal residues, including the
highly conserved D200, which is part of the
conserved DXXG sequence motif found in all the
regulatory G proteins of the Ras superfamily, adopt
similar side-chain conformations in the Gαi1-T329A
mutant and WT proteins.
1n 1998, Coleman and Sprang solved structures of
WT Gαi1 in the presence of different concentrations
of Mg2+.40 They showed that the Mg2+-binding site
in the catalytic pocket of WT Gαi1 has 70% occu-
pancy at 10 mM Mg2+ concentration and 100%
occupancy at 100 mM Mg2+ or above in the
crystallization buffer.40 To address the issue of
Mg2+ binding, we solved the structure of the GDP-
bound form of the Gαi1-T329A mutant with 10 mM
Mg2+ in the crystallization buffer. The structure still
revealed a complete absence of Mg2+ from the
catalytic pocket, which was consistent with our
primary crystallographic data set at 2 mMMg2+. We
also saw similar secondary-structural and side-chain
orientations in the crystals grown at 10 mM MgCl2,
as in the structure from the crystal with 2 mM Mg2+
(data not shown). This confirms the observation that
the T329A mutation indeed disrupts the Mg2+
Fig. 3 (legend on next page)
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coordination sphere in the catalytic pocket. The
absence of Mg2+, in conjunction with other destabi-
lizing structural changes, facilitates the release of
bound GDP from the catalytic pocket, explaining the
increase in release rates of GDP from the mutant
Gαi1 proteins.
To investigate the influence of Mg2+ on the
kinetics of the nucleotide-exchange process, we
performed the GTPγS-binding assay on the WT
and mutant Gαi1 proteins as a function of Mg
2+
concentration. Interestingly, the results showed that
the rates of exchange depended significantly on the
concentration of Mg2+ present in the reaction buffer.
In general, increasing Mg2+ concentration decreased
the rate of GDP release (Fig. 4c). The greatest
decrease in the rate of exchange as a function of
increasing concentrations of Mg2+ was observed for
the WT Gαi1. The effect of increasing Mg
2+
concentration can be rationalized by our earlier
structural observations. The high concentration of
Mg2+ might induce order in the structure and
stabilize the GDP-bound state. This would make
the rate of nucleotide exchange slower at higher
concentrations of Mg2+. The induction of similar
structural changes due to increasing Mg2+ concen-
tration was also shown earlier by Coleman and
Sprang.40 Interestingly, the rate of nucleotide ex-
change for the slower-exchange mutants (Q52A,
V332A, Q52A/T329A) was also influenced by the
concentration of Mg2+ present in the reaction
mixture. This may be due to a partially intact Mg2+
coordination sphere where binding of Mg2+, albeit
with lower affinity, might stabilize the bound
nucleotide. The rates of nucleotide exchange for the
rapid-exchange mutants Gαi1-T329A and Gαi1-
F336A are, by and large, unaffected by increasing
Mg2+ concentrations. This substantiates the struc-
tural findings related to the disruption of the Mg2+
coordination sphere in the Gαi1-T329A·GDP struc-
ture as noted above. We thus propose that the
accelerated rate of the activation process in the
mutants is coherently coupled in part to the loss of
Mg2+ from the catalytic pocket. In receptor-induced
nucleotide exchange, the receptor might possibly be
inducing similar structural rearrangements to facil-
itate a faster nucleotide exchange.
As stated earlier, the superimposition of the static
secondary-structural elements in the crystal struc-
ture of the Gαi1-T329A·GTPγS·Mg
2+ and WT Gαi1·
GTPγS·Mg2+ complexes revealed an r.m.s.d. of only
0.29 Å. There were no observable significant
secondary-structural differences between these two
structures (Fig. S3). This highlights the fact that the
activated state is well ordered and almost identical
for WT Gαi1 and the Gαi1-T329A mutant. The
mutation affects only the less ordered GDP-bound
form of the protein, inducing an increased rate of
nucleotide exchange. The presence of an intact Mg2+
coordination sphere in the activated form leads to
tight ordering of the switch I region, which is
conformationally more dynamic in the GDP-bound
form. The residues that constitute the GTPγS-
binding domain have identical orientation with
minimal conformational differences. The nucleotide
positioning in the catalytic pocket is more definitive
and static, with complete overlap between the
respective nucleotides in the mutant and WT Gαi1
structures (Fig. 4d).
Thermodynamics and kinetics of the activation
process
The mutations of the α5 helix residues cause
disruption of certain key electrostatic interactions
within the Gα subunit. The influence of the mutation
on the rate of activation suggests that the mutation
Fig. 3. Switch I movement and changes in GDP interactome within the catalytic pocket. (a) The T329Amutation on the
α5 helix allosterically induces an extensive outward movement of the switch I region of Gαi1-T329A·GDP (green) in
comparison to the switch I regions of WT Gαi1·GDP·Mg
2+ (salmon) (PDB code 1BOF), Gαi1-T329A·GTPγS·Mg
2+ (orange)
or WT Gαi1·GTPγS·Mg
2+ (blue) (PDB code 1ASO). This movement of a key structural determinant in Gαi1-T329A·GDP
leads to changes in the orientation of side chains of the residues lying along the switch I region in the Gαi1-T329A·GDP in
comparison to other forms of Gαi1. (b) A zoom into switch I consisting of electrostatic potential surface of Gαi1-
T329A·GDP and WT Gαi1·GDP·Mg
2+ shows extensive movement of the switch I corresponding region on the proteins.
The outward movement of switch I in the mutant exposes an exit route readily available for the bound nucleotide, which
could facilitate faster rates of nucleotide exchange. However, inWTGαi1, switch I is rigidly positioned to act as a lid on the
exit channel, thereby limiting the kinetics of the nucleotide-exchange process. The residues interacting with the guanine
ring (N269, D272, K270 and A326) are the same in both (c) the mutant and (d) the WT Gαi1, although the H-bond
stabilizing interactions are slightly stronger (due to closer proximity of interacting ends) in the mutant. In the T329A
mutant, additional residues, namely, R178, L273, T327 and K270, are involved in hydrophobic interactions with the
guanine ring through their side chains than in WT Gαi1. In WT Gαi1, the ribose ring of GDP engages the 2′- and 3′-
hydroxyl groups in a H-bonding network with the backbone carbonyls of L175 and R176, whereas this bicentric
stabilizing interaction is replaced by a single side-chain hydroxyl group of S151 in T329A, contributing to the decreased
stability of the nucleotide in the pocket. The α- and β-phosphates interact with multiple amino acid side chains and
backbones. A crucial H-bonding interaction between the oxygen atoms of the α- and β-phosphates on GDP and the
protonated side chain of R178 is lost in the mutant, contributing further to the decrease in the stability of the bound
nucleotide. The flipping of the R178 side chain outside the pocket also contributes to a larger pocket size in comparison to
WT Gαi1, where this interaction is tightly regulated. These effects of the mutation at a distance are tremendous, and
overall cause the loss of Mg2+ from the binding pocket. The lack of Mg2+ in turn disrupts multiple electrostatic interactions
with amino acid residues, such as S47 and T181, along with the oxygen atoms present on the β-phosphate of GDP. The
T329A mutation overall lowers the activation barrier of nucleotide exchange by allosterically modulating the orientation
and general conformation of the residues constituting the GDP interactome.
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might be affecting the activation energy for the
nucleotide-exchange process. In order to analyze
quantitatively the effect of mutation on the activa-
tion energy, we performed GTPγS-binding assays
over a linear temperature gradient. The fluorescence
enhancement of W211 due to activation was
monitored and rates were calculated. Experiments
were performed for the WT Gαi1 and Gαi1-T329A
mutant and kapp values were calculated for each
data set at different temperatures. A plot of ln k
versus 1/T was fit to the Arrhenius equation to give
activation energies for both WT and mutant. The
analysis revealed that the barrier for activation of the
mutant is lower by 5.1 kcal/mol than that of the WT
Fig. 4 (legend on next page)
889Heterotrimeric G Protein GDP Release Mechanism
(Fig. S5a). This implies that the T329A mutation
causes allosteric modulation of residues defining the
catalytic pocket, which leads to destabilization of
interactions involved in GDP binding. The net effect
is a lowering of the activation threshold, thereby
resulting in faster rates of nucleotide exchange.
We performed isothermal titration calorimetry
(ITC) to analyze the effect of amino acid replacement
on the apparent binding affinity of the nucleotide
ligand and its influence on the nucleotide-exchange
process. ITC experiments, in principle, give the net
change in the enthalpy for this exchange reaction
(Fig. S5b). The binding of GTPγS to the Gαi1-T329A
mutant was more exothermic than GTPγS binding
to WT Gαi1 (data not shown). The crystal structures
of Gαi1-T329A·GTPγS·Mg
2+ and WT Gαi1·GTPγS·
Mg2+ are almost identical, with an r.m.s.d. of 0.29 Å.
Thus, the final GTPγS-bound states of the two
complexes can be assumed to have the same energy
level on a reaction profile diagram. However, the
crystal structure of the GDP-bound form of the Gαi1-
T329A mutant displays significant conformational
changes that destabilize its GDP-bound state.
Hence, transition from the energetically higher
GDP-bound state should give larger reaction en-
thalpy. Our ITC data are in excellent agreement with
this rationale. The high activation barrier for the WT
protein makes the process of spontaneous basal
nucleotide exchange slow and unfavorable, al-
though we observe strong binding constants for α5
helix mutants Gαi1-T329A, Gαi1-Q52A/T329A and
Gαi1-V332A (Fig. S4b). The loss of favorable inter-
actions caused by each α5 helix amino acid
replacement promotes faster release of the bound
GDP, which creates a nucleotide-free pocket readily
available for GTPγS binding. This observation is in
excellent agreement with the kinetic analysis of the
exchange process for different mutants as shown
earlier. Hence, the ITC experiments along with the
Arrhenius analysis show that thermodynamic gain
also contributes to faster rates of nucleotide ex-
change for the mutants in comparison to the WT
protein.
Discussion
Over the years, several hypothetical models have
been proposed to explain receptor-induced G
protein activation. One model elucidates the role
of the Gβγ subunit as a “lever” to reorient a cognate
exit route in Gα during receptor-promoted GDP–
GTP exchange. The β3–α2 loop or the “lip” of this
contact surface (between Gα and Gβγ subunits) and
switch I occlude the exit route for GDP. The
receptor-mediated exchange promotes alterations
in this region to facilitate the activation of G
proteins.8,41 Alternatively, a “gear-shift” model has
also been proposed where R⁎ binds to Gα and
induces a hinge motion at the Gα N-terminal tail.
This leads to tight packing of the Gα–Gβ subunits,
and the N-terminal tail of the Gγ subunit is engaged
to displace the Gα helical domain. The opening of
the cleft between the GTPase domain and the helical
domain allows for GDP release.42
Mutations of the α5 helix residues of Gt facing into
the protein cause a multifold increase in the basal
rate of nucleotide exchange.26,27 This suggests that
the α5 helix comprises a functional microdomain in
G proteins that affects basal nucleotide release rates
and mediates receptor-catalyzed nucleotide ex-
change at a distance from the nucleotide-binding
pocket. Interestingly binding to Gβγ or the receptor
is largely unaffected by these mutations. In 2006,
Fig. 4. Changes in catalytic pocket residues inGαi1-T329A andWTGαi1 and loss ofMg2+. (a) A superposition of the side
chains of residues in close proximity with GDP and those forming the coordination spheres of Mg2+ in the WT
Gαi1·GDP·Mg
2+ andGαi1-T329A·GDP structures reveals some key differences. The protonated side chain of R178 involved
in forming H-bonding interactions with the oxygen of the α- and β-phosphate on GDP in the WT Gαi1·GDP·Mg
2+ rotates
by almost 180° in T329A, thus nullifying this stabilizing interaction. Extensivemovement of switch I leads to flipping of the
K180 side chain away from the catalytic pocket into a more solvent-exposed environment. A key residue of the Mg2+
coordination sphere, T181, orients away from the Mg2+ binding site as well. The side chain of S47, a direct Mg2+-binding
ligand, undergoes a conformational switch orienting it away from theMg2+ binding site. All other proximal residues adopt
a side-chain conformation in themutant similar to that observed in theWT protein. Concomitantly, the T329A substitution
also leads to the displacement of the nucleotide in the catalytic pocket, indicative of the disruptions in the cooperative H-
bond network within the catalytic pocket in the mutant. (b) A superposition of the WT Gαi1·GDP·Mg
2+ (green) structure
with the Gαi1-T329A·GDP structure (salmon) shows distinct organization of the water molecules within the catalytic
pocket. The mutant structure shows absence of Mg2+ coordinating water molecules, namely, W801, W802 and W803,
further substantiating the observation of loss of Mg2+ from the catalytic pocket. (c) Coleman and Sprang showed that with
increasing concentrations ofMg2+,WTGαi1 undergoes conformational changes inducing order in the structure reminiscent
of the activated WT Gαi1·GTPγS·Mg
2+ state.40 The rate of nucleotide exchange for the WT Gαi1 protein and the slow-
exchange mutants (Q52A, V332A and Q52A T329A) is very much dependent on the concentration of Mg2+ present in the
reaction buffer, possibly due to the influence of a completely or partially intact Mg2+ coordination sphere stabilizing the
bound nucleotide. The rates of exchange for the rapid-exchange mutants, T329A and F336A, remain by and large
unaffected by increasingMg2+ concentrations, substantiating the structural determinants, consistentwith the disruption of
the Mg2+ coordination sphere in the Gαi1-T329A·GDP structure as shown above. (d) Unlike the GDP-bound state, the
residues aligned along the catalytic pocket involved in both electrostatic and hydrophobic interactions with the bound
nucleotide in the GTPγS-bound state are much more static. The side-chain orientations are similar or identical, with no
displacement of the bound nucleotide in either the Gαi1-T329A·GTPγS·Mg
2+ orWTGαi1·GTPγS·Mg
2+. These results show
that even if the rates of nucleotide exchange are different, post-exchange a higher degree of order is restored in the
structure, which is independent of amino acid substitution on the α5 helix.
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Hubbell and coworkers conducted a site-directed
spin-label EPR study of α5 helix residues and
suggested that R⁎-stimulated activation causes a
rigid-body movement of the α5 helix, which
perturbed the β6–α5 loop and thereby decreased
GDP stability in the catalytic pocket.28 In addition,
allosteric changes at the Gα–Gβγ interface triggered
by interactions with R⁎ were observed, along with
significant changes even in the dynamics of residues
(A300 on the α4 helix) distant to the receptor or the
Gα–Gβγ interface.29,30 An alternative hypothesis
suggested that the receptor first engages Gβγ and
then triggers the GDP release by interacting with
the CT of Gα in a “sequential” manner.43,44 All of
these studies suggest a potential important role for
the α5 helix of Gα in the activation pathway. The
receptor would engage the CT of Gα (connecting
to the α5 helix) to induce conformational changes
facilitating the release of bound GDP from the
catalytic pocket.
In the absence of R⁎, the CT is unstructured and
becomesmainly helical upon binding to the activated
receptor.45,46 This binding also induces conforma-
tional rearrangement within the receptor.33 How-
ever, intriguingly, the CT interacts with the receptor
primarily through its backbone atoms, which sug-
gests that the CT alone cannot provide specificity and
selectivity to the binding event coupled to G protein
activation. In contrast to this observation, Conklin et
al. earlier demonstrated through a series of experi-
ments that only a minimum of three amino acid
substitutions in the C-terminal region switches the
receptor specificity of Gαq to that of Gαi, highlighting
the contribution of CT.47 However, in Gαi2 and Gt,
the last eight residues are identical, but the α2-
adrenergic receptor only activated Gαi2 selectively.48
All these observations suggest that the CT alone
cannot be the sole determinant of R⁎–G protein
specificity, and other regions of the α-subunit along
with contributions from the Gβγ subunit49 must
provide elements that contribute to the overall
selectivity of this interaction.
The α5 helix of Gα is directly proximal to the CT
and is highly structured, pointing directly from the
N-terminal portion of CT into the nucleotide-binding
pocket. Therefore, we hypothesized earlier that α5
might be a key structural element in transmitting the
signal of Gα binding to R⁎ to the nucleotide-binding
pocket. This hypothesis was supported by the results
ofmutagenesis experiments showing that amino acid
substitutions in the α5 helix resulted in dramatically
enhanced rates of nucleotide exchange even in the
absence of receptor. Mutagenesis of Gt26,27 and
follow-up computational molecular dynamics
studies50 suggested that a receptor-induced move-
ment of theα5 helix of theGα subunitmight affect the
local structure of the GDP-binding pocket via the α1
helix and β2 and β3 strands. Although biophysical
studies of the A326S Gαi1 mutant suggested that it
might be a mimic of the receptor-bound activated
state, a follow-up crystal structure of Gαi1-
A326S·GDP showed that its GDP-binding pocket
was no different from that of WT Gαi1.
23
Structural studies on the Gαi1-T329A mutant
presented here show extensive movement of the
switch I region and disruption of the Mg2+
coordination sphere within the catalytic pocket.
There are also drastic changes in the conformations
of side chains of residues lining the catalytic pocket,
also resulting in decreased stability of the bound
GDP nucleotide. Interestingly, the residue R178
even in the structure of the heterotrimer (PDB code
1GG2) adopts a conformation where it is oriented
away from the catalytic pocket, as shown in Fig. S6.
As shown by Abdulaev et al., Gα adopts a
“preactivated” conformation when associated with
Gβγ.51 An altered conformation of R178 might
contribute to acquiring this state. These changes
concomitantly cause the destabilization and dis-
placement of the bound nucleotide.
Also, the results from the cell-based in vitro SEAP
assay (Fig. 2b and c) show that ligand-stimulated
inhibition is much stronger for the mutants in
comparison to theWT protein. This must be possible
only because the mutant, similar to WT protein, can
interact with the receptor and the Gβγ subunit. As
shown in Fig. S7, both WT and Gαi1-T329A subunits
can interact with Gβγ subunit in vitro, leading to
substantial inhibition of activation. The observation
and rationalization of these changes in the Gαi1-
T329A mutant suggest that the T329A replacement
has stabilized a structural intermediate along the
activation pathway. The structure of the mutant
subunit provides a plausible insight into the
mechanism of nucleotide exchange and allows us
to explain convincingly the allosteric effect of the α5
helix on the basal rate of exchange.
We did not observe any substantial movement of
the α5 helix itself or of the nucleotide-interacting
β6–α5 loop within the structures, probably because
the structure of the Gαi1-T329A mutant represents
an intermediate along the activation pathway and
not a true transition state in the exchange process.
We presume that a transient movement of α5 along
with other contributing conformational changes
must occur earlier in the process, which could not
be trapped in the crystal structure of the T329A-Gαi1
mutant. In support of this explanation, a recent
molecular dynamics simulation reported by
Scheerer et al. shows that the α5 helix might act as
a transmission rod that undergoes both translation
and rotation upon engagement of G protein by the
activated receptor.52
Recently, Johnston and Siderovski solved the
crystal structure of the WT Gαi1·GDP subunit
bound to two peptides corresponding to the N-
terminal region of the third intracellular loop of the
D2-dopamine receptor and a Gβγ surrogate peptide
(KB-752).22 Each of these peptides can act as a Gα
guanine nucleotide exchange factor (GEF). Their
work showed that binding of the peptides to the
GDP-bound form displaces the β6 strand away from
the α4 helix and toward the α5 helix from its
position in the unbound protein. The Gαi1-T329A
replacement described here promotes a similar
movement of the β6 strand in the GDP-bound
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structure (Fig. S8), which further supports the
hypothesis that the mutation most likely traps an
intermediate along the activation pathway.
Based on our analysis, we propose a sequential
release model for G protein activation (Fig. 5).
Initially, the activated receptor interacts with the
heterotrimer (Gαβγ) and induces a helical confor-
mation into the unstructured CT of the α-subunit.
This binding event translates to an activation signal,
which we propose is transmitted to the catalytic
pocket via the α5 helix. During activation, the switch
I region of the α-subunit undergoes extensive
Fig. 5. A proposed sequential release model of G protein activation by GPCRs. The prototypical GPCR opsin (salmon)
complexedwith the C-terminal (CT) peptide (residues 340–350) from transducin (Gt) (green) (PDB code 3DQB) is depicted
as a ribbon diagram in a cartoon. The heterotrimeric G protein subunits Gα (gray), Gβ (light pink) and Gγ (blue) are
shown as a complex (PDB code 1GG2) with Gαi1·GDP replaced with the mutant Gαi1-T329A·GDP structure. The α5 helix
of Gαi1 is highlighted in red. Since the CT is not resolved in the structure of the heterotrimer, the G protein is docked to the
active receptor (R⁎) as suggested by Scheerer et al.33 Upon G protein activation, switch I (S1, dark pink) and switch II (S2,
light green) of the α subunit undergo conformational changes. The switch I region is highlighted to show the extent of
movement. In our proposed model of the G protein activation cycle: (1) The receptor first engages the CT of the α subunit,
which brings the α5 helix directly to the surface of R⁎. (2) Receptor binding along with docking of the Gββγ subunit
facilitates allosteric structural modulation of the α subunit to cause an outward movement of its switch I region. (3) These
accumulating conformational changes disrupt the Mg2+ binding site in the catalytic pocket leading to its dissociation. (4)
The loss of Mg2+ and structural rearrangements of key residues (S47, T181, R178) overall destabilizes the bound GDP and
facilitates its faster release from the catalytic pocket. (5) The transient intermediate of empty pocket Gαβγ bound to R⁎ is
formed. GTP andMg2+ rebind to Gα leading to the dissociation of the heterotrimer into the Gα and Gβγ subunits. Finally,
the bound GTP is hydrolyzed to GDP+Pi and the inactive Gα·GDP subunit can reassociate with Gβγ to initiate another G
protein activation cycle. The structure of the T329A mutant, which shows an increased rate of receptor-independent GDP
release, may represent an intermediate that mimics the Mg2+ free state of the G protein during the activation cycle.
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outward movement away from the catalytic pocket,
as seen on comparison of Gαi1-T329A·GDP and
Gαi1·GDP·Mg
2+estructures. This spatial rearrange-
ment of switch I coupled to conformational changes
in the side chains of key residues (S47, T181, R178)
lining the catalytic pocket together disrupt the
coordination sphere of Mg2+. The loss of Mg2+
along with the accumulating conformational
changes destabilizes the bound GDP, which can
now be exchanged for GTP at a much more rapid
rate to accelerate G protein activation. This activa-
tion triggers the dissociation of the heterotrimer into
the Gα and Gβγ subunits, rendering them available
for interacting with their respective downstream
effectors.
As expected, the kinetics of the overall process of
nucleotide exchange is modulated by the presence of
Mg2+. However, the rapid-exchange mutants (Gαi1-
T329A and Gαi1-F336A) show an increased rate of
activation independent of the concentration of Mg2+.
This can be rationalized by the absence of a
coordination sphere for Mg2+ in the crystal structure
of Gαi1-T329A. However, as seen inWTGαi1, GTPγS
binding assays with the slow-exchange mutants
(Gαi1-Q52A, Gαi1-V332A, Gαi1-Q52A/T329A)
show a decrease in the rate of activation with
increasing concentration of Mg2+, probably due to
a partially intact Mg2+ coordination sphere in the
catalytic pocket. This model suggests the existence of
an “allosteric switch,” meaning that a transient
ternary complex with a finite lifetime should exist
between GDP-bound G protein and R⁎ complex, as
suggested earlier by Heck and Hofmann using a
kinetic analysis.53 The alternate model would be a
so-called hit-and-run model, where R⁎ and GDP
binding to Gα would be mutually exclusive. Our
structural studies suggest, in fact, a transient state
between R⁎·G[GDP-Mg2+] and R⁎·G[empty], name-
ly, R⁎·G[GDP- ], where Mg2+ has exited and GDP
remains, causing destabilization of the GDP-binding
pocket.
G proteins comprise a superfamily consisting of
both the heterotrimeric and small monomeric G
proteins.54,55 Similar to heterotrimeric G proteins,
small G proteins also undergo conformational
changes in switch regions upon activation. Binding
to GTPγS induces order in both switch I and switch
II regions.56,57 Recently, Thomas et al. solved the co-
crystal structure of a plant small G protein Rop4
(Rho of plants) in complex with the catalytic PRONE
domain of RopGEF8.58 The structure of this never
previously observed ternary complex of Rop4,
PRONE domain and GDP suggested a general
mechanism of small G protein activation. Namely,
Rop4 binding to RopGEF8 causes displacement of
Mg2+ through steric hindrance of its binding site,
moves switch I away from the nucleotide and
pushes switch II toward the conserved phosphate-
binding P-loop. The extended movement of the
switch I region further facilitates the sequential exit
of Mg2+ followed by GDP from the catalytic pocket,
leading to accelerated exchange of nucleotide. Our
structural studies of a heterotrimeric G protein α-
subunit mutant also highlight the disruption of the
Mg2+ coordination sphere and movement of the
switch I region with concomitant destabilization of
the bound nucleotide. These independent, yet
obviously related, observations hint at a similar
shared mechanism of activation for the two sub-
classes of G proteins, heterotrimeric G proteins and
small, single-subunit G proteins.
In summary, our results provide novel structural
insights toward understanding the mechanism of
nucleotide exchange by heterotrimeric G proteins.
The structural studies reported here, supplemented
with biophysical data, demonstrate a critical depen-
dence of basal nucleotide exchange rate on Mg2+. As
observed in the high-resolution crystal structure of
the Gαi1-T329A mutant, with an amino acid
replacement in the α5 helix, movement in the switch
I region disrupts the coordination sphere of Mg2+
and increases the effective size of the nucleotide-
binding pocket. These changes, in association with
the conformational changes of other binding pocket
residues, result in overall destabilization of the
bound GDP, leading to rapid exchange of GDP for
GTPγS. The complete conservation of residues T329
and F336 across different classes of G protein α-
subunits suggests a critical role of these residues
(Fig. S9). Furthermore, our mutational analysis
suggests that similar mechanisms of activation
might be utilized for the different α-subunits. We
believe that the novel mechanistic aspects highlight-
ed here, along with the observations from other
relevant studies on related systems, allow a greater
understanding of the allosteric mechanism of
nucleotide exchange by G proteins.
Materials and Methods
Reagents
GDP sodium salt and GTPγS tetralithium salt were
purchased from Sigma-Aldrich (St. Louis, MO). The
fluorescent GTPγS analogue, mant-GTPγS was purchased
from Jena Biosciences (Jena, Germany). The His6-tagged
mutants of WT Gαi1 were generated by site-directed
mutagenesis using the high-fidelity thermostable DNA
polymerase Pfu (Stratagene, CA). All crystallographic
reagents were purchased from Hampton Research (Aliso
Viejo, CA). All reagents and chemicals used were of
highest available purity.
Construction, expression and purification of
Gαi1 proteins
The DNA fragment containing the WT rat Gαi1 subunit
(residues 1–354) was amplified by PCR and cloned into the
pET28a(+) expression vector (Amersham Biosciences,
Piscataway, NJ) with the BamHI and NotI restriction
sites. The vector was used to transform BL21 (DE3) cells to
express anN-terminal His6-tagWTGαi1 protein containing
a PreScission protease site directly after the His6-tag. The
same construct served as a template for introducing site-
specific mutations in the protein with the QuickChange
system (Stratagene, La Jolla, CA) according to the
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manufacturer's protocol. Themutationswere confirmed by
DNAsequencing (DNASequencing Facility, Genelink,NJ).
The WT and the mutants were expressed in BL21 (DE3)
cells grown in the presence of kanamycin (50 μg/ml). Cells
were grown at 37 °C to A600 nm of ∼0.7 and then induced
with 400 μM isopropyl-β-D-thiogalactoside (IPTG) (US
Biological). The culture was then grown overnight at 17 °C
at an agitation speed of 180 rpm. Cells were harvested by
centrifugation, and the resulting pellets were resuspended
on ice in a buffer containing 50 mM Tris–HCl (pH 8.0),
150 mM NaCl, 2 mM MgCl2, 10 μM GDP, 50 mM β-
mercaptoethanol, bovine lung aprotinin (20mg/ml), 2 mM
PMSF and complete EDTA (ethylenediaminetetraacetic
acid)-free protease inhibitor cocktail tablets (Roche). The
cells were snap-frozen in liquid nitrogen and stored at
−80 °C. For purification, the cells were thawed on ice and
lysedwith a Frenchpress (Avestin). The lysatewas spun for
90 min at 16,500 rpm. The resulting supernatant fraction
was filtered through a 0.45-μm filter (Nalgene) and loaded
onto a nickel–nitrilotriacetic acid (Ni–NTA) Superflow
resin column (GE Healthcare) that was equilibrated with
buffer A [50 mM Tris–HCl (pH 8.0), 150 mM NaCl, 2 mM
MgCl2, 10 μM GDP, 50 mM β-mercaptoethanol]. The
protein-loaded resin was washed with buffer A and the
bound protein was eluted, using a gradient of buffer B
(buffer A supplemented with 500 mM imidazole). The
eluted protein fractions were pooled, extensively dialyzed
against buffer A and cleaved with 1:1000 A280 unit of
glutathione S-transferase PreScission protease for 48 h in
order to remove the N-terminal his-tag. The sample was
then loaded onto aNi–NTA column to separate the cleaved
protein from the cleaved His-tag and any uncleaved
fraction. Next, the protein solution was loaded onto a
glutathione Sepharose 4B column (GE Healthcare) to
separate the glutathione S-transferase fusion PreScission
protease protein from the cleaved protein. The resin was
equilibrated with buffer A. The resin was first washed in
buffer A and the bound PreScission protease was eluted
using a gradient of buffer B (buffer A supplemented with
20 mM reduced glutathione). SDS-PAGE was used to test
the purity of the chromatography fractions. Thereafter, the
appropriate fractions were pooled and concentrated to a
volume of less than 5 ml and loaded onto a Superdex 200
26/60 column (GE Healthcare) that was equilibrated in
buffer C [50 mM Tris–HCl (pH 8.0), 150 mM NaCl, 2 mM
MgCl2, 10 μM GDP, 2 mM DTT]. After elution, the
protein-containing fractions were pooled, concentrated to
N50 mg/ml, snap-frozen in liquid nitrogen and stored at
−80 °C. The average yield for WT Gαi1 and each mutant
was N10 mg/l of culture.
Fluorescence-based kinetic assays
Time-based fluorescence measurements were per-
formed in a SPEX Fluorolog-2 spectrofluorometer (SPEX
Industries, Edison, NJ) at 25 °C. WT Gαi1 was incubated in
the reaction buffer [50 mM Tris–HCl (pH 8.0), 150 mM
NaCl, 2 mM MgCl2 and 1 mM DTT] for 5 min with
constant stirring. GTPγS (178 μM) was added to the
reaction mixture with WT Gαi1 (178 nM) and the relative
increase in intrinsic fluorescence (λex=295 nm, λem=
340 nm) was measured as a function of time. The same
procedure was carried out for all Gαi1 mutants. Mg
2+-
dependent nucleotide exchange rates were determined by
varying the concentration of Mg2+ in the reaction buffer.
Pseudo-first-order exchange rates were determined by
fitting the data to an exponential association curve,Y=Y0+
a[1−exp(−kappt)], using Sigma Plot 10.0, where kapp is the
apparent rate constant and t is the time in seconds. The t1/2
values were calculated using t1/2=(ln 2)/kapp. The pseudo-
first-order kinetic analysis was valid due to the presence of
excess GTPγS in the reaction mixture. The data are
reported as the average value obtained from three to five
experiments. The GTPγS-binding assay was also done
with a linear temperature gradient from 5 to 35 °Cwith the
same method. A kapp was calculated for each temperature
step at intervals of 5 °C by pseudo-first-order kinetic
analysis. The activation energy for reaction Ea was
calculated using kapp=A exp[-Ea/(RT)] for the Arrhenius
analysis, where A is the preexponential factor, Ea is the
activation energy of the exchange reaction, R is the
universal gas constant (8.314 J mol− 1 K−1) and T is the
temperature in kelvins. For mant-GTPγS binding assays,
Gαi1 protein samples (178 nM) were incubated for 5 min
(same buffer as the GTPγS binding assay) at 25 °C,
followed by the addition of mant-GTPγS (300 nM). FRET
was monitored by exciting the intrinsic Trp fluorescence at
295 nm andmeasuring the mant-GTPγS fluorescence from
310 to 540 nm. In all cases, blank spectra containing buffer
alone were subtracted from the final spectra.
Cell-based assay of Gαi1-T329A
The EE-tagged WT and constitutively active (GTPase
deficient) human Q204L expression constructs were
obtained from the Missouri S&T cDNA Resource Center†.
The T329A point mutation was generated with site-
directed mutagenesis and confirmed by sequencing.
HEK293 cells (ATCC) were maintained in Dulbecco's
modified Eagle's medium (Invitrogen) with 10% (v/v)
fetal calf serum (FCS) at 37 °C and 5% CO2. For the SEAP
assay described below, cells were plated in 10-cm dishes
and transiently transfected with pCRE-SEAP (BD Bio-
sciences) and pcDNA3.1(+) control, WT Gαi1 or mutant-
Gαi1 expression constructs using Lipofectamine Plus
(Invitrogen). Briefly, 3.5 μg of total DNA (0.5 μg of
pCRE-SEAP+3 μg of G protein expression vector) was
complexed with 10 μl of PLUS reagent and 17 μl of
Lipofectamine reagent and incubated for 15 min at room
temperature before addition of the DNA–lipid mixture to
cells. Cells were plated 24 h after transfection at a density
of 20,000 cells per well in poly-D-lysine-coated 384-well
plates. Cells were serum-starved in 0.1% FCS overnight
and subjected to the SEAP assay, which was performed as
described previously with somemodifications to employ a
384-well format. About 48 h after transfection, cells were
left untreated (basal) or stimulated with FK for 6 h in 0.1%
FCS. Briefly, 2 μl of culture medium supernatant fractions
were transferred to white 384-well low-volume ProxiPlate
(PerkinElmer) containing 5 μl of dilution buffer [150 mM
NaCl and 40 mM Tris–HCl (pH 7.2)] and heat inactivated
at 65°C for 20 min (to heat inactivate the endogenous
alkaline phosphatase). Equal volumes (7 μl) of assay buffer
(2 M diethanolamine, 10 mM MgCl2, 20 mM L-homo-Arg,
adjusted to pH 9.8), reaction solution containing enhancer
solution (Tropics, Bedford, MA) and 0.4 mM SEAP
chemiluminescent substrate (Tropics) were added to
each well. Luminescence was quantified 15 min after
substrate addition with an EnVision Multimode Plate
Reader (Perkin Elmer). To allow comparison between
different experiments and to assess the effect of different
mutant G proteins, data were normalized relative to signal
obtained in mock-transfected cells in the presence of
12.5 μM FK, defined as 100%. Dose response experiments
†www.cdna.org
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were performed with FK ranging from 0.2 to 25 μM.
Assays were performed in triplicate and data were
analyzed using Origin 7.0 software.
Crystallization and structural determination
The protein stock solution of Gαi1-T329A·GDP at
120 mg/ml in storage buffer (50 mM Tris–HCl, 150 mM
NaCl, 2 mM MgCl2, 10 μM GDP, 2 mM DTT) was diluted
to 10 mg/ml using the dilution buffer [50 mM EPPS
(pH 8.0), 1 mM EDTA, 2 mM MgCl2, 5 mM GDP, 5 mM
DTT]. Crystals of Gαi1-T329A bound to GDP were
obtained by the hanging-drop vapor-diffusion method in
1.8–2.1M (NH4)2SO3 and 100mM sodium acetate (pH 5.9–
6.3), as described earlier by Sprang and coworkers.59
Crystals of size 0.2 mm×0.5 mm×0.5 mm formed in 5–7
days at 20 °C in the space group I4 (a=b=120.4 Å,
c=69.8 Å, α=β=γ=90°) with one Gαi1-T329A·GDP
molecule in the asymmetric unit. Crystals for Gαi1-
T329A·GDP at 10 mM MgCl2·6H2O in the dilution buffer
were grown under similar conditions and showed the
same space group. A similar strategy was used to grow
crystals of Gαi1-T329A·GTPγS·Mg
2+ by preparing a
solution of 10 mg/ml by incubating the protein stock
for 60 min with 5 mM GTPγS in storage buffer instead of
GDP. The Gαi1-T329·GTPγS·Mg2+ complex crystallized in
the space group P3221 (a=b=78.93 Å, c=105.62 Å) with
one Gαi1-T329A·GTPγS·Mg
2+ molecule in the asymmetric
unit. For data collection at 100 K, crystals were
transferred to well solution supplemented with 20%
glycerol and 2.5 M (NH4)2SO3 for ∼30 s followed by
immersion in liquid nitrogen. The native data sets were
collected at beam line NE-CAT (24ID) of the Advanced
Photon Source (APS) at Argonne National Laboratory.
The data sets were indexed and processed using
HKL200060 and Mosflm.61 The structures of Gαi1-
T329A·GDP and Gαi1-T329A· GTPγS·Mg
2+ complexes
were determined by molecular replacement using only
the Cα backbone from 1BOF (WT Gαi1·GDP·Mg
2+) and
1AS0 (Gαi1-G42V·GTPγS·Mg
2+) structures as search
models for Phaser in the CCP4 suite‡. Thereafter, CNS
was utilized to obtain simulated annealing generated
models for both GDP- and GTPγS-bound states of Gαi1-
T329A. Finally, model building was performed in Coot,62
wherein nucleotide and Mg2+ were fitted into the
observed densities with refinement conducted by
Refmac5 in CCP4 as well as a combination of rigid-
body, simulated annealing, energy minimization, and B-
factor protocols in CNS.63 The structural superpositions
were done using SSM superposition for Cα carbon
backbone in Coot. All structural images were made
with PyMOL§ unless otherwise indicated. The ligand
coordination images for GDP and GTPγS were made
using Ligplot.64
PDB accession numbers
Structure factors and coordinates are deposited in the
Research Collaboratory for Structural Bioinformatics
protein database with PDB codes 3FFA (Gαi1-T329A·
GTPγS·Mg2+) and 3FFB (Gαi1-T329A·GDP) for the respec-
tive structures.
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Figure S1. mant-GTPγS uptake by α5 helix mutants. Fluorescently-labeled nucleotide 
(mant-GTPγS) was used to do FRET studies for monitoring rates of nucleotide exchange. 
The α5 helix mutants Gαi1-T329A (top left), Gαi1-F336A (top middle), Gαi1-V332A (top 
right), Gαi1-(Q52A T329A) (bottom middle) and Gαi1-Q52A (bottom right) all show 
overall fast rates of nucleotide exchange in comparison to WT Gαi1 protein (lower left 
panel).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure S2. The T329A mutation and model building. The crystal structure of 
heterologously expressed Gαi1-T329A shows (a) density for alanine at the 329 position in 
its protein sequence confirming the correctly characterized and crystallized protein. 
Simulated Annealing OMIT-maps were generated for Gαi1-T329A•GDP while omitting 
GDP from the analysis and for Gαi1-T329A•GTPγS•Mg2+ while excluding GTPγS and 
Mg2+. A 2Fo-Fc simulated annealing OMIT-map contoured at 2σ for (b) Gαi1-
T329A•GDP (green) and (c) Gαi1-T329A•GTPγS•Mg2+ (yellow) is shown. The structures 
for WT Gαi1•GDP (salmon) and WT Gαi1•GTPγS•Mg2+ (blue) are also superimposed. 
The fit of the final model into the electron density is presented for the critical regions 
close to the nucleotide for each structure. The nucleotide interacting β6/α5 loop is shown 
in yellow. The residues corresponding to Switch 1 and Mg2+ coordination sphere are 
shown in (d) pink for Gαi1-T329A•GDP and shown in (e) blue for Gαi1-
T329A•GTPγS•Mg2+.   
 
 
 
 
 
 
 
 
 
 
 
Figure S3. Structural changes in the GTPγS-bound form of WT Gαi1 and Gαi1-
T329A structures. (A) The catalytic pocket of the GTPγS•Mg2+ bound (activated) form 
of Gαi1-T329A shows the expected conservation of residues involved in the interaction 
with both diphosphate and triphosphate nucleosides. The presense of Mg2+ also promotes 
a greater degree of order and coordination density within the catalytic pocket, increasing 
the overall stability of the state. (B) A superposition of the WT Gαi1-GTPγS•Mg2+ and 
Gαi1-T329A-GTPγS•Mg2+ structures shows almost identical secondary structures. There 
are also no observable differences in the orientation of the bound nucleotide.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Figure S4. Structural changes amongst the GDP-bound forms of WT Gαi1 and Gαi1-
T329A. The superposition of WT Gαi1•GDP and Gαi1-T329A•GDP shows key structural 
differences. A zoom into the Ras domain (top) (and removal of the a3 helix for clarity) 
reveals the displacement observed in the β6 strand between the structures. A zoom into 
the catalytic pocket (below) shows a drastically altered switch 1 conformation between 
the WT Gαi1•GDP and Gαi1-T329A•GDP structures. The superposition also shows the 
bound Mg2+ in the WT Gαi1•GDP structure along with key residues, namely R178 and 
T181, lining the catalytic pocket. A small displacement in position of the bound 
nucleotide can also be observed. 
 
  
 
Figure S5.  Thermodynamics analysis of the activation process. (A) In order to 
analyze quantitatively the effect of mutation on the activation energy for the nucleotide 
exchange process, we performed GTPγS-binding assays over a linear temperature 
gradient. The fluorescence enhancement of W211 due to activation was monitored and 
rates were calculated. Experiments were performed for the WT Gαi1 and Gαi1-T329A 
mutant and kapp values were calculated for each data set at different temperatures. A plot 
of lnk versus 1/T was fit to the Arrhenius equation to give activation energies for both 
WT and mutant T329A Gαi1.  The analysis revealed that the barrier for activation of the 
mutant was lower by 5.1 kcal/mol compared to the WT.  
Isothermal titration calorimetry (ITC) was performed to analyze the effect of 
amino acid replacement on the apparent binding affinity of the nucleotide ligand and its 
influence on the nucleotide exchange process. (B) ITC experiments of the binding of 
GTPγS to three mutant Gαi1 subunits are shown along with their calculated 
thermodynamic parameters.  The binding of GTPγS to the Gαi1-T329A mutant was more 
exothermic than GTPγS binding to WT Gαi1 (data not shown), possibly because it does 
not exchange as rapidly as the mutants. The crystal structures of Gαi1-
T329A•GTPγS•Mg2+ and WT Gαi1•GTPγS•Mg2+ are almost identical, with an r.m.s.d. of 
0.29 Å.  Thus, the final GTPγS-bound states of the two complexes can be assumed to 
have the same energy level on a reaction profile diagram.  However, the crystal structure 
of the GDP-bound form of the Gαi1-T329A mutant displays significant conformational 
changes that destabilize its GDP-bound state. Hence, transition from the energetically 
higher GDP-bound state should give larger reaction enthalpy. Our ITC data are in 
excellent agreement with this rationale. The high activation barrier for the WT protein 
makes the process of spontaneous basal nucleotide exchange slow and unfavorable, 
although we observe strong binding constants for Gαi1-T329A. Since both the GTPγS-
bound states of the WT Gαi1 and Gαi1-T329A proteins show almost identical structures, 
the higher affinity of Gαi1-T329A can be explained by the initial lower affinity for the 
bound GDP. The loss of favorable interactions caused by the α 5 helix amino acid 
replacement promotes faster release of the bound GDP. This creates a nucleotide-free 
pocket readily available for GTPγS binding. The initial higher affinity of WT Gαi1 for 
GDP explains its lower binding affinity for GTPγS, resulting in lower enthalpy of 
reaction. The kinetically slower mutants Gαi1-Q52A/T329A and Gαi1-V332A display 
lower apparent binding affinities for the triphosphate ligand than does Gαi1-T329A, 
suggesting that replacements of Q52 and V332 destabilize the GDP-bound state to a 
lesser extent than the T329A replacement.   
ITC was performed at 25°C (298 K) using a MicroCal VP-ITC (MicroCal, 
Northhampton, MA) calorimeter. Protein samples were dialyzed against the titration 
buffer (50 mM Tris-HCl, pH8.0, 150 mM NaCl, 2 mM MgCl2, 10 µM GDP, 1 mM TCEP 
(Tris-(2-carboxyethyl) phosphine)). Three buffer exchanges (each 4 hrs or more) were 
done to remove DTT from the protein stock. GTPγS was not dialyzed due to its small 
size. The GTPγS stock solution was prepared using the final dialysis buffer for the 
protein solution. Both the experimental protein and GTPγS samples were thoroughly 
degassed. Contents of the sample cell were stirred continuously at 280 rpm during the 
experiment. A typical titration of Gαi1 mutants with GTPγS involved 50 injections each 
of 5 µ l of GTPγS solution (500 µM) into a sample cell containing 1.4 ml of WT or 
mutant Gαi1 (50 µM). The heat of dilution of the titrant (GTPγS) was subtracted from the 
titration data for base-line correction. The base line-corrected data were analyzed with 
MicroCal OriginTM 6.0 software to determine the enthalpy (ΔH), association constant 
(Ka), and stoichiometry of binding (N). Thermal titration data were fit to single site 
binding model and thermodynamic parameters ΔH, Kd and entropy change (ΔS) were 
obtained from the fits to the model. The parameters were calculated based on three or 
more independent titration experiments. Each numerical value reported is the mean 
experimental value ± S.E.M from three independent data sets. Gαi1-T329A displays 
highest affinity for GTPγS in comparison with Q52A T329A and V332A mutant Gαi1 
subunits. WT Gαi1 could not be tested because of its low affinity for the nucleotide and 
its very slow basal GTPγS uptake rate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure S6. Differential orientation of R178 residue. A superposition of α-subunits 
from WT Gαi1•GDP•Mg2+ (PDB Code 1BOF) (Coleman & Sprang, 1998), WT 
Gαi1•GDP•Mg2+ (from the heterotrimer complex) (PDB Code 1GG2) (Wall et al, 1995) 
and Gαi1-T329A•GDP structures show differential orientation of the R178 residue. In the 
WT Gαi1•GDP•Mg2+ structure R178 points into the catalytic pocket making electrostatic 
interactions with the α- and β-phosphates of GDP whereas in the heterotrimer the R178 is 
flipped outwards by 900 away from the catalytic pocket. Even in the Gαi1-T329A•GDP 
structure the R178 residue flips away by almost 1800 and moves away from the catalytic 
pocket.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Figure S7. Inhibition of G protein activation in the presence of Gβγ. WT G protein α-
subunit or the T329A-Gαi1 in the GDP bound form are mixed with equimolar (178nM 
each) quantities of Gβ1γ2 and AlF4- uptake is monitored by measuring the fluorescence 
enchancement. Both WT and T329A-Gαi1 exhibit decrease in the fluorescence 
enhancement observed in the presence of Gβ1γ2 in comparison to the α -subunits alone 
suggesting a direct interaction between these difference components of the heterotrimeric 
G proteins.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S8. Structural changes facilitating nucleotide exchange. The structure of WT 
Gαi1•GDP bound to two peptides (KB-752 and D2N) which interact with different 
regions of the protein and synergistically cause an increase in the nucleotide exchange 
rates, apparently acting as GEFs (guanine-nucleotide exchange factors) was recently 
solved (Johnston & Siderovski, 2007) (PDB code 2hlb). Superimposition of the α5-β6-α4 
domain of WT Gαi1•GTPγS•Mg2+, WT Gαi1•GDP•Mg2+, Gαi1-T329A•GDP and WT 
Gαi1•GDP/KB-752/D2N shows a similar orientation of β6 strand for the T329A mutant 
as observed by Siderovski et al. Unlike the case of T329A, the β6 strand in the active and 
inactive forms of WT Gαi1 do not undergo any conformational changes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure S9. Sequence alignment of C-terminal residues of Gα subunits. The sequence 
alignment of the last 31 residues of various α -subunits comprising the P-loop, α5 helix 
and CT shows high degree of conservation. The residues T329 and F336 in WT Gαi1 
show 100% conservation across various classes of α -subunits. The sequence alignment 
was generated using the software clustalW.  
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